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Abstract 
Signals via the T cell receptor (TCR) are critical for the development of T cells in the 
thymus, maintenance of a self-tolerant peripheral T cell repertoire and the activation 
of T cells in secondary lymphoid organs. A dynamic balance between tyrosine 
phosphorylation and dephosphorylation is essential for the maintenance of 
homeostasis and proper regulation of the immune system. The cytoplasmic 
phosphatase, PTPN22 (protein tyrosine phosphatase non-receptor type 22) is 
involved in negative modulation of signal transduction through the TCR and plays a 
central role in regulating lymphocyte homeostasis.  
Genome wide association studies reveal that point mutations in PTPN22 confer an 
increased risk of developing multiple autoimmune diseases in humans. The precise 
function of PTPN22 and how mutations contribute to autoimmunity is controversial. 
Loss-of-function mutations in PTPN22 are associated with elevated T effector cell 
expansion and autoreactive B cells in both humans and mice. 
A thorough dissection of the molecular involvement of PTPN22 and its allelic 
variant R619W is important to delineate its role in autoimmunity, to this end we 
utilised the Ptpn22-/- mice generated in our laboratory. In order to address whether 
R619W allelic variant is a gain- or loss-of-function mutation, we expressed both 
PTPN22WT and PTPN22R619W constructs in primary activated Ptpn22-/- T 
lymphocytes using lentiviral transduction. Surprisingly expression of either wild type 
or variant phosphatase showed no affect on cytokine production. Preliminary results 
from bone marrow chimeras generated by retroviral expression of PTPN22WT and 
PTPN22R619W in Ptpn22 deficient mice showed reduced T cell activation compared 
to Ptpn22-/- T cells. PTPN22WT appeared to be more suppressive of T cell responses 
than variant PTPN22R619W. Consistent with studies conducted in comparable knock-
in mouse models, our data point to the variant PTPN22R619W as being a partial loss of 
function allele.  
To elucidate the mechanism of PTPN22 action in context of an autoimmune disease, 
we investigated the effect of Ptpn22 deficiency on the phenotype of SKG mice. The 
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SKG mouse harbours a point mutation (W163C) within the carboxyl terminal SH2-
domain of ZAP-70, which results in decreased TCR signalling and impaired 
thymocyte development with defective positive and negative selection. These mice 
are prone to developing CD4+ T cell mediated autoimmune arthritis that closely 
resembles rheumatoid arthritis in humans.  
We found that thymus differentiation was partially restored in SKG Ptpn22-/- 
thymocytes and Ptpn22 deficiency enhanced TCR mediated signalling in              
SKG Ptpn22-/- thymocytes relative to SKG thymocytes. Consistent with increased 
signalling observed in the thymocytes, there was improved in vitro proliferation and 
IL-2 production of CD4+ T lymphocytes from SKG Ptpn22-/- mice compared to SKG 
mice. By contrast to SKG mice, SKG Ptpn22-/- mice developed less severe mannan-
induced arthritis and showed decreased proportions of Th17 and higher numbers of 
regulatory T cells. These results show that removal of PTPN22 can compensate, at 
least partially, for the deficient ZAP-70 activity in the SKG mouse, thus linking 
PTPN22 and ZAP-70 to the same signalling pathway. 
This study advances our understanding of how manipulating TCR signals impacts on 
downstream T cell functions, suggesting PTPN22 may be a valuable target for the 
treatment of autoimmune diseases. Further studies to determine physiological role of 
the phosphatase and its disease-associated variants could provide insight into 
mechanism of immune activation, tolerance and autoimmunity. 
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Lay Summary 
T cells fight against infections but occasionally can turn on themselves. Failure to 
regulate immune responses increases the risk of autoimmunity and tumour 
development. One such protein tyrosine phosphatase acting as a molecular switch to 
negatively regulate T cell function is PTPN22. Interestingly, genetic studies show 
that aberrations in this phosphatase are associated with autoimmune diseases. A 
thorough dissection of the molecular involvement of PTPN22 is important to 
delineate its role in autoimmunity. To this end, we utilised a mouse model where we 
have deleted the PTPN22 protein in the mouse cells. Consistent with the role of 
PTPN22 as an inhibitor of T cell signalling, PTPN22KO mouse show increased T 
cell activity, however these mice fail to develop any autoimmunity.  
To understand the mechanism of PTPN22 action in context of an autoimmune 
disease, we investigated the effect of loss of Ptpn22 deficiency on the phenotype of 
SKG mice. The SKG mice is a naturally occuring mouse strain which spontaneously 
develops arthritis that resembles rheumatoid arthritis in humans due to mutation in a 
molecule, ZAP-70 that positively regulates T cell function. Arthritis can also be 
elicited in these SKG mice by injection of fungal products (such as mannan). We 
crossed the Ptpn22 deficient mouse with the SKG mouse to generate SKG Ptpn22-/- 
mice. Our results show that loss of PTPN22 resulted in less incidence and severity of 
mannan induced arthritis on the SKG background. This study shows that lack of a 
negative regulator (PTPN22) can partially compensate for the dysfunction in a 
positive regulator (ZAP-70) therefore linking these two molecules to similar 
signalling pathway.  
This study advances our understanding of how manipulating T cell signals impacts 
on downstream T cell functions, suggesting PTPN22 may be a valuable target for the 
treatment of autoimmune diseases. Further studies to determine physiological role of 
the phosphatase and its disease-associated variants could provide insight into 
mechanism of immune activation, tolerance and autoimmunity. 
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Chapter 1: Introduction  
1.1  An Overview of the Immune system  
The mammalian immune system functions to protect the hosts against a wide range 
of pathogenic organisms. All the major circulating immune cells arise from the 
pluripotent hematopoietic stem cells (pHSCs), which further differentiate into the 
myeloid stem cell or the common lymphoid progenitors. Protection by the immune 
system is established by execution of four related activities: recognition of foreign 
pathogens, elimination of the pathogen by effector responses, tightly controlled self 
regulation of the immune response and formation of immunological memory. Two 
components of the immune system: innate and adaptive immunity collaborate 
together to protect the host system.  
1.2 Innate immunity  
Innate immunity is defined as the “hard wired responses” encoded in their mature 
form by germline genes of the host and is inherited from parent to child. The innate 
immune system recognizes conserved molecular patterns on microorganisms known 
as pathogen-associated molecular patterns (PAMPs) through a limited and invariant 
repertoire of receptors called pattern recognition receptors (PRRs) (Murphy et al., 
2012). It constitutes the first-line of host defence and comprises of physical and 
chemical barriers, which together with the molecular and cellular components 
provide a rapid-response mechanism to prevent microbial invasions.  
The first hurdle for the pathogen involves breaching the barriers protecting the host. 
These include anatomical barriers such as the skin, the internal epithelia and the 
mucosal membranes lining the respiratory, gastrointestinal and genitourinary tracts. 
A variety of soluble factors contribute to innate immunity, either present 
constitutively in biological fluids (such as lysozyme, complement proteins) or that 
are released from cells that are activated following recognition of invading pathogens 
(e.g. cytokines and chemokines). Integral cellular mediators of the innate immune 
system originate from the myeloid lineage and include macrophages, neutrophils, 
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eosinophils, basophils, mast cell, dendritic cells (DCs), and some cells of the 
lymphoid lineage such as natural killer (NK) and natural killer (NKT) T cells.  
1.3 Adaptive immunity  
Although the innate immune system has evolved sufficiently to provide generalised 
rapid sensing and elimination of pathogens, it is limited in its ability to recognise the 
rapidly evolving microorganisms. The adaptive immune system overcomes the 
constraints of limited diversity and provides a more specific targeted immune 
response. The adaptive immune system arises from the lymphoid lineage of pHSCs 
and comprises B and T lymphocytes that are characterised by their unique cell 
surface antigen (Ag) receptors (BCR and TCR, respectively). These antigenic 
receptors are custom tailored through a process of somatic gene recombination to 
generate diverse repertoires of receptors to recognise various pathogens. The 
adaptive immune response confers the host with Ag specific immunological memory, 
thereby permitting a more effective host response against the specific pathogens 
when encountered again.  
1.3.1 The Generation of BCR and TCR Diversity 
Both B and T lymphocytes originate from the common lymphoid precursor (CLP). 
While the B cells develop within the bone marrow and differentiate into mature B 
cells (plasma cells), which secrete antibodies with specificity similar to that of the 
BCR. While T cell precursors are generated in the bone marrow, they develop in the 
thymus as naïve T cells which upon activation differentiate into effector T cells.  
The BCR comprises membrane-bound immunoglobin that is composed of four 
polypeptides – two identical 50 kD heavy chains (H) and a pair of identical 25 kD 
kappa (#) or lamda (&) light chains (L) held together by disulphide bonds. The N-
terminal amino acid sequence of both the heavy and light chains forms the Ag-
binding region and varies extensively between antibody molecules, known as the 
variable (V) region. The variable regions of heavy and light chain form the 
hypervariable loops, creating a surface complementary to antigen, commonly called 
as complementarity-determining regions 1, 2 and 3 (CDR1, CDR2, CDR3). The 
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variable region of the H chain is assembled from individual gene segments, classified 
as variable (V), diversity (D) and joining (J). The carboxyl terminal of the heavy 
chains comprises the constant region, (C) region, which determines the functional 
activity of the antibody molecule. The five main antibody classes IgM, IgD, IgG, IgA 
and IgE are determined by their corresponding heavy chains and denoted by Greek 
letters (µ, ', $, % and " respectively). IgG is the most abundant in humans (Murphy et 
al., 2012). 
The majority of TCR consists of a heterodimer of two different polypeptide % and ! 
chains that are structurally similar to the antigen-binding fragment (Fab) of an 
immunoglobin molecule. The TCR % chain is made up of three gene segments, the 
variable amino terminal (V), joining (J) and the constant regions and the TCR ! 
chain is composed of V, D (diversity) and J segments. A minor subset of T cells 
bears an alternative TCR made of a different pair of polypeptides ($) and ('), called 
$' T cells. The $' T cells mainly reside in the skin epithelium and mucosa rich tissue 
such as the gut and have a less diverse TCR repertoire (Girardi, 2006).  
The generation of diversity of lymphocyte receptors is similar in T and B cells. The 
V, D and J gene segments are randomly assembled by DNA recombination, mediated 
by the recombinase-activating genes 1 and 2 (RAG1/RAG2) to generate variable 
regions, that when fused to the constant (C) region form Ag receptors with unlimited 
diversities. The clonal diversity is generated by multiple mechanisms first by the 
combinatorial variation in the V-D-J gene segment joining, second by junctional 
diversity occurring as a result of inaccurate splicing creating frame shift mutations 
and third, by insertion of nucleotides at the V-D and V-J junction by the enzyme 
deoxyribonucleotidyl transferase (TdT) (Cabaniols et al., 2001; Parkin and Cohen, 
2001). Mice lacking either of the Rag gene, present with a complete block in the 
lymphocyte development (Mombaerts et al., 1992). 
1.3.2 B cells  
In humans B cells constitute approximately 15% of peripheral blood leukocytes and 
undergo a developmental program in the bone marrow by staged maturation from 
pro-B cell, to pre-B cell and finally into immature B cells with membrane-bound 
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immunoglobin, BCR. In the Pro-B cell stage the recombinase enzyme catalyses 
rearrangement of the immunoglobin heavy-chain locus with DH to JH joining, 
followed by secondary rearrangement of VH regions joining the DH-JH segments. 
Successful rearrangement of the heavy chain VDJ locus leads to expression of intact 
µ heavy chain, further rearrangements ceases and the pro-B cells become pre-B cells. 
In the pre-B-cell stage, the V and J regions of & or # light chains are rearranged. The 
successful assembly of VJ rearranged light chains combined with the µ chains forms 
immature B cell expressing IgM molecules (Pieper et al., 2013). On reaching the 
immature stage, B cells exit the bone marrow and migrate to the spleen where they 
undergo further differentiation into naïve, follicular, or marginal zone B cells. The 
successfully rearranged heavy and light chains are subject to allelic exclusion, 
ensuring that only one of the two alleles of a gene is expressed. As well as allelic 
exclusion, light chains also display isotypic exclusion; that is expression of only one 
type of light chain, either # or & by an individual B cell (Pieper et al., 2013). Upon 
stimulation by antigen, B cells can undergo class switching to express a different Ig 
heavy chain. Somatic hyper mutation in mature B cells generates further diversity of 
the BCR to generate clones with enhanced Ag binding. Affinity maturation ensures 
that the clones with highest affinity survive and mature into antibody- producing 
cells (Pieper et al., 2013). 
In contrast to conventional B cells described above (also referred as B2 cells), B1 
cells are derived from the foetal-liver hematopoietic stem cells that are long lived and 
are particularly found in the peritoneal cavity and in gut-associated lymphoid tissues. 
These self-renewing B1 cells produce a significant portion of IgM natural 
autoantibodies in serum that are crucial for defence against encapsulated bacteria. B-
1 cells are further subdivided into B1-a (CD5+) and B1-b (CD5-) subsets (Hardy, 
2006). Unlike the conventional B2 cells, the B1 cells can respond to antigens 
independent of T cells. B1-a cells and their natural antibody products provide innate 
protection against bacterial infections in naive hosts, whereas B1-b cells function 
independently as the primary source for long-term adaptive antibody responses to 
polysaccharides during infection (Engel et al., 2011). The hallmarks of B1 B cells are 
their polyreactivity and their low affinity for various ligands, a possible consequence 
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of positive selection by self-Ags. However, their low threshold of activation makes 
them highly reactive to high loads and/or altered self-Ags, which could potentially 
exacerbate autoimmune disease (Engel et al., 2011). B1-a cells can contribute to 
autoimmunity by the autoreactivity of natural antibodies, the production of IL-10 
cytokine and enhanced antigen presentation capabilities (Duan and Morel, 2006).  
1.3.3 T cells  
T cells develop through various stages in the thymus (discussed later in 1.4) and can 
be broadly divided into two major classes depending on the selective surface 
expression of the glycoprotein CD4 or CD8 producing CD4+ or CD8+ T cells 
respectively. After T cells leave the primary lymphoid tissues (BM and thymus) they 
home to secondary lymphoid tissues (lymph nodes (LN) and spleen) and 
continuously circulate between blood and lymphatic circulatory systems. Naïve T 
cells are multipotent and survive in the periphery by contact of the TCR with ligands 
of self-peptide major histocompatibility complex (MHC) and exposure to interleukin 
7 (IL-7) (Sprent and Surh, 2011). Once naïve T cells encounter specific Ag they 
undergo activation and clonal expansion of the Ag specific T cells. CD4+ and CD8+ 
T cells differentiate into functionally different subsets following exposure to antigen, 
contingent on the integration of multiple signals from the local microenvironment 
(Fig 1.1). 
CD4+ T cells 
Resting naïve CD4+ T (designated as Th) cells release very low levels of cytokines. 
Upon stimulation by antigen presented in context of MHC II and signalling via the 
IL-2 receptor Th cells progress to Th0 cells that mainly secrete IL-2. Depending on 
the milieu of cytokines present, the Th cells can differentiate into a variety of 
lineages, for example, Th1, Th2 or Th17 subsets (Sallusto and Lanzavecchia, 2009). 
In the past, a classical model assigned CD4+ effector T cells either into Th1 and Th2 
subsets, each with its own distinct cytokines, transcription factors and functions 
(Mosmann et al., 1986). The lineage specification of the different CD4+ T cells 
subsets depend on the concerted actions of cytokine-induced signal transducer and 
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activator of transcription (STAT) factors and “master regulators”, transcription 
factors, which provide cell extrinsic feedback loops by production of cytokines, as 
well as cell-intrinsic transcriptional networks guiding each developmental program 
(Murphy and Reiner, 2002). The development of the Th1 subset, results from the 
sequential actions of STAT1 induced by IFN$ and STAT4 induced by IL-12 that 
ultimately promote expression of T-bet, a central transcription factor important for 
Th1 programming. The Th2 subset is induced by IL-4 induced STAT6 signalling 
which upregulates the transcription factor GATA3 (Murphy and Reiner, 2002). Th1 
cells are associated with protection against intracellular pathogens and virally 
infected targets while the Th2 phenotype regulates humoral immunity and is 
involved in protection against extracellular pathogens (Zhu et al., 2010).  
Recently in addition to the well characterized Th1 and Th2 subsets, a number of 
other functional Th subsets have been described for CD4+ T cells, including Th17, T 
regulatory (Treg), Th3 and T follicular helper (Tfh), which secrete different 
cytokines to facilitate specific immune responses. Transforming growth factor ! 
(TGF-!) and IL-6 are crucial factors involved in the de novo differentiation of Th17 
(Bettelli et al., 2006; Veldhoen et al., 2006) and IL-23 is required for their survival 
and expansion (Aggarwal et al., 2003). Alternatively, Th17 cells can also be induced 
by IL-6, IL-1! and IL-23, independent of TGF-! and these “alternatively - derived” 
Th17 cells are more pathogenic than those derived from TGF-! and IL-6 alone 
(Bedoya et al., 2013). Differentiated Th17 cells produce a variety of cytokines 
including IL-17A, IL-17F, IL-21, IL-22, GM-CSF, TNF%, IL-9, IL-10 and IFN$ 
depending upon the cytokine milieu present at the time of differentiation (Bedoya et 
al., 2013). IL-17A is considered to be the primary effector cytokine secreted by Th17 
and can elicit the production of other inflammatory cytokines by fibroblasts and 
epithelial cells, such as IL-6, IL-8, GM-CSF and MCP-1 (Cooke, 2006). The central 
modulator of the Th17 is the retinoic acid-related orphan nuclear receptor $ 
(ROR$T), which drives the transcription of IL-17A and IL-17F (Ivanov et al., 2006). 
Other transcription factors involved in directing naïve CD4+ T cell towards Th17 
differentiation include STAT3, interferon regulatory factor 4 (IRF4), the aryl 
hydrocarbon receptor (AHR), NOTCH and basic leucine zipper transcription factor 
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(BATF) (Bedoya et al., 2013). IL-6 and IL-23 activates STAT3 and regulate 
expression of ROR$T. STAT3 deficiency impairs ROR$T expression leading to 
elevation of T-bet and the nuclear transcription factor Forkhead box P3 (Foxp3) 
(Bedoya et al., 2013). STAT3 is thought to further enhance cell commitment to the 
Th17 lineage by directly binding the IL17 gene promoter (Bedoya et al., 2013). 
Elevated levels of IL-17 are implicated in multiple autoimmune conditions such as 
multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematous and 
experimental autoimmune encephalomyelitis (EAE) (Cooke, 2006).  
CD4+CD25+ regulatory T cells (Tregs) are vital for maintaining immune tolerance by 
counter-balancing adaptive immune responses (Liston and Gray, 2014). Adoptive 
transfer of purified CD4+CD25- T cells from normal mice into nude mice that lack T 
cells of their own resulted in development of number of autoimmune diseases such as 
thyroiditis and gastritis (Sakaguchi et al., 1995). Depending on the site of 
development Tregs are broadly classified, into natural Tregs (nTregs) that develop in 
the thymus or induced Tregs (iTregs), which develop in the periphery upon T cell 
activation (Josefowicz and Rudensky, 2009). The expression of Foxp3, an X-
chromosome encoded member of the winged-helix protein family of transcription 
factors, is crucial for the function and maintenance of both subsets (Fontenot et al., 
2003). IL-2 has been shown to play an important role in the maintenance of nTregs 
and stimulation of nTregs in response to IL-2 provides regulation of IL-2 producing 
effector T cells (Fontenot et al., 2005). The differentiation of naïve CD4+ T cells into 
iTregs was found to be dependent on cytokines such as TGF-!, IL-4 and IL-10 
(Apostolou and von Boehmer, 2004). Additionally, TGF-! induced signals are 
critical for the expression of Foxp3, the size of the peripheral Treg compartment and 
the suppressive function of Tregs (Marie et al., 2005). The Foxp3 gene is highly 
conserved with similar functions in mouse and man and mutations in Foxp3 protein 
results in severe and fatal autoimmune pathologies affecting multiple organs in both 
species (Rudensky, 2011). Differentiation of both Th17 and Treg subsets of CD4+ T 
cells are overlapping and are determined by the concentration of TGF-!; at low 
doses, TGF-! synergises with proinflammatory cytokines, IL-6 and IL-21 to promote 
expression of the IL-23 receptor favouring Th17 differentiation whereas at high 
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doses it favours the Foxp3 mediated repression of ROR$T favouring iTreg 
differentiation (Zhou et al., 2008).  
Th3 is a unique subset of Tregs, which differentiates from naïve CD4+ T cells 
following ingestion of an oral antigen. This subset is known to secrete TGF-!, assist 
in IgA secretion and suppress functions of both Th1 and Th2 cells. It resembles Treg 
in the expression of CD4 and CD25, however there are controversial reports about 
expression of Foxp3 in these cells. (Gol-Ara et al., 2012).  
The Tfh subsets are characterised by the surface expression of PD-1, ICOS, Bcl-6, 
IL-21 and chemokine receptor CXCR5, which mediates their recruitment into B cell 
follicles to regulate development of Ag-specific B cell immunity (Crotty, 2011).  
CD8+ T cells 
On encountering Ag presented by MHC I molecules, naïve CD8+ T cells undergo 
rapid proliferation, generating large populations of clonally expanded Ag-specific T 
cells which can differentiate into either effector T cells known as cytotoxic T 
lymphocytes (CTLs) or long-lived memory cells (Williams and Bevan, 2007). 
CD8+ T cells require antigen stimulation, CD28-dependent co-stimulation, and IL-12 
or Type I interferons (IFNs) for activation and commitment to clonal expansion and 
effector cell differentiation (Williams and Bevan, 2007). CTLs recognise their target 
cells expressing cognate peptide-MHC I complexes and facilitate their clearance by 
either direct lysis or by production of antiviral cytokines TNF and IFN$ cytokines 
(Barry and Bleackley, 2002). Two major pathways of cytotoxicity have been 
described in CTL: Ca2+ dependent perforin/granzyme and Ca2+ independent Fas 
ligand (FasL) mediated apoptosis, these are mediated by TCR signalling. The first 
mechanism requires rearrangement of effector-cell cytoplasm, resulting in release of 
lytic granules containing perforin and granzyme B at the immunological synapse.  
Perforin is a potent pore forming protein, which creates pores in the membrane of 
target cells, enabling delivery of granzyme B that cleaves various intracellular 
substrates, including pro-apoptotic factors such as Bid (Barry and Bleackley, 2002). 
CTLs express Fas ligand (CD95, also known as death receptor) and initiate apoptosis 
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of target molecules by binding Fas-molecules on target cells via caspase dependent, 
death-inducing signalling complex (DISC) (Barry and Bleackley, 2002). 
A majority (90-95%) of clonally expanded CTLs die by apoptosis after antigen 
clearance and the surviving effector cells are able to differentiate into long lived 
memory CD8+ T cells which produce low levels of perforin, granzyme B and IL-2 
(Murali-Krishna et al., 1998). Memory T cells can be divided into effector (TEM; 
CCR7-CD62L-) or central (TcM; CCR7+ CD62L+) subsets based on the expression of 
chemokine receptor CCR7 and L-selectin, CD62L (Sallusto et al., 2014). 
1.3.4 Antigen Presentation  
In contrast to B cells that are capable of recognising antigens on their own, Ag 
recognition by %! T cells requires Ag to be processed into peptides that are presented 
in context of MHC molecules. MHC molecules are highly polygenic and 
polymorphic as they are encoded by several different sets of genes arranged into 
large clusters in the genomes and can have allelic variants differing by up to 20 
amino acids. MHC polymorphisms occur mainly in the peptide-binding groove to 
increase the diversity of peptides that can be bound by MHC molecules. MHC 
molecules are divided into two classes – MHC class I which is expressed on the 
surface of all nucleated cells and presents peptide antigens to CD8+ T cells and MHC 
class II that are predominantly expressed on professional antigen presenting cells 
(APC) such as dendritic cells (DCs), macrophages and B cells and present peptides 
to CD4+ T cells (Kindt et al., 2007). 
Both class I and class II MHC molecules are structurally similar, comprising a 
heterodimeric % and ! peptide binding domain and two Ig-like domain (Rudolph et 
al., 2006). In class I MHC, the peptide binding cleft (%1%2) binds peptides of 8-10 
amino acids in length whereas the binding pocket in class II MHC molecules is less 
restricted and can bind peptides up to 13-17 amino acids in length. MHC class II 
molecules are more flexible as they are formed through non-covalent association of 
two polypeptides chains (% and !) (Rudolph et al., 2006).  
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MHC class I molecules mainly bind antigenic peptides derived from intracellular 
proteins that are endogenously processed by immunoproteases within the cytosol of 
APC and are transported to the endoplasmic reticulum (ER) via a family transporters 
associated with Ag processing-1 and-2 (TAP-1 and TAP-2). Within the ER, TAP and 
chaperon proteins act as a scaffold for the assembly of MHC class I molecules (% and 
!2M) with the peptides. These chaperons include tapasin, that stabilises the TAP1/2 
heterodimer, calnexin that helps to retain partially assembled MHC molecules until 
they are fully formed, and calreticulin, which stabilises the MHC class I to receive 
the peptide (Sadasivan et al., 1996). The newly assembled pMHC complex is then 
translocated to the plasma membrane through the Golgi complex.  
By contrast MHC class II molecules, bind peptides derived from pathogens that are 
ingested in intracellular vesicles or from the extracellular proteins that are 
internalized by endocytosis. During assembly of the MHC class II molecule (%!) in 
the ER, the binding cleft is blocked by the preassembled trimeric protein called 
invariant chain (Ii) while the cytoplasmic tail of Ii expresses a motif, which targets 
the complex to the endosomal/lysosomal compartment via trafficking through the 
Golgi complex. Subsequently the Ii chain is gradually degraded by proteolysis. 
However, a short fragment of Ii called class II associated invariant chain peptide 
(CLIP) remains bound within the peptide binding groove, to prevent premature 
binding of antigenic peptide (Kindt et al., 2007). The human leukocyte Ag HLA-
DM, structurally related to MHC class II molecules is primarily located within the 
endosomal compartment and facilitates the exchange of CLIP for the antigenic 
peptide, enabling the stable pMHC to be directed to the cell surface (Denzin and 
Cresswell, 1995).  
1.4 Immunological Tolerance & Autoimmunity 
The immune system has evolved to achieve effective immunity against foreign 
pathogens without mounting detrimental responses to self thus preserving the 
integrity of the host’s own tissues. Immunological tolerance is a state of 
unresponsiveness towards self and maintenance of immune competence and 
reactivity to all the other foreign antigens (Murphy et al., 2012). The inability to 
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remain tolerant to self is the fundamental cause of autoimmunity. A number of 
immune tolerance induction mechanisms work in synchrony to maintain the fine 
balance between effective immunity and autoimmunity. The mechanisms of immune 
tolerance are classically divided into two categories: central tolerance and peripheral 
tolerance. To review the mechanisms controlling the induction of tolerance in T cells 
it is important to first discuss the development of T cells within the thymus. 
1.4.1 T Cell Development  
T cells are derived from the common lymphoid progenitors (CLP) that originate from 
the pHSCs found in the fetal liver and bone marrow. These CLPs migrate to and 
colonise the thymus where they can differentiate into T, B or NK cells (Ardavin et 
al., 1993). Following lineage commitment, developing thymocytes undergo a series 
of TCR rearrangements with eventual assembly of TCR complexes maturing into $' 
T cell and %! T cell lineages. The different developmental stages are marked by 
expression of cell surface receptors (Fig 1.2). The %! T cells diverge further into 
CD4+ T cells, CD8+ T cells, NKT cells and Tregs (Rothenberg et al., 2008).  
The interaction of thymocytes with thymic stromal cells drives the development of 
the T cell lineage. The thymus is made up of an outer cortex and an inner medulla 
region that comprise distinct epithelial stromal cells known as cortical thymic 
epithelial cells (cTECs) and medullary thymic epithelial cells (mTECs) respectively 
(Anderson and Takahama, 2012). Nude mice, lack a thymus and thus mature cTECs 
due to loss of function of the transcription factor, FoxN1 and consequently the 
thymus, is completely devoid of all T cells (Manley and Blackburn, 2003). T cell 
development is initiated by the recruitment of the CLPs to the thymus by P-selectin 
an adhesion molecule, that is expressed on thymic endothelial cells (TECs) (Rossi et 
al., 2005) and by chemokines such as chemokine ligand (CCL) 21, CCL25 and 
CXCL12 expressed by TECs (Liu et al., 2006). The unique thymic 
microenvironment not only provides supportive cytokines such as c-kit ligand and 
IL-7 that maintain and expand early thymic precursors (ETP), but also crucially 
provides an environment that is rich in Notch ligand Delta-like ligand 4 (DLL4) 
(Rothenberg et al., 2008; Schmitt and Zuniga-Pflucker, 2002). There is accumulating 
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evidence that Notch signalling is critical for determination of T cell fate during 
maturation from pHSCs. It has been shown to favour T cell development over B cell 
formation, as Notch-/- mice demonstrate an early block in T cell development (Pui et 
al., 1999; Radtke et al., 1999) and overexpression of constitutively active Notch-1, 
by retroviral transduction, resulted in development of immature CD4+CD8+ double 
positive (DP) cells in the BM (Pui et al., 1999).  
The early thymic progenitors (ETP) enter the outer cortex and lack expression of the 
co-receptors CD4 and CD8 and are referred to as double negative (DN) cells. The 
DN population can be subdivided into four sequential stages (DN1, DN2, DN3 and 
DN4) characterised by the surface expression of CD44, an adhesion molecule and 
CD25, the alpha chain of IL-2 receptor. In addition, proliferation and survival of 
ETPs in the DN population is dependent on signals from IL-7 and IL-7R and from 
tyrosine kinase receptor c-kit and its ligand and stromal cell factor (SCF). The DN1 
population is phenotypically defined as c-kit+CD44+CD25-, is very heterogenous and 
can give rise to all subsets of T cells including NKT and $' T cells. As the DN1 cells 
proliferate they commence up-regulation of CD25, and enter the DN2 stage 
becoming CD44+CD25+. The DN2 stage is further subdivided into DN2a (c-kithi) and 
DN2b (c-kitmed). During the DN2 stage of development, cells commence the 
rearrangement of the TCR!, $ and ' genes. Finally at the DN3 (CD44-CD25+) 
expression of both c-kit and CD44 is turned off and the cells can be further 
subdivided as DN3a (CD27lo) pre-! or CD27hi DN3b $' cells (Rothenberg et al., 
2008). In the DN3 stage, the first checkpoint for committed %" thymocytes verifies 
proper TCR gene rearrangement and is known as !–selection. It requires the 
thymocytes to signal through a pre-TCR consisting of a properly rearranged TCR! 
chain, pre-TCR% chain, CD3 complex and ( chain (Carpenter and Bosselut, 2010).  
The assembly of the pre-TCR complex signals allelic exclusion of the TCR! locus, 
proliferation and down-regulation of CD25 expression so that cells enter the DN4 
stage (CD44-CD25-) and differentiation into CD4+ CD8+ double positive (DP) 
thymocytes. Inability of pre-TCR complex to associate with CD3( chain halts the 
development at DN3 stage, so thymocytes with out-of-frame TCR! rearrangements 
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do not receive survival signals and undergo apoptosis (Malissen and Malissen, 1996). 
In addition, any defects in the Rag1, Rag2 genes causing failure in rearrangement of 
! chain, or defects in pre-TCR", TCR!, CD3# and CD3$ genes, causes the results in 
absence of DP thymocytes which are blocked in the DN3 stage (Fehling et al., 1995; 
Malissen et al., 1995; Mombaerts et al., 1992; Shinkai et al., 1992).  
In the DP stage thymocytes stop proliferating and down-regulate the expression of 
IL7R (CD127). The Tcrb locus, encoding TCR! proteins becomes inaccessible and 
the accumulation of RAG1 and RAG2 proteins initiates rearrangement of the Tcra 
locus, encoding the TCR% chain, resulting in the surface expression of the TCR%! 
complex (Germain, 2002). DP thymocytes undergo positive selection and CD4/CD8 
lineage determination within the cortex. Nearly ~90% of double positive thymocytes 
express TCRs that interact so weakly with available self-peptide MHC that signals 
required to sustain viability are not generated resulting in cell death (Huesmann et 
al., 1991). Thymocytes with TCRs with intermediate affinity for self-peptide MHC 
receive survival signals and are positively selected (Starr et al., 2003). By contrast, 
thymocytes expressing TCRs with high affinity for self-peptide MHC complex are 
induced to undergo either clonal deletion or inactivation in the medulla.  
DP thymocytes that survive positive selection within the cortex undergo CD4/CD8 
lineage commitment to differentiate into either CD4+ or CD8+ single positive (SP) 
cells in the medulla. Interaction of the DP thymocytes with cTECs, upregulates the 
expression of C-C chemokine receptor, (CCR7) and receptor activator of nuclear 
factor kappa- B ligand (RANKL). These DP thymocytes follow the signals 
emanating from mTECs (ligands for CCR7 - CCL19 and CCL21 and the receptor for 
RANKL, RANK) and migrate into the medulla (Anderson and Takahama, 2012; 
Petrie and Zuniga-Pflucker, 2007). It is in medulla, that negative selection takes 
place, removing SP thymocytes with autoreactive TCRs from the repertoire and 
establishing central tolerance.  
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1.4.2 Central Tolerance 
The downside of generation of diverse repertoire of T and B cells by random 
recombination events during development in the thymus and bone marrow is the 
production of a large number of self-reactive TCRs and BCRs, respectively. Central 
tolerance is the process that works to eliminate the autoreactive T and the B cells. 
Indeed, many self-reactive clones are eliminated efficiently in the thymus and clonal 
deletion plays a central role in immunological tolerance (Hogquist et al., 2005). 
Other mechanisms of tolerance induction such as anergy (Schwartz, 2003) and 
receptor editing (McGargill et al., 2000) have been described, however they 
contribute less significantly than clonal deletion.  
Central tolerance is achieved by the deletion of autoreactive thymocytes through 
negative selection and is critically dependent on the interaction of thymocytes with 
other cells in the thymic microenvironment. The medulla is enriched with two types 
of antigen presenting cells – mTECs and DCs both of which are crucial for negative 
selection (Anderson and Takahama, 2012). The medullary TECs are known sites of 
promiscuous gene expression and are therefore capable of expressing a large 
diversity of “tissue specific antigen” (TSA) that represent antigens expressed outside 
the thymus (Palmer, 2003). The expression of these TSAs are driven by a 
transcription factor known as autoimmune regulator (AIRE) that is selectively 
expressed by the mTECs thus enabling the negative selection of tissue-specific 
autoreactive T cells in the medulla (Anderson et al., 2002). The critical role of AIRE 
in tolerance induction is illustrated by the multi-organ autoimmunity developing in 
patients and mice deficient for AIRE (Anderson et al., 2002; Peterson et al., 1998). 
The autoimmune disease observed in various mouse strains that have impaired 
medullary characteristics further elucidates the importance of the medullary 
architecture for establishing central tolerance: REL-B deficient mice, Nikaly/Nikaly, 
which carry the alymphoplasia mutation in Nik (nuclear factor-#B (NF-#B)-inducing 
kinase); lymphotoxin-! receptor (LT-!R)- deficient mice and tumor necrosis factor 
(TNF)-receptor-associated factor-6 (TRAF-6)-deficient mice. All of these mutant 
mouse strains show reduced levels of AIRE, which promotes the expression of 
peripheral tissue-specific antigens by mTECs (Hogquist et al., 2005).  
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In addition to mTECs, the majority of thymic DCs are resident in the medulla and 
have an important role in central tolerance as they can cross-present antigens that are 
synthesized by mTECs and inducing the apoptosis of self-reactive thymocytes 
(Gallegos and Bevan, 2004). mTECs might also contribute to central tolerance 
through their regulated expression of co-stimulatory molecules such as CD40, CD80 
(B7-1) and CD86 (B7-2) (Hogquist et al., 2005).  
The thymic architecture spatially separates positive (cortex) and negative selection 
(medulla) events during thymocyte development, however a key question for 
understanding clonal deletion is how a DP thymocyte can discriminate between 
various peptide-MHC ligands and initiate distinct positive and negative selection 
signals. The strength of interaction between the TCR and pMHC complexes 
expressed by the TECs is a crucial parameter of selection; with thymocytes that 
recognise self-peptide MHC with low affinity undergo positive selection, whereas 
those with high affinity undergo negative selection (Starr et al., 2003). There are 
currently two proposed mechanisms of how a developing thymocyte might make the 
distinction between low and high affinity signals. First is a “zipper” model, which 
suggests that low and high affinity interactions trigger qualitatively different 
responses, (Palmer and Naeher, 2009). It is based on the observation that a single 
pMHC complex can engage and activate multiple TCRs over time and by increasing 
the number of TCR interactions, serial triggering leads to multiplication of pMHC 
induced TCR signals (Rachmilewitz and Lanzavecchia, 2002; Valitutti et al., 1995). 
The model posits that a high-affinity TCR-pMHC complex induces a stable 
“zippering” between the membrane proximal domains of CD8 % and ! TCR chains, 
which causes stronger signal transduction leading to negative selection. Conversely a 
low-affinity interaction leads to incomplete zippering and partial phosphorylation of 
CD3 immunoreceptor tyrosine-based activation motif (ITAM), consequently 
triggering positive selection (Palmer and Naeher, 2009).  
The second model is the kinetic proof reading model of T cell activation, which takes 
into account the dwell time of pMHC complex binding with the TCR (McKeithan, 
1995). This model proposes that a high-affinity pMHC would occupy the TCR for a 
longer time (slower off-rate) and have a longer half-life providing sufficient time for 
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the formation of fully activated TCR-CD3 complexes while a low-affinity pMHC 
would have a faster off-rate and a shorter half-life resulting in partial activation of 
TCR-CD3 complexes (Kalergis et al., 2001; Kersh et al., 1998; Savage and Davis, 
2001). Support for this model comes from surface plasmon resonance studies that 
show that high-affinity pMHC ligands occupy the TCR for a longer period of time 
with slower-off rates (Alam et al., 1996). In terms of signal transduction, low-affinity 
ligands would induce a set of early TCR signals, whereas the high-affinity ligands 
would induce both early and late TCR signals (Palmer, 2003).  
Differential activation of signalling pathways has been shown to direct the fate of 
developing thymocytes. One signalling pathway proposed to be involved in positive 
versus negative selection is the extracellular signal regulated kinase (ERK) belonging 
to mitogen activated protein kinase (MAPK) pathway. Low affinity-pMHC (positive 
selecting) ligands induce ERK activation more slowly and over long sustained 
periods of time resulting in positive selection. Whereas the high-affinity negative 
selecting ligands induce a rapid and robust ERK activation, which is associated with 
death (Mariathasan et al., 2001; McNeil et al., 2005). Additionally the cellular 
localisation of ERK is influenced by signal strength and determines the positive and 
negative selection in thymocytes, with strong signals recruiting ERK to the plasma 
membrane while weak positively selecting signals recruiting ERK to the Golgi 
complex (Daniels et al., 2006). Another key T cell specific protein, called thymocyte 
expressed molecule involved in selection (THEMIS), seems to be involved in 
determining the strength and kinetics of Ca2+ influx and phosphorylation of ERK (Fu 
et al., 2009). This facilitates TCR recognition of very fine differences in affinities 
(analogue input) and converts it into clear-cut selection outcome (digital output). 
Finally, changes in gene expression induced by high-affinity interaction are also 
known to be important in cells undergoing clonal deletion. Two genes that are 
consistently upregulated are Nur77 and Bim, which are important in inducing self-
reactive thymocytes to apoptose (Baldwin and Hogquist, 2007). 
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1.4.3 Peripheral Tolerance 
Negative selection in the thymus does not eliminate all self-reactive lymphocytes, in 
part because not all self-antigens are expressed in the thymus. This holds true for 
epitopes recognized by T cells causing EAE, MS or T1D, where the limited 
availability of these epitopes in thymus results in incomplete negative selection, such 
that the escaping T cell clones can be activated in the periphery where these antigens 
are more abundant (von Boehmer and Melchers, 2010). In addition, autoreactive T 
cells escape negative selection in the thymus when their TCR avidity for self-pMHC 
is sufficiently low (Liu et al., 1995; Zehn and Bevan, 2006). Therefore, peripheral 
tolerance mechanisms act to control the activation of potentially self-reactive mature 
T cells to prevent them from causing autoimmunity.  
One of the principle regulatory mechanisms in maintenance of peripheral immune 
tolerance is mediated by regulatory T cells, which express Foxp3 and suppress 
immune responses through numerous mechanisms, including production of anti-
inflammatory cytokines, direct cell-cell contact and by modulating the activation 
state and function of APCs (Sakaguchi et al., 2008; Vignali et al., 2008). The 
development and function of Tregs is dependent on the activity of Foxp3. Induced 
knockout or spontaneous mutation of mouse Foxp3 gene (Scurfy mice) led to a 
systemic autoimmune disease associated with absence of Tregs (Fontenot et al., 
2003; Hori et al., 2003; Khattri et al., 2003). Similarly, mutations in the human 
Foxp3 gene cause immunodysregulation, polyendocrinopathy, enteropathy X-linked 
syndrome (IPEX) a fatal disorder known to share several features with common 
scurfy mice. In addition, to high constitutive expression of IL-2 receptor alpha chain 
(CD25) Tregs are positive for CTLA4 and GITR and express low levels of the IL-7 
receptor alpha chain (CD127) (Shevach, 2009). Tregs are generated in the thymus by 
intermediate affinity interaction with agonist ligands therefore recognition of self-
reactive TCR ligands is a key event initiating Treg development (Itoh et al., 1999; 
Jordan et al., 2001). Besides TCR signal strength, costimulation signals mediated by 
CD28 and IL-2 are required for survival of Tregs (Hsieh et al., 2012). Both in vitro 
and in vivo studies have shown the importance and ability of cytokine TGF! in 
          Chapter 1 
    18 
converting mature T cells to the Treg lineage in the peripheral lymphoid organs 
(Apostolou and von Boehmer, 2004).  
Ignorance is one of the simplest mechanisms of peripheral tolerance mechanism, 
wherein low-affinity self-reactive T cells ignore self-antigen in the periphery either 
because the self-antigens are sequestered in sites that are not easily accessible 
‘immune privileged sites’ e.g. the physical blood-brain or because they are not 
present in sufficient quantities to overcome a threshold and trigger a T cell response 
(de Souza et al., 2010). Alternatively, encounters of T cells with self-antigens in the 
absence of co-stimulatory signals, might lead to a state of long-term 
hyporesponsiveness or functional inactivation called anergy that is characterised by 
an active repression of TCR signalling and IL-2 expression (Schwartz, 2003). 
Co-stimulatory pathways provide the secondary signal crucial for T cell activation 
and is achieved mainly by the interaction of the CD28 molecules on T cells and the 
B7 molecule family (CD80 and CD86) present on the surface of APCs (de Souza et 
al., 2010). Besides promoting T cell activation, co-stimulatory pathways can also 
provide negative signals that inhibit T cell responses. Two key molecules that are 
upregulated in anergic cells are programmed death 1 receptor (PD-1), its ligand PD-
L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Evidence that PD-1 
plays a critical role in control of self-reactivity is demonstrated by development of 
lupus-like autoimmune disease in mice lacking PD-1 (Pdcd-1-/-), which develop 
lupus-like autoimmune disease (Nishimura et al., 1999). CTLA4 is a CD28 
homologue with inhibitory function (Krummel and Allison, 1995; Walunas et al., 
1996). Ctla4-/- mice show lethal lymphoproliferative disorder (Tivol et al., 1995), in 
addition CTLA4-deficient CD4+ T cells are resistant to anergy induction in vivo 
(Perez et al., 1997).  
Another effective mechanism of peripheral tolerance is deletion of autoreactive T 
cells by activation induced cell death (AICD). Two apoptotic pathways exist in 
mammals – a cell intrinsic and a cell extrinsic pathway, which converge when the 
caspase cascade is activated (Leavy, 2008). The cell extrinsic pathway is induced by 
engagement of the Fas receptor (CD95) by FasL (CD178) and induction of Bim- 
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dependent triggering of a Bcl-2 and Bcl-xL regulated mitochondrial death pathway 
(Marrack and Kappler, 2004). Mice that carry mutations in Fas (Fas-deficient lpr or 
lprcg mice or FasL-deficient gld mice) are not able to engage the AICD pathway 
develop progressive lymphadenopathy and splenomegaly (Cohen and Eisenberg, 
1991). Defects in the Fas pathway in humans are also associated with autoimmune 
lymphoproliferative syndrome (de Souza et al., 2010). Initiation of the cell-intrinsic 
pathway involves the activation of pro-apoptotic B-cell lymphoma 2 (Bcl-2)-family 
members such as Bcl-2-interacting mediator of cell death (Bim). Mice deficient for 
Bim are also resistant to apoptosis, and with age these mice spontaneously develop 
immune complex-mediated glomerulonephritis (Bouillet et al., 1999). In contrast to 
AICD, the killing of the antigen-activated T cells during down-regulation of an 
immune response to an acute infection requires Bim and not Fas (Bouillet et al., 
2002). 
1.4.4 Autoimmunity  
When mechanisms of self-tolerance fail autoimmunity ensues and the subsequent 
malfunction of the immune system resulting in inflammation and tissue destruction 
causes autoimmune disease. Autoimmunity is thought to result from a combination 
of genetic variants and acquired environmental triggers such as infections (Rioux and 
Abbas, 2005). Classic examples include type 1 diabetes, a chronic polygenic disease 
in which the pancreatic !-cells (which produce insulin) are selectively destroyed by 
autoreactive CD8+ T cells and innate immune cells (Lehuen et al., 2010) and 
rheumatoid arthritis resulting from the uncontrolled inflammation of synovial joints 
driven by a dysregulation of Th1 immune response (Burmester et al., 2014).  
The environmental triggers for autoimmune diseases act in the presence of genetic 
predisposition to the disease. Many studies implicate infection as a trigger for 
developing autoimmune diseases mainly, as it can readily disrupt peripheral 
tolerance by exposure of self to the immune system through breakdown of immune 
system barriers (Javierre et al., 2011). In addition, there is the alternative, or perhaps 
complementary, process of molecular (antigenic) mimicry, whereby an antigen of a 
microorganism or a constituent of food that sufficiently resembles a self-molecule 
          Chapter 1 
    20 
can induce a cross-reactive autoimmune response (Kindt et al., 2007). This is 
highlighted by the detection of serum autoantibodies that also recognise pathogenic 
epitopes, for example the anti-SM autoantibodies obtained from SLE patients are 
also reactive with the EBNA-1 epitope of Epstein Barr virus (Javierre et al., 2011). 
Genetic susceptibility has a major role in autoimmunity. Genome wide association 
studies have identified polymorphisms in over 200 bona fide loci, which contribute 
to autoimmune diseases and many of which are common to different autoimmune 
diseases (Cho and Gregersen, 2011). These include genes encoding molecules of 
MHC complex, TCR and BCR, and those important in maintenance of peripheral 
tolerance and apoptosis such as Bim.  
1.5 T Cell Receptor Signal Transduction 
T cells are central players in the adaptive immune system and effective adaptive 
immunity relies critically on the antigen specific activation of naive resting 
lymphocytes. T cells are activated by ligation of a clonotypic T cell receptor with 
antigenic peptide bound to MHC molecules presented on the surface of antigen 
presenting cells. This interaction originates with engagement of the TCR at the 
immunological synapse, which further triggers, several signal transduction pathways 
that involve protein kinases, protein phosphatases, adapter proteins, second 
messengers and key intermediates (Mustelin and Tasken, 2003).  
The first signalling molecules that are activated following TCR ligation feed into 
radiating and intricately branched network of signalling cascades that culminates 
with the induction of gene transcription, which then initiates a diverse array of 
developmental and functional events such as differentiation, proliferation and 
cytokine production that are optimally tailored to provide an appropriate immune 
response. In addition, the selection, survival and proper development of T cells also 
depend on signals emanating from the TCR.  
The complex signalling cascade resulting in T cell activation can be conveniently 
divided into signal initiation, propagation and diversification, each of which involves 
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a separate yet interconnected module of signalling molecules that are regulated to 
fine-tune the TCR response. 
1.5.1 TCR Signal Initiation  
The TCR complex consists of the TCR%! (or TCR$') heterodimer plus three pairs of 
the invariant signalling protein CD3 subunits (CD3"-CD3$, CD3"-CD3' and CD3(-
CD3() (Wucherpfennig et al., 2010). T cell signalling is initiated by engagement of 
the TCR-CD3 complex with the processed antigenic peptide bound to MHC 
molecules on the surface of antigen presenting cells. The TCR-CD3 complex lacks 
intrinsic enzymatic activity and relies on the recruitment and activation of the Src 
family of protein kinases (SFKs): Lck (p56-Lck) and (p59-Fyn) (Palacios and Weiss, 
2004; Salmond et al., 2009) which bind the cytoplasmic domains of the TCR co-
receptors CD4 and CD8 (Veillette et al., 1988). SFKs are important for providing 
tonic survival TCR signals in naïve T cells (Seddon and Zamoyska, 2002). 
Approximately 40% of Lck is constitutively active in naïve cells that maintain a 
basal state of phosphorylation of TCR associated CD3( chains (Nika et al., 2010; 
Stefanova et al., 2002). The activity of Lck is tightly regulated by the 
phosphorylation states of two tyrosine (Tyr) residues – the inhibitory residue Tyr505 
in the C-terminal domain and the activating Tyr394 residue in the catalytic domain. 
Phosphorylation of Tyr505 residue by C-terminal tyrosine Src kinase (Csk) stabilises 
an inactive closed conformation of Lck. The complete kinase activity of Lck is 
achieved by relieving the closed inactive form; by dephosphorylation of the Tyr505 
residue by the phosphatase, CD45 and the auto-phosphorylation of Tyr394 residue, 
which stabilises the active open confirmation (Fig 1.3 insert). The activating 
tyrosine residue is dephosphorylated by several phosphatases including CD45 and 
the cytosolic phosphatases PTPN6 and PTPN22.  
Once activated, Lck phosphorylates the immunoreceptor tyrosine based activation 
motifs (ITAMs) present on the cytoplasmic domain of the CD3 subunits. These 
phosphorylated ITAMs provide docking sites for the recruitment of zeta-associated 
protein kinase of 70 kDa (ZAP-70) via its tandem Src homology-2 (SH2) domains 
(Chan et al., 1992). The binding of ZAP-70 molecules to the ITAMs unlocks ZAP-70 
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from its inactive configuration (Deindl et al., 2007), allowing it to be auto-
phosphorylated and activated by phosphorylation at the Tyr493 residue by Lck. This 
promotes its kinase activity and results in further downstream phosphorylation of its 
target substrates, that including the key adaptor molecule, linker for activation of T 
cells (LAT) (Smith-Garvin et al., 2009). 
1.5.2 TCR Signal Propagation 
The presence of 10 ITAMs in the TCR complex, allows up to 10 ZAP-70 molecules 
to cluster to the TCR-CD3 complex. Two adapter molecules, LAT and SH2 domain 
containing leukocyte phosphoprotein of 76-kDa (SLP-76), comprise the important 
first targets of ZAP-70 in this multi molecular complex and form the focal point for 
integration and activation of multiple signalling pathways (Acuto et al., 2008). Both 
LAT and SLP-76 are crucial for TCR signalling as loss of either LAT or SLP-76 
results in complete loss of TCR signal transduction (Smith-Garvin et al., 2009). The 
cytosolic tail of LAT contains nine conserved tyrosine residues (Sommers et al., 
2004), which upon phosphorylation following TCR engagement binds SH2 domain 
containing proteins, including phospholipase C gamma (PLC-$), phosphoionositide 
3-kinase (PI3K), the adapters Grb2 and Grb2-related adapter downstream of Shc 
(Gads) (Smith-Garvin et al., 2009). SLP-76 is recruited to the LAT through its 
constitutive interaction with Gads. The complex of LAT-Gads-SLP76 complex 
forms LAT signalosome (Malissen et al., 2005) (Fig 1.3) and is responsible for the 
recruitment of several other signalling molecules such as PLC-$, the adaptors Gads2, 
Nck and ADAP (adhesion and degranulation promoting adaptor protein), the Rho 
family GTPase exchange factor Vav, IL-2 induced tyrosine kinase (Itk) and 
hematopoietic progenitor kinase 1 (HPK1) (Koretzky et al., 2006; Smith-Garvin et 
al., 2009).  
The cooperative binding of LAT and SLP-76 serve to precisely nucleate a large 
effector complex, which result in the activation of PLC-$ by Itk-mediated 
phosphorylation. Activated PLC-$ hydrolyses and cleaves the membrane lipid, 
phosphatidylinositol 4,5-bisphosphate (PIP2) producing the second messenger 
inositol 1, 4, 5 – triphosphate (IP3) and diacylglycerol (DAG) (Fig 1.3).  
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PLC-$ mediated IP3 production stimulates the Ca2+ permeable ion channel receptors 
IP3R on the ER membrane to release Ca2+ from intracellular storage reserves into the 
cytoplasm. On depletion of the ER Ca2+ reserves, there is a sustained influx of 
extracellular Ca2+ by the ‘store operated’ mechanism of Ca2+ entry through the 
CRAC channels in the plasma membrane (Oh-hora and Rao, 2008). Increase in the 
intracellular levels of Ca2+ due to sequential release from the internal and external 
reserves acts as an important trigger for activation of transcriptional factors and 
signalling proteins such as calcineurin and Ca2+ calmodulin dependant kinase 
(CaMK) (Smith-Garvin et al., 2009). Ca2+ activates calcineurin that 
dephosphorylates the nuclear factor of activated T cells (NFAT), this results in its 
translocation to the nucleus where it complexes with activator protein (AP-1) that 
results in the production of IL-2 (Rao et al., 1997; Smith-Garvin et al., 2009).  
TCR induced production of DAG results in the activation of two major signalling 
pathways involving Ras and Protein Kinase C (PKC)). Ras, a small G protein 
activated by GTP, is required for the activation of the serine threonine kinase Raf-1 
that initiates a cascade of protein kinases known as the mitogen activated protein 
kinase (MAP Kinase) pathway. Phosphorylation of the end product of this pathway 
MAP kinase (ERK-1 and ERK-2) allows it to activate Elk, a transcription factor 
necessary for the activation of Fos. Phosphorylated Fos associates with Jun and 
together they are known as AP1, which is an essential transcription factor for T cell 
activation (Genot and Cantrell, 2000). 
The other signalling pathway regulated by DAG is PKC),  a PKC family member 
with specific lipid binding domain for DAG. PKC) is implicated in the regulation 
and activation of crucial transcription factor nuclear factor kappa B (NF-kB). TCR 
stimulation leads to the assembly of a trimolecular membrane bound complex of 
proteins that include CARMA1, BCL-10 and MALT1. This complex, once 
assembled drives the activation of IKK (inhibitor of #B kinase). a multiprotein 
enzyme which phosphorylates the inhibitor of #B, (I#B). In resting cells, I#B bound 
NF-#B is retained it in the cytosol. IKK mediated phosphorylation of I#B, releases 
NF-#B which migrates to the nucleus, where it activates genes involved in the 
function, survival and homeostasis of T cells (Hayden and Ghosh, 2011). 
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1.5.3 TCR Signal Diversification 
Antigen stimulation of T cells induces their strong adhesion to the APCs. This 
adhesion is mediated mainly by activation of surface integrin molecules on T cells. 
The major integrins expressed by T cell surface are leukocyte function associated 
antigen-1 (LFA-1) and very late antigen (VLA-4), which bind their respective 
ligands: intracellular adhesion molecules (ICAM-1) and vascular cellular adhesion 
molecule (VCAM), and fibronectin on other immune cells, endothelial cells, 
fibroblasts and extracellular matrix proteins. TCR mediated signalling results in 
conformational change of the integrins which increases their affinity for their ligands 
triggering ‘inside-out’ signals from TCR to integrins (Menasche et al., 2007).  
The signals that regulate integrin activation following TCR stimulation are still 
unclear, however the small GTPase Ras-proximity-1 (Rap1) is thought to be an 
important player, by increasing TCR induced adhesion to ICAM-1 (Katagiri et al., 
2003; Sebzda et al., 2002). In addition, some elements of the LAT signalosome are 
also known to be critical for the inside out signalling and include the cytosolic 
adaptor ADAP that constitutively associates with another adapter protein, Src kinase-
associated phosphoprotein of 55 kDa (SKAP-55). Both of which interact with SLP-
76 in the signalosome. The ADAP/SKAP-55 complex recruits RAP-1 via a third 
adapter, Rap1-GTP interacting adapter molecule (RIAM). This is constitutively 
bound to SKAP-55 and associates with activated RAP-1 upon TCR ligation, 
resulting in the localisation of RAP-1 to the membrane (Smith-Garvin et al., 2009). 
Activated RAP-1 is also known to associate with the regulator of cell adhesion and 
polarisation enriched in lymphoid tissues (RAPL), which is localised in the 
membrane and binds to LFA-1(Katagiri et al., 2003).  
This model of ADAP/SKAP-55 mediated activation of RAP1 initiated LFA-1 
signalling is a major pathway of integrin activation in many T cell subsets, however 
an alterative route of LFA-1 activation by Tregs has been reported. Using a knock-in 
mouse containing a point mutation in the kinase domain of ZAP-70 (ZAP-70AS), 
Au-Yueng et al. showed that the kinase activity of ZAP-70 could be selectively 
inhibited in in vitro cultured ZAP-70AS T cells by a specific small molecule 
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inhibitor (Au-Yeung et al., 2010). 70AS). They further showed that inhibition of 
ZAP-70 kinase activity in peripheral T cells abrogated the activation and effector 
function of T cell subsets, but interestingly had no effect on GTP-bound RAP-1 
activity of the Treg subset (Au-Yeung et al., 2010). Recruitment of kinase dependent 
SLP-76- VAV1/ADAP to LAT does not occur in the absence of phosphorylation of 
tyrosine residues on LAT, however ZAP-70 itself can act as an adaptor molecule for 
‘inside-out’ signalling. Therefore, signals initiated from the TCR can diversify either 
through the generation of LAT signalosome or through the associated adaptor 
function of ZAP-70 kinase. 
1.5.4 Regulation of TCR signalling 
As outlined above, signals through the TCR are driven by an array of biochemical 
events that ultimate lead to activation of multiple effector pathways. Activation of T 
cells is actively regulated both positively and negatively to allow the signals to be 
controlled and halted and to ensure an appropriate response. The negative regulation 
of TCR signalling is mediated both through by regulating the pathways and the 
different molecules involved in the signalling cascade and include inhibitory 
membrane-bound receptors such as CTLA4, PD1 and CD5 which recruit tyrosine 
phosphatases (Acuto et al., 2008). The importance of these receptors in TCR 
signalling is underscored by the observation that deficiency of PD1 and CTLA4 
results in lupus like disease and lymphoproliferative disease in humans and mice 
respectively (Nishimura et al., 1999; Tivol et al., 1995). Even though CD5 deficiency 
does not cause any immune disorders, the mice display altered T cell development 
(Tarakhovsky et al., 1995). In addition, no overt phenotype is seen in mice lacking 
inhibitory membrane scaffold proteins such as phosphoprotein associated 
glycosphingolipid-enriched microdomains (PAG) and Lck-interacting membrane 
protein (LIME) despite their pivotal role in recruiting kinases and phosphatases to 
the immunological synapse, suggesting there are multiple mechanisms that 
compensate for the loss of these molecules (Acuto et al., 2008). 
One of the most critical and actively regulated module of TCR signalling event is the 
SFK component, Lck. Opposing actions of Csk and CD45, either phosphorylates or 
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dephosphorylates the inhibitory Tyr505 residue resulting in inactive or active forms of 
Lck (Veillette et al., 2002). In addition, the activity of Lck is also regulated by 
dephosphorylation of the activating Tyr394 residue by cytoplasmic phosphatase 
PTPN22, which is recruited to the plasma membrane via its association with Csk 
(Cloutier and Veillette, 1996, 1999). Furthermore, fine-tuning of the TCR signals to 
distinguish between strong and weak ligands occur by dephosphorylation of the 
active site of Lck by another phosphatase, SHP-1 in the presence of weak antagonist 
signals (Stefanova et al., 2003). Conversely, in the presence of strong agonist TCR 
signals, ERK is rapidly activated and phosphorylates Ser59, which prevents the SHP-
1 binding, thus keeping Lck active to sustain TCR signals and further amplify ERK 
activity (Stefanova et al., 2003).  
The activity of SFK within the lipid rafts may be regulated by the transmembrane 
adapter molecule PAG. In resting T cells, Csk is localised to the lipid rafts by 
interaction of its SH2 domain with constitutively phosphorylated PAG tyrosine 
residues Tyr314/ Tyr317 (in mice and humans respectively) (Brdicka et al., 2000). The 
association of PAG with Csk enables Csk to modify both Lck and Fyn in resting cells 
by phosphorylating the negative regulatory tyrosine residues, promoting a closed 
conformation. Upon TCR ligation Fyn phosphorylates PAG at the Tyr314 residue 
(Filby et al., 2007; Yasuda et al., 2002), which releases Csk and results in its loss 
from the lipid rafts (Davidson et al., 2007). Of note, PAG association with Csk is 
probably not the the only mechanism by which Csk gets to the membrane, as PAG-/- 
mice do not show any T cell phenotype and Csk was independently recruited to the 
plasma membrane (Dobenecker et al., 2005; Xu et al., 2005). 
Adaptor proteins, Dok-1 and Dok-2 have been reported to be involved in attenuating 
the TCR signalling (Yasuda et al., 2007). Dok can associate with several negative 
regulators including SHP-1, Csk and RasGAP (Dong et al., 2006). Recently 
Schoenborn et al. described a potential interaction between Dok1 and Csk that may 
contribute to negative regulation of Lck activity in response to TCR ligation 
(Schoenborn et al., 2011). Consistent with their role in negatively regulating TCR, 
Dok1-/- Dok2-/- mice have increased TCR induced IL-2 production and proliferation 
with prolonged phosphorylation of ZAP-70, LAT, SLP-76 and Akt. Furthermore, 
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these mice develop a lupus-like renal disease with high anti-double stranded DNA 
antibody titers (Dong et al., 2006; Yasuda et al., 2007). 
In addition to regulating the early/proximal signalling mechanism, downstream 
adaptor SLP-76 can also be a target of negative regulation. The serine/threonine 
kinase HPK1 upon Lck-mediated activation inducibly binds the SH2 domain of SLP-
76 and phosphorylates a serine residue; Ser376. This mediates recruitment of the 14-3-
3 family of ubiquitously expressed regulatory proteins (Di Bartolo et al., 2007). 
Recruitment and HPK1 mediated phosphorylation of SLP-76 occurs 10-15 minutes 
post TCR stimulation and lasts up to an hour (Di Bartolo et al., 2007) suggesting a 
late time point in regulation of the TCR signalling cascade. In support of its role as a 
negative regulator, HPK-1 deficiency results in enhanced TCR-dependent tyrosine 
phosphorylation of SLP-76, PLC$, LAT, Vav1 and ZAP-70, leading to development 
of a severe form of EAE in mice (Shui et al., 2007).  
Besides phosphorylation, early T cell receptor responses are also modulated by 
ubiquitin ligases of Casitas B-lineage lymphoma family (CBL) through degradation 
of components of the TCR signalling machinery, including CD3(, ZAP-70, PLC$, 
phosphoinositide 3-kinase (PI3K) and PKC) (Loeser and Penninger, 2007). The Cbl 
family of proteins comprising of c-Cbl and Cbl-b, are ubiquitously expressed in 
hematopoietic cells and contain a ring finger domain through which they interact 
with E2 ubiquitin ligases (Thien and Langdon, 2001). c-Cbl is highly phosphorylated 
upon TCR stimulation. It is recruited to the TCR-CD3 complex through its 
interaction with src-like adaptor protein SLAP in T cells. In addition c-Cbl can 
associate via its SH2 domain with tyrosine phosphorylated Lck, Fyn, ZAP-70 and 
LAT leading to their ubiquitylation (Janssen and Zhang, 2003). c-Cbl-/- mice have 
increased thymocyte numbers, with DP cells being hyper-responsive to stimuli, 
demonstrating increased phosphorylation of CD3, TCR!, Lck and Fyn (Murphy et 
al., 1998). Furthermore, in mice deficient in c-Cbl there is increased expression of 
TCR, CD3, CD4, CD5 and CD69 (Murphy et al., 1998; Naramura et al., 2002). In 
agreement with its role in negative regulation of TCR signals, overexpression of c-
Cbl in Jurkat T cells leads to the inhibition of the transcription factors AP1 and 
NFAT (Rellahan et al., 2003). 
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1.6 Phosphatases 
Protein phosphorylation is a widely used in post-translational modification and is a 
fundamental part of cellular information processing regulating numerous 
physiological functions, including immune defences. The human genome encodes at 
least 518 protein kinases (PTKs) of which 90 are specific for phosphorylation of 
tyrosine residues (Mustelin et al., 2004). Protein tyrosine phosphatases (PTPases) are 
enzymes that remove the phosphates from the Tyr substrates. A dynamic balance 
between tyrosine phosphorylation and dephosphorylation is crucial for the 
maintenance of homeostasis and proper regulation of the immune system. 
Aberrations in phosphorylation can have profound consequences, such as 
dysregulation in apoptosis or cell cycling, and the onset of malignancies. Protein 
tyrosine phosphatases play a crucial role in keeping T cells in a resting state in the 
absence of antigens as well as reversion of activated T cells back to the resting 
phenotype upon removal of the activating stimulus (Mustelin et al., 2004). 
Based on their structure and specificities of target substrates human PTPases can be 
divided into four major subfamilies; class I, class II, class III which all use cysteine 
as a nucleophile for catalysis and class IV PTPs which use aspartic acid as a 
nucleophile (Alonso et al., 2004). Class I PTPases represent the largest sub-family 
containing 99 members, further subdivided into 38 well known “classical” tyrosine 
specific which have mouse homologues and 61 “dual specific” PTPases (DSPs) 
which have diverse substrate specificities (Andersen et al., 2004). The classical PTPs 
can be further divided into non-receptor (NRPTPs), intracellular PTPs that contain a 
single catalytic domain and various amino- or carboxy- terminal domains. Examples 
include SHP1, SHP2 and the PEST family of phosphatases including PTPN22 and 
the transmembrane receptor like PTPs (RPTPs). The latter generally have an 
extracellular, putative ligand binding domain, a single transmembrane region and one 
or two cytoplasmic PTP domains and include CD45 and CD148 phosphatases 
(Andersen et al., 2004).  
The DSPs which also belong to class I phosphatase contain VH1-like phosphatases 
(as the first DSP cloned was the VH1 protein from Vaccinia virus) that have very 
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diverse specificities such as: phospho-tyrosine and phospho-threonine for MAP 
kinase phosphatases (MKPs): phospho-inositides in the case of PTEN (Alonso et al., 
2004). Class II phosphatases contain only one member, the low molecular weight 
PTP (LMPTP) that consists of a single-phosphatase domain. Class III phosphatases 
have 3 members, CDC25A, CDC25B and CDC25C. These cysteine based PTPs 
dephosphorylate inhibitory tyrosines on CDKs to initiate progression of cells through 
the cell cycle (Honda et al., 1993). The last group, class IV PTPs use aspartate – 
based mechanisms for catalysis and has 4 members known as EyA but their 
biological function remains unknown (Tootle et al., 2003).  
1.7 Phosphatases in autoimmunity 
Protein tyrosine phosphatases (PTPs) act in a coordinated manner with protein 
tyrosine kinases to control cell signalling thereby regulating various physiological 
processes (Tonks, 2006). Both receptor-type and non-receptor type PTPs have been 
implicated in TCR mediated signal transduction. Some positively regulate 
lymphocyte activation and development (CD45 and CD148), whereas others inhibit 
these processes (SHP1, PTPN2, PTPN22, PTP-PEST). Alteration of the expression 
or activity of PTPs involved in TCR signal regulation has been shown to cause 
immunopathology in mice and recent genome wide association studies have 
identified a large number of single nucleotide polymorphisms in PTPs that are linked 
to several human autoimmune diseases (Consortium, 2007; Todd et al., 2007). These 
studies highlighted the link between dysfunctional regulation of phosphorylation and 
disease, underscoring the need to elucidate the underlying regulatory mechanisms 
controlled by phosphatases. 
CD45 (PTPRC) 
Protein Tyrosine Phosphatase receptor Type C (PTPRC), also known, as CD45 is a 
large 180 - 220 kDa receptor type PTP encoded by the PTPRC gene, which is 
abundantly expressed in all hematopoietic cells except red cells and exists in 
different functional isoforms {reviewed in (Hermiston et al., 2003; Vang et al., 
2008)}. Structurally, CD45 comprises of an N terminal extracellular domain of 
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variable length, followed by fibronectin-type repeats, a transmembrane segment and 
a cytoplasmic tail containing 2 consecutive PTP domains, of which only membrane 
proximal domain is functionally active and is capable of auto-inhibition by 
homodimerasation (Xu and Weiss, 2002). CD45 positively regulates T cell activation 
by dephosphorylating the inhibitory tyrosine residues of SFKs Lck and Fyn (Tyr505 
in Lck and Tyr528 in Fyn) (Ostergaard et al., 1989). CD45 is an important regulator of 
signal transduction via the TCR complex at multiple stages of T cell development, 
evident from the studies demonstrating that CD45 deficient mice have few peripheral 
T cells owing to impaired thymic development (Byth et al., 1996; Kishihara et al., 
1993). Similar to its role in T cells, CD45 dephosphorylates the C terminal tyrosine 
of Lyn in B cells however their activation is only partially compromised in CD45-
deficient mice (Katagiri et al., 1999). 
Some studies also implicate a negative role for CD45. Where it is responsible for 
dephosphorylating the positive regulatory site on Lck (Tyr394) thus leading to Lck 
inactivation (Mustelin et al., 1989). Given the ability of CD45 to dephosphorylate the 
activatory and inhibitory tyrosine of SFKs, these two functions need to be 
differentially regulated in cells. It is possible that phosphorylation state of Lck 
dictates the action of CD45 resulting in the dephosphorylation of the activating or 
inhibitory tyrosine residue. It is thought that CD45 is temporally sequestered from 
the vicinity of Lck once it is activated, so that it cannot be inactivated. In keeping 
with this idea, several studies show that CD45 is transiently present in the lipid rafts, 
sufficient to activate Lck, but is excluded from the immune synapse upon activation 
(Edmonds and Ostergaard, 2002; Freiberg et al., 2002; Penninger et al., 2001). In 
addition to directly modulating Lck and Fyn, CD45 also dephosphorylates PAG at 
Y314, inhibiting Csk recruitment from the cytosol, which in turn phosphorylates the 
inhibitory Tyr505 residue on Lck downregulating its function in activated T cells 
(Davidson et al., 1997).  
In accordance with the function of CD45 in promoting cell activation, the nucleotide 
polymorphism C77G in the gene encoding CD45 gene that results in impaired 
dimerization of CD45 has been found at greater frequency in a cohort of patients 
with multiple sclerosis and autoimmune hepatitis than in healthy controls (Jacobsen 
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et al., 2000). Though a subsequent study was unable to replicate these results 
(Barcellos et al., 2001). Therefore evidence from studies in both mouse and human 
studies highlight the importance of CD45 in regulation of the immune system and its 
perturbation maybe linked to autoimmunity.  
CD148 (PTPRJ) 
Similar to CD45, CD148 is a receptor-type PTP encoded by PTPRJ, however it is 
distinguished from CD45 in possessing an extracellular domain containing five 
fibronectin-type repeats and only a single PTP domain. Although in humans CD148 
is expressed in both B and T cells, in mouse high expression is only seen in B cells 
and not in T cells (Hermiston et al., 2009). Mice lacking CD148 show partially 
blocked B cell development and decreased B cell activation due to increased 
phosphorylation of the inhibitory C terminus residue (Tyr507) of major B cell SFK, 
Lyn (Zhu et al., 2008). The functions of both CD45 and CD148 are analogous and 
perhaps redundant, in support of this notion, mice lacking both CD45 and CD148 
show a greater block in B cell development and BCR signalling than mice with either 
CD45 or CD148 deficiency (Zhu et al., 2008). In addition augmented expression of 
CD148 in CD45-deficienct Jurkat T cells ‘rescues’ the defect in TCR signalling 
further supporting the complementary roles of CD45 and CD148 in T cell signalling.  
SHP1 (PTPN6) 
SHP-1 (encoded by PTPN6) and SHP-2 (encoded by PTPN11) are two related 
mammalian intracellular PTPs containing tandem amino-terminal SH2, domains, a 
central phosphatase domain and a carboxyl terminal domain with potential tyrosine 
phosphorylation sites {reviewed in (Lorenz, 2009; Vang et al., 2008)}. While the 
expression of SHP-1 is restricted to hematopoietic cells and epithelial cells, SHP-2 is 
ubiquitously expressed. The predominant mechanism of activation of SHP-1 is 
mediated by engagement of its SH2 domains, through which it interacts with 
receptors carrying an immunoreceptor tyrosine based inhibitory motif (ITIM) in their 
cytoplasmic tails.  
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The immunological importance of SHP-1 comes from the study of motheaten mice 
that have mutant SHP-1, which is characterized by spotty hair loss and abnormal 
immune system functioning and leukocyte types (Shultz et al., 1997; Shultz et al., 
1993; Tsui et al., 1993). T lymphocytes from these mice are hyper-responsive to 
TCR stimulation (Pani et al., 1996). Defects in T cell development have been 
observed, and the thymus involutes at an early stage (Shultz et al., 1997). Together 
these studies suggest that T cell activation is negatively regulated by SHP-1, in part 
this is mediated through direct dephosphorylation of ZAP-70, resulting in decreased 
downstream signalling (Brockdorff et al., 1999).  
In contrast to SHP-1, the closely related SHP-2 does not appear to be a negative 
regulator (Neel et al., 2003; Vang et al., 2008). SHP-2 has been shown to influence 
TCR signalling by dephosphorylation of PAG in transfection studies involving 
catalytically inactive SHP-2. Additionally SHP-2 is known to positively regulate the 
MAP kinase pathway (Zhang et al., 2004). Unlike SHP-1, deletion of the SHP-2 gene 
is embryonically lethal in mice (Saxton et al., 1997). Like CD45, lower levels of 
SHP-1 protein have been detected in patients with systemic lupus erythematosus 
(SLE) (Huck et al., 2001) whereas, gain of function mutations in SHP-2 result in 
Noonan’s syndrome (Tartaglia et al., 2001).  
TC-PTP (PTPN2) 
T cell-protein tyrosine phosphatase is an ubiquitously expressed intracellular PTP, 
encoded by PTPN2 that is characterised by an N-terminal PTP domain and a proline-
rich C-terminal region {reviewed in (Doody et al., 2009)}. It exists as two isoforms 
and it is particularly important in signalling in the Jak-STAT pathway. Mice deficient 
in PTPN2 have impaired B and T cell functions (Dupuis et al., 2003). Mice with 
conditional PTPN2 deficiency in T cells demonstrate a cell-intrinsic role for PTPN2 
in T cells, having augmented positive selection of thymocytes, accumulation of T 
cells with effector/memory phenotype in the peripheral lymphoid organs. PTPN2 
knockout mice develop autoantibodies as they age (Wiede et al., 2011). At the 
cellular level, PTPN2-deficient T cells show increased phosphorylation of tyrosine 
residues. In keeping with the role of PTPN2 in cytokine-receptor signalling, 
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conditional PTPN2-deficient T cells show increased proliferation and show greater 
IL-2 induced STAT5 activation than WT cells (Wiede et al., 2011). Therefore, 
PTPN2 negatively regulates T cell activation by inhibiting both TCR and IL-2 
receptor signalling. Furthermore, several reports have identified PTPN2 as a 
susceptibility locus for autoimmune diseases such as type 1 diabetes, rheumatoid 
arthritis and Crohn’s disease (Burton, 2007; Consortium, 2007; Smyth et al., 2008; 
Todd et al., 2007). Recently, the type-1 diabetes-linked PTPN2 variant rs1893217(C) 
was associated with decreased IL-2R signalling and reduced PTPN2 expression in 
CD4+ T cells (Long et al., 2011). 
PTP-PEST (PTPN12) 
PTP-PEST is an intracellular PTP, which belongs to the family of proline-, glutamic 
acid-, serine- and threonine-rich (PEST) family of phosphatases encoded by PTPN12 
that is ubiquitously expressed {reviewed (Veillette et al., 2009)}. PTP-PEST is an 
important regulator of cell migration and adhesion as shown by overexpression 
studies in fibroblasts or transformed cell lines and PTP-PEST deficient mouse 
fibroblasts (Veillette et al., 2009). PTP-PEST is important for normal cellular 
physiology as mice lacking PTP-PEST exhibit embryonic lethality with severe 
abnormalities in embryonic vascularisation, mesenchyme formation, liver 
development and neurogenesis (Sirois et al., 2006). Overexpression of PTP-PEST in 
B cell or T cell lines resulted in suppression of antigen receptor signalling (Arimura 
et al., 2008; Davidson and Veillette, 2001). T cell specific deletion of PTP-PEST 
showed that PTP-PEST was not necessary for T cell development and primary T cell 
responses. However, it was required for secondary T cell activation and inhibition of 
anergy (Davidson et al., 2010). These activities correlated with the selective capacity 
of PTP-PEST to dephosphorylate Pyk2, a substrate of Fyn, involved in adhesion and 
migration. In keeping, with it important role in adhesion, lack of PTP-PEST resulted 
in enhanced formation of homoaggregates between T cells in Ptpn12-/- T cells 
compared to wild-type T cells. Further the PTP-PEST deficiency reduced 
susceptibility to EAE and the affect was attributed to the decrease in the secondary T 
cells responses (Davidson et al., 2010).  
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1.8 Protein Tyrosine Phosphatase Non receptor Type 
22 (PTPN22) 
Another member of the PEST family of phosphatases is PTPN22, which belongs to 
the non-receptor like subfamily of class I phosphatases (Cohen et al., 1999; 
Matthews et al., 1992). The human gene PTPN22 maps to chromosome 1p13.3-13.1 
and encodes an 807 amino acid residue, intracellular tyrosine phosphatase protein 
referred as lymphoid specific phosphatase LYP (referred as human PTPN22 from 
this point onwards) in humans and proline enriched phosphatase (PEP, referred as 
mouse PTPN22 from this point onwards) in mice (Cohen et al., 1999; Matthews et 
al., 1992). Both human and mouse PTPN22 are closely related and share overall 70% 
homology with 89% identity in their catalytic phosphatase domain and 61% 
homology in the C-terminal domain (Cohen et al., 1999; Matthews et al., 1992) and 
are expressed exclusively in hematopoietic cells (Matthews et al., 1992) and are 
approximately 105kDa and 110kDa in size respectively (Cohen et al., 1999).  
The intracellular distribution of PTPN22 has been controversial. For mouse PTPN22, 
it was initially reported to reside primarily in the nucleus when overexpressed in 
HeLa cells (Flores et al., 1994), and mapping of the potential nuclear localization 
signal identified a requirement for residues 788 - 802 in the P4 domain (Flores et al., 
1994). By contrast, another study that overexpressed HA-tagged PTPN22 in Jurkat 
cells found it to be abundant in cytoplasm with low nuclear compartmentalization 
(Gjorloff-Wingren et al., 2000). 
This study also showed that the C-terminus was important for the observed 
cytoplasmic enrichment, while deletion of both the C-terminal domain or N-terminal 
catalytic domain abolished low level nuclear localisation (Gjorloff-Wingren et al., 
2000). Another study using epitope overexpression or GFP-labelling showed that 
human PTPN22 was found exclusively in the cytoplasm, with low nuclear 
localisation (Chien et al., 2003; Cohen et al., 1999). Seemingly, most PTPN22 is 
distributed in the cytoplasm, whilst a fraction translocates to nucleus under certain 
conditions.  
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1.8.1 Structure of PTPN22 
The PEST family of proteins is a group of three intracellular phosphatases that 
contain PTPN22, PTP-PEST (also referred as PTPN12) and PTP-hematopoietic stem 
cell fraction (PTP-HSCF, also termed as brain derived phosphatase, BD1 or PTP20). 
They share a common structural organisation with an amino terminal phosphatase 
domain, a highly divergent central region containing proline rich motifs and a 
carboxyl-terminal homology (CTH) (Veillette et al., 2009). 
The N-terminal of PTPN22 contains a conserved serine phosphorylation site at 
position 35 and catalytic phosphatase domain between residues 23 to 288 (Matthews 
et al., 1992). Although the catalytic domain for mouse PTPN22 has not been 
crystallized, it may to be very similar to human PTPN22 as they share about 90% 
homology. The crystal structure of the catalytic domain of human PTPN22 reveals, a 
phosphotyrosine recognition loop (amino acid 54 - 60), a WPD loop (amino acid 193 
- 204) and a phosphatase signature motif responsible for catalysis (amino acid 226 - 
233) (Tsai et al., 2009; Yu et al., 2007). Furthermore, the ability to enzymatically 
dephosphorylate tyrosine is critically dependent on residues C227 and D195 within 
the PTPN22 catalytic domain, which work by acting as nucleophilic acceptors of a 
phosphate moiety and facilitate the hydrolysis of the phosphate-enzyme 
intermediates (Wu et al., 2006). 
The interdomain region connecting the amino-terminal and the C-terminal end spans 
300 amino acids. Mutational analysis has revealed that the human PTPN22 
interdomain region between amino acid residues 300-320 forms an intramolecular 
interaction with the catalytic domain and inhibits enzymatic activity, thus important 
in self-regulation of phosphatase (Liu et al., 2009). Furthermore, there is evidence 
that Lck regulates human PTPN22 by tyrosine phosphorylation at the Tyr536, present 
in the interdomain region (Fiorillo et al., 2010). Bottini et al. proposed a model 
where binding of human PTPN22 to Csk recruits it to the membrane, in close 
proximity to Lck, which then phosphorylates PTPN22 on Tyr536 to turn off its 
activity thus potentiating T cell signalling. In support of the model, overexpression of 
mutant human PTPN22 Y536F results in reduced NFAT/AP1 luciferase reporter 
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activation, inhibited CD69 expression and increased phosphatase activity of 
immunoprecipitated PTPN22 Y536F compared to wild-type PTPN22 (Fiorillo et al., 
2010). 
The C-terminal domains of both human and mouse PTPN22 contain highly 
conserved proline rich regions called P1, P2, P3 and P4 (Cohen et al., 1999).It is 
known to interact with the SH3 domain of Csk via the P1 motif (Cloutier and 
Veillette, 1996; Cohen et al., 1999). The structural basis of the association between 
Csk and mouse PTPN22 became clear following the co-crystallization studies of the 
Csk SH3 domain and PTPN22 derived P1 peptide (Ghose et al., 2001). The residues 
PPPLPERTPES-FIV, which form the first polyproline motif P1, were shown to 
abrogate Csk binding when individually substituted by alanine residues (underlined 
residues) (Gregorieff et al., 1998). In addition, two hydrophobic residues (residues 
indicated in bold) located towards the carboxyl terminal of the P1 core motif were 
shown to be important for the high affinity Csk-PTPN22 association (Gregorieff et 
al., 1998) (Fig 1.4). Although the P2-P4 motifs are conserved between mouse and 
human, no specific function or association for these domains have been established. 
In addition, PTPN22 contains five PEST domains between amino acid residues 607-
802. These are frequently found in proteins with high turnover (Rogers et al., 1986). 
Pulse chase analyses have shown that the resting cell half-life of PTPN22 in resting 
cells is greater than 5h (Flores et al., 1994), suggesting that it is not rapidly degraded.  
Human PTPN22 has three splice variants, designated at LYP 1–3 (Cohen et al., 
1999; Wang et al., 2010). The full-length protein of LYP1 (807 amino acid), is the 
most abundant of the 3 isoforms. LYP2 is the shortest splice form and contains only 
the first P1 motif within the C-terminal due to an alternative stop codon resulting in 
truncation of the protein (Cohen et al., 1999). The LYP3 variant results from an 
alternative splicing and has a different C-terminus containing a 28 amino acid 
deletion between P1 and P2 motifs (Wang et al., 2010). LYP 1 is the most studied 
variant and not much is known about the other two variants. No equivalent isoforms 
have been described for mouse PTPN22.  
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Human PTPN22 protein is not highly expressed in resting naïve cells. Cohen et al. 
showed that expression of PTPN22 is upregulated at 24 hours post stimulation with 
anti-CD3 Ab or PHA with a further increase noted at 48 hours (Cohen et al., 1999). 
LYP1 expression was seen in Jurkat cell lines, Ramos and Daudi B cell lines but not 
in myeloid cell lines like K562 or U937 (Cohen et al., 1999). Mouse PTPN22 
expression is high in all cells of the immune system including T cells, B cells, 
immature dendritic cells, macrophages, mast cells, natural killer cells (NK), natural 
killer T cells (NKT) and neutrophils with particular high expression in NK and NKT 
cells (Arimura and Yagi, 2010).  
1.8.2 Function of PTPN22 in T cells  
The role of PTPN22 in T cell activation was hypothesised from initial studies 
showing that it forms a complex with the cytoplasmic protein tyrosine kinase, Csk 
(Cloutier and Veillette, 1996). Csk potently suppresses T cell activation by 
phosphorylating the inhibitory tyrosine residue of the SFKs Lck and Fyn, thereby 
antagonising the action of CD45 (Veillette et al., 2002). Cloutier and colleagues 
show that nearly 25-50% of the total cellular mouse PTPN22 is in complex with 5-
6% of Csk in resting mouse T cells (Cloutier and Veillette, 1996). Later, similar 
results were confirmed with human PTPN22 in primary human T cells (Vang et al., 
2012). Overexpression of wild-type mouse PTPN22 in a mouse T cell hybridoma 
(BI-141) showed pronounced inhibition of TCR-induced protein tyrosine 
phosphorylation and cytokine production (Cloutier and Veillette, 1999). Similarly 
overexpression of mouse PTPN22 in anti CD3/CD28 stimulated Jurkat T cells 
showed reduced cell activation, as determined by an NFAT/AP-1 luciferase reporter 
system (Gjorloff-Wingren et al., 1999). The inhibitory action of PTPN22 was shown 
to be dependent on its enzymatic activity, as mutants lacking the C-terminal domain 
were unable to exert similar effects (Gjorloff-Wingren et al., 1999). In addition, 
overexpression studies comparing wild-type mouse PTPN22 with a mutant lacking 
the Csk-binding P1 domain, and co-expression of wild-type mouse PTPN22 with 
Csk in Jurkat T cells, suggested that physical interaction between PTPN22 and Csk 
enables synergistic inhibition of TCR signalling through their combined ability to 
phosphorylate the inhibitory tyrosine residue Tyr505 (via Csk) and dephosphorylate 
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the activatory tyrosine Tyr394 (via PTPN22) on Lck (Cloutier and Veillette, 1999; 
Gjorloff-Wingren et al., 1999).  
Using human Jurkat T cell lines, substrate-trapping analysis was conducted by 
mutating the C227S/D195A sites of PTPN22 within the phosphatase domain. These 
studies indicated that CD3", CD3(, ZAP-70, valosin containing protein (VCP), Vav, 
Grb-2 and E3 ubiquitin ligase, c-Cbl were all substrates of PTPN22 (Cohen et al., 
1999; Hill et al., 2002; Wu et al., 2006). Furthermore, PTPN22 was shown to 
dephosphorylate both Lck and ZAP-70 at their activating tyrosine residues, Tyr394 
and Tyr493, respectively in vitro (Wu et al., 2006). More evidence that Lck is a 
physiological substrate for PTPN22 came from studies showing increased Lck 
phosphorylation in TCR-stimulated Ptpn22-deficient T cells (Brownlie et al., 2012; 
Hasegawa et al., 2004) and in human Jurkat T cells treated with chemical PTPN22 
inhibitors (Vang et al., 2012). Another bona fide substrate for PTPN22 is CD3( that 
is dephosphorylated in vitro by recombinant PTPN22 (Wu et al., 2006) and also 
shows increased phosphorylation in primary human T cells treated with PTPN22 
inhibitors (Vang et al., 2012).  
Human PTPN22 was shown to be a negative regulator of TCR signalling in various 
in vitro studies. A pivotal study by Begovich et al. used RNAi to knockdown 
PTPN22 reported an increase in NF-#B transcription (Begovich et al., 2004). 
Another putative substrate of PTPN22, identified using a substrate profiling 
approach, is Src-kinase associated protein of 55 kDa homolog, SKAP-HOM, an 
adapter protein that is important in lymphocyte adhesion regulation (Yu et al., 2011). 
Although in vitro studies suggest SKAP-HOM to be a putative PTPN22 substrate, 
direct evidence that PTPN22 controls phosphorylation of Tyr75 in SKAP HOM under 
physiologic condition is lacking. In summary, these studies stress the importance of 
PTPN22 as a potent negative regulator with a very receptor proximal point of action. 
The inhibitory role of PTPN22 in normal T cells has further been demonstrated by 
characterization of Ptpn22-deficient mice. The mice revealed an age dependent 
increase of effector and memory cells in both the CD4+ and CD8+ T cell peripheral 
populations (Hasegawa et al., 2004). Phenotypically the mice exhibited increased 
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size of lymph nodes and spleen with spontaneous generation of germinal centres 
along with elevated serum antibody levels (Hasegawa et al., 2004). In vitro generated 
effector CD4+ T cells displayed increased phosphorylation of Tyr394 on Lck and 
concomitant ZAP-70 and MAPK activation, elevated calcium levels and increased 
proliferation in response to TCR stimulation (Hasegawa et al., 2004). Despite 
presenting with skewed lymphocyte populations and activated phenotype, the 
Ptpn22-/- mice failed to develop any autoimmune or lymphoproliferative disease on 
C57BL/6 background. Nonetheless, combining PTPN22 deficiency with a specific 
point mutation in CD45 (E613R), which alone drives a lupus-like disease on a mixed 
129/B6 but not a wild-type C57BL/6 background (Majeti et al., 2000), resulted in 
lupus-like disease and accelerated memory T cell formation on a C57BL/6 
background (Zikherman et al., 2009). 
Our group independently generated a Ptpn22-deficient mouse model and showed that 
there was a concomitant increase in the Treg cell numbers, that counter balanced the 
increased effector cell numbers observed in Ptpn22-deficient mice (Brownlie et al., 
2012). In addition, we showed that there was an increase in the intrinsic suppressive 
capacity of Treg from Ptpn22-/- mice, as demonstrated by the ability to suppress 
effector T cell proliferation and colitis in Rag-/- mice (Brownlie et al., 2012). 
Furthermore, this study provided evidence that Ptpn22 deficiency resulted in 
increased RAP1 phosphorylation in effector T cells and increased LFA-1 mediated 
adhesion in Tregs, suggesting that PTPN22 modulates integrin-dependent T cell 
migration and adhesion (Brownlie et al., 2012). 
Initial studies from Ptpn22-deficient mouse models showed no differences in 
activation markers, proliferation and phosphorylation of PTPN22 substrates in wild-
type and Ptpn22-/- naïve T cells, suggesting that PTPN22 function was mainly 
important in effector cells (Brownlie et al., 2012; Hasegawa et al., 2004). However, a 
recent study from our group showed that naïve T cell responses were influenced by 
loss of PTPN22 (Salmond et al., 2014). Using OT-I TCR transgenic Ptpn22-deficient 
mice (that have transgenic expression of MHC class I- restricted ovalbumin (Ova) 
specific TCR), we showed that naïve Ptpn22-/- OT-I T cells had increased ERK 
phosphorylation and proliferation in response to low-affinity peptides compared with 
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wild-type OT-I T cells. In contrast, responses to high affinity peptide were 
comparable between the two genotypes, suggesting that in naïve T cells PTPN22 
may function to limit signalling by weak agonists and self-antigens but does not 
impede responses to strong agonists antigens (Salmond et al., 2014). Also PTPN22 
was shown to be important for regulating homeostatic proliferation, as in absence of 
PTPN22, increased lymphopenia-induced proliferation, driven by low affinity self-
peptide MHC was noted in naïve Ptpn22-/- T cells compared to wild-type T cells both 
on polyclonal and OT-I transgenic backgrounds (Salmond et al., 2014).  
In summary, experiments using genetic or pharmacologic manipulation of PTPN22 
provide strong evidence that the phosphatase serves as a negative regulator of 
signalling through the TCR.  
1.8.3 The role of PTPN22 in other cell populations 
PTPN22 is expressed in primary B cells (Arimura and Yagi, 2010; Zikherman et al., 
2009) and can be dynamically regulated. In vitro CpG stimulation resulted in an 
increase in mRNA and protein expression of PTPN22 in B cells (Dai et al., 2013), 
whereas lipopolysaccharide (LPS) stimulation suppressed expression (Arimura and 
Yagi, 2010). The Ptpn22-deficient mice, showed no difference in total peripheral B 
cell numbers or alteration in signalling through the BCR, as evidenced by normal 
calcium mobilisation following BCR engagement (Hasegawa et al., 2004). Modest 
increase in selected IgG subtypes and B cell rich germinal centres were seen in 
Ptpn22-/- mice (Hasegawa et al., 2004), however, disinhibited T cell function could 
account for the observed alteration in the germinal centres rather than perturbed B 
cell signalling defects (Maine et al., 2014; Zikherman et al., 2009).  
A previous report provided some evidence for role of PTPN22 in B cell signalling. 
Reduction of PTPN22 protein by expression of antisense PTPN22 cDNA in the 
immature mouse-B cell line WEHI-231, resulted in a decrease in BCR-induced 
apoptosis, which is a crucial event in the elimination of potentially autoreactive 
immature B cells (Hasegawa et al., 1999). Thus indicating a possible role for 
PTPN22 in promoting negative selection of immature B cells. PTPN22 may also play 
a role in malignant B cell signalling. A recent report showed that high levels of 
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PTPN22 was found in chronic lymphocytic leukaemia (CLL) blasts and knock-down 
of PTPN22 or inhibition of its enzymatic function promoted BCR-triggered 
apoptosis in CLL blasts, suggesting that PTPN22 may act to protect malignant cells 
from antigen receptor-induced cell death (Negro et al., 2012).  
PTPN22 is highly expressed in myeloid cells such as dendritic cells and 
macrophages (Arimura and Yagi, 2010; Heng and Painter, 2008). Myeloid cells 
function by secreting proinflammatory cytokines, initiating host defences, presenting 
antigen and providing secondary costimulation signals. They carry out these 
functions by recognising environment signals via the myeloid cell pattern-
recognition receptors (PRR) (Broz and Monack, 2013). A recent study showed that 
PTPN22 selectively promotes type I interferon production via PRR in human and 
mouse macrophages and DCs (Wang et al., 2013). Efficient type I interferon 
induction after TLR engagement requires activation of the signalling cascade that 
involves phosphorylation of interferon response factors (IRFs), IRF3 and IRF7 and is 
critically dependent upon the Lys63 linked auto-ubiquitination of the E3 ligase TNF 
receptor associated factor 3 (TRAF3) (Hacker et al., 2011).  
PTPN22 selectively associates with TRAF3 in myeloid cells and promotes Lys63 
linked auto-ubiquitination of TRAF3 following stimulation through PRR, resulting in 
production of type I interferon, which was reduced in Ptpn22-/- or Ptpn22 knock-
down myeloid cells (Wang et al., 2013). In addition, the effect of PTPN22 in the 
TLR pathway was not mediated by PTPN22 catalytic activity, but instead was reliant 
upon scaffolding properties within the C-terminal domain of the protein, as treatment 
of mouse bone marrow derived macrophages or a macrophage cell lines with 
pharmacologic inhibitors of PTPN22 demonstrated no effect on TLR-stimulated type 
I interferon production (Wang et al., 2013). Furthermore, another study showed that 
PTPN22 is differentially expressed in the M1 (classically activated) and M2 
(alternatively activated) macrophages and PTPN22 suppresses M1 polarization of 
macrophages and reciprocally promotes the expression of M2-associated genes 
(Chang et al., 2013). PTPN22 was shown to play a protective role in inflammatory 
bowel disease, as loss of PTPN22, rendered mice more susceptible to dextran 
sulphate sodium (DSS) induced colitis (Chang et al., 2013).  
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Therefore PTPN22 has a dual role in regulation of immune cell signalling, wherein it 
restricts and dampens signalling downstream of the TCR in the adaptive immune 
system and selectively promotes functions of myeloid cells in the innate immune 
system.  
1.8.4 Association of C1858T polymorphism in PTPN22 with 
autoimmune diseases 
The recognition that the PTPN22 gene is a major risk factor for autoimmunity was 
initiated by identification of a single nucleotide polymorphism (SNP) in PTPN22 
exon 14, which substituted cytosine at position 1858 with a thymine (1858C>T) and 
was associated with an increased predisposition to type 1 diabetes (Bottini et al., 
2004), rheumatoid arthritis (Begovich et al., 2004) and systemic lupus erythematosus 
(SLE) (Kyogoku et al., 2004). The PTPN22-C1858T confers a change of amino acid 
at position 620 (619 in mouse) from arginine (R) to tryptophan (W) within the P1 
motif (Bottini et al., 2004) (Fig 1.4). The SNP was further shown to disrupt the 
interaction of Csk with PTPN22, resulting in diminished binding of Csk with 
PTPN22 (Bottini et al., 2004). Since its initial finding, hundreds of reports 
supporting the link between C1858T and increased predisposition to autoimmune 
diseases have been published {reviewed in (Bottini and Peterson, 2014)}. 
Furthermore, genome-wide association studies conducted in humans show that the 
1858C>T SNP in PTPN22 ranks as the second highest risk factor for development of 
rheumatoid arthritis (after MHC) and the third highest risk factor for type 1 diabetes 
(Todd et al., 2007).  
The frequency of PTPN22 1858T allele varies significantly among different 
populations. In Europe, a northeast to southwest gradient exists, with the highest 
frequency of 15-17% observed in the North European countries. Moving southwest 
the frequency of allele decreases to 7-8% and decreases even further to 2-3% in the 
southern Italian and Sardinian populations (Bottini and Peterson, 2014; Burn et al., 
2011). PTPN22 C1858T allele is rare (< 1%) in African, Middle Eastern, Native 
American and Asian populations (Bottini and Peterson, 2014; Burn et al., 2011). 
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While the associated risk with many autoimmune diseases have been well established 
with the PTPN22 1858T allele, many autoimmune diseases do not share this 
susceptibility locus including ulcerative colitis and Crohn’s disease (Diaz-Gallo et 
al., 2011; van Oene et al., 2005), multiple sclerosis (Begovich et al., 2005) and 
psoriasis (Criswell et al., 2005). These findings indicate that the PTPN22 C1858T 
polymorphism is a common risk factor for some, but not all autoimmune diseases. 
In addition to autoimmune diseases, PTPN22 1858 C>T also affects susceptibility to 
infectious diseases. Carriers of the 1858T allele are at increased risk of bacterial 
infections, including invasive pneumococcal infections, bacterial pulmonary 
infections in patients with chronic mucocutaneous candidiasis and to leprosy (Bottini 
and Peterson, 2014). Remarkably, the R620W variant has been associated with 
reduced risk of developing tuberculosis (Bottini and Peterson, 2014; Burn et al., 
2011). Presumably, while the R620W is a common risk allele for some autoimmune 
disease, the modest protective effect that it provides against the infections may be a 
reason for its maintenance in the human population.  
Besides the 1858C>T SNPs of PTPN22, other SNPs have also been identified, one of 
which is located within the catalytic domain, PTPN22 788 G>A and confers a 
R263Q amino acid change (Carlton et al., 2005). The R263Q mutation was shown to 
be associated with a lower risk of development of RA in a larger cohort (Rodriguez-
Rodriguez et al., 2011). While the R263Q mutation is demonstrated to decrease the 
phosphatase activity of the PTPN22, compared to the wild-type protein, as shown by 
reduced ability to down regulate ERK phosphorylation, NFAT activation and in vitro 
phosphatase activity of the Q263 variant (Orru et al., 2009). Interestingly, the authors 
found an association between the R263Q variant and reduced risk of SLE, indicating 
that this loss-of function variant actually provides a protective effect against 
autoimmunity (Orru et al., 2009). 
The point mutation of PTPN22 associated with autoimmunity has been the focus of 
both human (PTPN22R620W) and mouse (PTPN22R619W) in vitro studies over the last 
10 years with conflicting results. Overexpression of PTPN22R620W in Jurkat cells 
showed significant inhibition of TCR signalling and was hence assumed to be a 
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‘gain-of function’ mutation (Vang et al., 2005). An initial study utilising primary T 
cells transfected either with PTPN22WT or PTPN22R619W showed a decrease in IL-2 
production upon anti-CD3 antibody stimulation in PTPN22R619W compared to cells 
expressing PTPN22WT (Vang et al., 2005). In addition, expression of PTPN22R619W 
showed decreased phosphorylation of proximal signalling molecules like CD3( and 
LAT, which correlated to reduced levels of ERK activity (Vang et al., 2005). In 
support, a study with primary human T cells isolated from carriers of PTPN22R620W 
polymorphism demonstrated impaired calcium flux and upregulation of activation 
markers upon TCR activation (Rieck et al., 2007). By contrast, the point mutation 
has been described as a hypomorph mutation wherein transfection of PTPN22R620W 
in Jurkat cells alone or in the context of Csk, resulted in higher pERK than 
PTPN22WT following TCR stimulation (Zikherman et al., 2009). Further support for 
the loss-of-function model comes from two independently generated R619W knock-
in mice, analogous to the human R620W variant, both of which describe a phenotype 
similar to the PTPN22- deficient mouse (Dai et al., 2013; Zhang et al., 2011). The 
most recent of the papers show that R619W knock-in mice fails to develop signs of 
autoimmunity on the B6 background but on a mixed 129/B6 genetic background, the 
mice manifested systemic autoimmunity characterized by high-titers of 
autoantibodies and vasculitis, lymphoid infiltrates in multiple organs (Dai et al., 
2013). 
Interestingly, neither the PTPN22 KO nor R619W mutation is sufficient to develop 
spontaneous autoimmunity on B6 background therefore the use of established 
autoimmune models or multiple gene knock-outs/ mutations have been used to study 
this gene in a disease specific context (Maine et al., 2012; Maine et al., 2014; Yeh et 
al., 2013; Zheng and Kissler, 2013; Zikherman et al., 2009). The SKG mouse strain, 
on the BALB/c background contains a spontaneous point mutation W163C in the 
SH2 domain of ZAP-70 and are prone to develop CD4+ T cell mediated chronic 
autoimmune arthritis in the mice that resembles human rheumatoid arthritis when 
maintained in conventional facilities (Sakaguchi et al., 2003). The arthritis is 
characterized with progressive symmetric progression of inflammation from 
interphalangeal joints of the forepaws and hind paws to larger joints (wrists and 
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ankles) (Sakaguchi et al., 2003). Arthritis can also be elicited under specific pathogen 
free (SPF) conditions either through antigen non-specific activation of innate 
immunity, (e.g. by administration of crude or purified fungal extracts) or by 
provoking homeostatic proliferation of self-reactive T cells upon transfer to the T 
cell-deficient environment of nude mice (Yoshitomi et al., 2005). To investigate the 
effect of PTPN22 on T cell signalling in context of an autoimmune disease, we 
crossed the SKG mice with mice containing global deletion of Ptpn22.  
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1.9 Thesis Aims 
The overall aims of this thesis are to understand how intracellular signals and the 
interplay of various signalling molecules influence downstream T cell function. 
Signals through the T cell receptor are transmitted initially by the SFK, Lck whose 
activity is modified by the phosphatase PTPN22. PTPN22 is a known negative 
regulator of T cell signalling, however the precise dissection of molecular 
involvement of PTPN22 at various stages of signal transduction cascade is yet to be 
elucidated. Several studies show that there is a robust association between the 
R620W polymorphism in PTPN22 with development of autoimmune diseases. 
However whether the substitution renders PTPN22 a more or less potent regulator of 
T cell signalling is still controversial. We therefore used the Ptpn22-/- mice to address 
the following aims in this thesis.  
• To characterise the functional effects of the R619W polymorphism in 
primary murine T cells using lentiviral transduction technology. 
• To identify the signalling pathways in which PTPN22 is involved to gain 
further insight into its function.  
• To understand the molecular mechanism of PTPN22 action in the context of 
an autoimmune disease.  
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Figure 1.1 Differentiation of Effector T cells (adapted from Swain et al 2012 and O’Shea et al 
2010) 
Following recognition of a specific antigen presented by antigen presenting cells, naïve T cells 
undergo several rounds of division and differentiate into different effector subsets depending on the 
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Figure 1.2 T cell development in thymus (From Germain, 2002) 
Committed progenitor lymphoid cells migrate from the bone marrow into the thymus. The early 
thymic precursors (ETP) that enter the cortex lack expression of TCR, CD4 and CD8 markers, and are 
termed as double negative (DN). As the cells progress through the subsequent DN2 to DN4 stages 
they express the pre TCR composed of pre TCR% chain and rearranged TCR! chain. At the DN4 stage 
the cells express both CD4 and CD8 and are termed as double positive (DP). The DP cells then 
undergo positive selection, which critically depends on interaction of TCR with self-peptides; most of 
the cells die as they have very low affinity towards self-peptide (death by neglect), those which react 
with increased affinity are deleted by negative selection (in medulla) on those cells which have 
intermediate affinity are positively selected and mature into CD4+ or CD8+ SP cells and migrate from 
medulla into peripheral lymphoid organs. 
 
          




Figure 1.3 Overview of T cell receptor signalling (Adapted from Brownlie et al. 2013 and Acuto et al. 2008) 
Following TCR/CD3 engagement by pMHC, Lck is activated and recruited to the TCR/CD3 complex Lck then phosphorylates the ITAM motifs within the CD3 
subunits. The activity of Lck is tightly regulated by Csk, which phosphorylates the inhibitory (Tyr505) maintaining Lck in inactive state. Activation of Lck is 
mediated by CD45 by dephosphorylating Tyr505 residue, thereby counteracting activity of Csk. The T-cell specific adaptor protein (TSAD) then binds to and 
positively regulates Lck. Together, Csk, CD45 and TSAD are involved in maintaining an equilibrium between inactive, primed and active states of Lck (insert). 
The phosphorylated ITAMs provide docking sites for recruitment of ZAP-70, which is activated by phosphorylation by Lck.  ZAP-70 further recruits and 
phosphorylates SLP-76 and LAT, which form the LAT signalosome and recruit more signalling molecules. The LAT signalosome propagates the signals to three 
major signalling pathways; Ca2+, MAPK and NF!B pathway leading to mobilization of transcription factor critical for gene expression. Signals via the TCR are 
also important for actin reorganization and activation of integrin mediated inside out signalling. 
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Figure 1.4 Structural requirement for Csk and PTPN22 interaction. 
A schematic representing the primary structure of Csk and PTPN22 and the residues required for the 
interaction. Csk is a kinase and comprises of N-terminal SH3, SH2 and a C-terminal catalytic domain. 
Structurally PTPN22 comprises of an N-terminal phosphatase domain connected via the interdomain 
to a non-catalytic proline rich carboxyl terminal. The location of P1-P4 proline motifs are shown. The 
proline motif located within the P1 region of PTPN22 important for interacting with Csk is 
highlighted, with the essential amino acids critical for binding underlined. The position of the 
autoimmunity linked single nucleotide polymorphism that is mutated to tryptophan (R619W) is 
highlighted in red. 
 
Figure 1.5 PTPN22 negatively regulates T cell signalling by dephosphorylating multiple 
proximal signalling molecules (Adapted from Burn et al 2011 and Bottini et al, 2014). 
Substrate trap experiments show that PTPN22 interacts with multiple proximal signalling molecules 
and attenuates TCR signalling by dephosphorylating them on activating tyrosine residues, which 
include Tyr394, Tyr 417 and Tyr 493 on Lck, Fyn and ZAP-70. Other putative substrates that undergo 
PTPN22 mediated dephosphorylation include TCR - CD3!, CD3" chains, adaptors Grb2, Vav and 
valosin containing protein (VCP). Recently in vitro studies have identified Tyr72 on SKAP to be a 
potential substrate of PTPN22. 
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Chapter 2:  Materials and Methods  
2.1  Buffers and Solutions 
2.1.1  Buffers for plasmid DNA miniprep 
Buffer P1  
50mM Tris Acetate, pH 8.0 (Calbiochem-Novabiochem UK) 
10mM Ethylene diamine tetra acetic acid (EDTA) (Sigma-Aldrich UK) 
100µg mL-1 RNAse A (Invitrogen, UK) 
 Buffer P2 
0.2N Sodium Hydroxide (Sigma-Aldrich UK) 
1% SDS (Fisher-Scientific, UK) 
Buffer P3 
3M Potassium Acetate (Sigma-Aldrich UK) 
2.1.2 Luria Bertini Broth 
10gL-1 Tryptone (Sigma-Aldrich UK) 
10gL-1 Sodium Chloride (Sigma-Aldrich UK) 
5gL-1 Yeast Extract (Sigma-Aldrich UK) 
2.1.3  Luria Bertini Agar 
10gL-1 Tryptone (Sigma-Aldrich UK) 
10gL-1 Sodium Chloride (Sigma-Aldrich UK) 
5gL-1 Yeast Extract (Sigma-Aldrich UK) 
14gL-1 Agar (Sigma-Aldrich UK) 
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2.1.4 TAE Buffer (10X) 
48.5 gL-1 Tris Base (Fisher-Scientific, UK) 
11.4 ml Glacial acetic acid (Fisher-Scientific, UK) 
20mL of 0.5M EDTA (pH 8.0) 
2.1.5  TE Buffer 
10mM Tris pH 8.0 (Fisher-Scientific, UK) 
1mM EDTA (Sigma-Aldrich, UK) 
2.1.6 HBS Buffer 2X (pH 7.12) 
281mM Sodium Chloride (Sigma-Aldrich, UK) 
100mM HEPES (Sigma-Aldrich, UK) 
1.5mM Disodium hydrogen phosphate (Na2HPO4) 
2.1.7 Western Blot Lysis Buffer  
20mM Tris pH 7.5 (Fisher Scientific, UK) 
150mM Sodium Chloride (Sigma-Aldrich UK) 
1% Triton X 100 (Fluka–Sigma-Aldrich UK) 
1% Maltoside (Merck Millipore) 
2mM EDTA (Sigma-Aldrich UK) 
1mM Sodium Orthovanadate (Sigma-Aldrich UK) 
1/100 Protease inhibitor cocktail (Sigma-Aldrich UK) 
1mM Sodium Fluoride (Sigma-Aldrich UK) 
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2.1.8 Western Blot 4X Reducing Sample Buffer 
160mM Tris-HCl pH 6.8 (Fisher Scientific, UK) 
40% v/v Glycerol (Sigma-Aldrich, UK) 
10% v/v SDS (Fisher Scientific, UK) 
0.05% w/v Bromophenol blue (Sigma-Aldrich, UK) 
9%v/v !-2-mercapthoethanol (Sigma- Aldrich, UK) 
2.1.9  Western Blot Running Buffer 
NuPAGE® MOPS SDS Running Buffer 20X for Bis-Tris gels (Invitrogen, UK) 
2.1.10 Western Blot Transfer Buffer 
20mM Tris-Cl pH 7.5 (Fisher Scientific, UK) 
150mM Glycine (Fisher Scientific, UK) 
20% Methanol (Fisher Scientific, UK) 
2.1.11 Western Blot Wash Buffer  
1X PBS (Gibco BRL, UK) 
0.1% Tween-20 (Scientific Laboratories Supplies, UK) 
2.1.12 Red Cell ACK Lysis Buffer (pH 7.4) 
150mM Ammonium Chloride (Sigma-Aldrich UK) 
10mM Potassium bicarbonate (Sigma-Aldrich UK) 
0.1mM EDTA (Sigma-Aldrich UK) 
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2.1.13 Flow Cytometry (FACS) Buffer 
1X Phosphate Buffered Saline pH7.2 (PBS; Gibco BRL, UK) 
5gL-1 Bovine Serum Albumin (Fisher Scientific, UK) 
0.05% Sodium Azide (Sigma-Aldrich UK) 
2.1.14 Magnetic Activated Cell Separation (MACS) Buffer 
1X PBS (Gibco BRL, UK) 
2mM EDTA (Sigma-Aldrich UK) 
0.5% BSA (Sigma-Aldrich UK) 
2.1.15 ELISA Wash Buffer  
1X Phosphate Buffered Saline pH7.2 (Gibco BRL, UK) 
0.05% Tween-20 (Scientific Laboratories Supplies, UK) 
2.2 Cell Lines 
2.2.1 293T  
293T cell line (Takara; Clontech, UK), also called HEK was established from human 
embryonic kidney cells. These cells constitutively express the simian virus 40 
(SV40) large T antigen. This is an easily transfected cell line and was used for 
generating high titers of lentivirus (Section 2.6).  
2.2.2 NIH-3T3 
The cell line was established from the primary mouse embryonic fibroblasts cells 
that were cultured by a designated protocol (primary mouse cells were transferred 
every 3 days at 3x105 cells, thus the name 3T3). NIH- 3T3 cells were established 
from the Swiss NIH mouse using the same protocol. The NIH -3T3 cell line was a 
kind gift from the laboratory of Dr. Amy Buck (University of Edinburgh) and was 
used for estimating the titer of lentivirus particles generated in the 293T cells.  
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2.3 Mouse Models  
All mouse strains used were maintained and bred under pathogen-free conditions, at 
the University of Edinburgh animal facilities, in accordance with the U.K. Home 
Office and local ethically approved guidelines. Wild type BALB/c and C57BL/6 
mice were bred in house. 
2.3.1 Ptpn22-/- mice 
Mice with global deletion of Ptpn22 were generated by the introduction of loxP 
recombination sites flanking exon 1 and crossing them with transgenic mice 
expressing Cre recombinase driven by the gene encoding protamine (Prm-Cre) and 
then backcrossed either to C57BL/6 mice for four generations (Ptpn22-/-) or with    
H-2Kb restricted OT-I strain with a congenital deficiency in mature B cells and T 
cells (Rag1-/-) background.  
2.3.2 SKG Ptpn22-/- mice 
The SKG mice on BALB/c background contains a spontaneous homozygous W163C 
mutation in the C-terminal SH3 domain of ZAP-70 (Sakaguchi et al., 2003) and were 
a kind gift from Prof. Shimon Sakaguchi (Osaka University, Japan). The SKG mice 
were backcrossed for greater than 8 generation onto the Ptpn22 deficient mouse line 
to generate SKG Ptpn22-/- mice. 
2.4 Peptide 
The OT-I transgenic TCR is designed to recognize ovalbumin residues 257 – 264. 
The SIINFEKL (Ser, Ile, Ile, Asn, Phe, Glu, Lys, Leu) octapeptide is the naturally 
occurring epitope presented to T cells by the MHC class I molecule, H-2Kb. Several 
different variants of Ova peptide, which differ by one amino acid at the 4th position 
(shown in bold) are used to alter the TCR affinity. N4 (Asparagine) being the 
strongest peptide, T4 (Threonine) being intermediate and G4 (Glycine) with lowest 
affinity.  
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2.5  Cell isolation, purification and culture 
2.5.1 Cell Culture Medium 
Iscove’s Modified Dulbecco’s Medium  (IMDM) (Sigma Aldrich UK) 
Supplemented with: 
5% Heat inactivated Fetal Calf Serum (FCS) (Serotec, UK) 
100U mL-1 Streptomycin (Sigma-Aldrich UK) 
100µg mL-1 Penicillin (Sigma-Aldrich UK) 
2x10-3 M L-Glutamine (Sigma-Aldrich UK) 
5x10-5 M !-2- Mercaptoethanol (Sigma-Aldrich UK) 
2.5.2 Isolation of thymocytes and peripheral T cells for in 
vitro analysis 
Mouse brachial, axillary, cervical, inguinal and mesenteric lymph nodes were 
harvested from age matched controls. For some experiments thymus (mice used for 
thymic analysis unless otherwise stated were always 6-7 week old) and spleen were 
also removed. Single cell suspension was prepared by teasing the organs through a 
70µm sterile cell strainer (BD Falcon, USA) with the end of 2mL syringe plunger. 
The cells were then washed by centrifugation at 300g for 5 min (Heraeus-Multifuge 
3S-R) and supernatant discarded before resuspension in fresh culture medium. 
Splenocytes were subjected to ACK lysis (5 mL for 3 min on ice), after which they 
were washed, re-filtered with a fresh 70"m sterile cell filter and resuspended in 
culture medium. An aliquot of cells was either counted on the CASY-1 automated 
cell counter according to manufacturer’s instruction (Scharfe System, Germany) or 
with a haemocytometer with 0.1% Trypan blue (Fluka-Sigma-Aldrich, Germany) to 
allow exclusion of dead cells. 
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2.5.3 Purification by negative selection using Dynabeads® 
(Invitrogen, UK) 
For in vitro CD4+ T cell proliferation assays, the T cells were enriched for CD4+ cells 
by negative selection using Dynabeads. Briefly, the single cell suspension of pooled 
lymph nodes taken from four individual mice were labelled with rat anti-mouse 
antibodies produced in-house (kindly provided by the Prof. David Gray, University 
of Edinburgh) (see table 2.1) at saturating concentrations in IMDM medium 
supplemented with 2% FCS, at a cell density of 2x108 cells mL-1, by incubating for 
30 min, in the dark, at 4°C (fridge). During the incubation, the cells were gently 
mixed after 15 min. While the cells were incubating with primary antibodies, sheep 
anti-rat IgG Dynabeads (Life-Technologies, UK) were prepared by washing twice 
with 5mL of medium supplemented with 2% FCS. After the 30 min incubation, the 
samples were washed twice with the 2% FCS medium and resuspended at 1x107 cells 
mL-1. The washed Dynabeads were added to the samples at 1:2 beads/cell ratio and 
incubated for an additional 20 min at 4°C with constant rotation. After the 
incubation, the unwanted cells, which were bound to the dynal beads were removed 
using a magnetic particle concentrator (Dynal) and the supernatant, containing the 
enriched CD4+ T cells, transferred to a fresh 15 mL Falcon tube (Corning, UK). The 
bound beads were removed from the magnet and resuspended in 5 mL of fresh 
medium and the bead isolation repeated before transferring the supernatant to the 15 
mL Falcon tube. Transferred cells were finally washed, counted and resuspended at 
the required cell concentration in culture medium containing 5% FCS.  
Table 2.1 Antibodies used for isolation of CD4+ T cells using anti-rat IgG dynabeads 
Specificity Clone  Host Stock Conc. Dilution  
MHC class II M5114 Rat 8mg mL-1 1:400 
CD8a  53 – 6.72 Rat  1.2mg mL-1 1:100 
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2.5.4 Cell sorting using Flow Cytometry  
A BD FACSAria I (BD Biosciences, UK) was used to sort CD4+ naïve 
(CD45hiCD25-) T cells, following the enrichment with Dynabeads. Antibody-labelled 
cells were suspended in 0.22!m filtered FACS buffer and passed through a 70µm 
cell filter (BD Falcon, USA) to remove any cell clumps. The cells were resuspended 
at 1x107 cells mL-1 in sterile FACS buffer and then purity sorted with FACSAria cell 
sorter (BD biosciences, UK) collecting the naïve cells in 1 mL of FCS containing 1% 
Penicillin/Streptomycin. After sorting, the cells were washed once in complete 
medium, counted and resuspended at the final desired concentration.  
2.6 Lentivirus production and Titration  
293 T cell culture and passage 
Iscove’s Modified Dulbecco’s Medium pH7.4 (IMDM) (Sigma Aldrich UK) 
Supplemented with: 
10% Heat inactivated Fetal Calf Serum (FCS) (Serotec, UK) 
100U mL-1 Streptomycin (Sigma-Aldrich UK) 
100µg mL-1 Penicillin (Sigma-Aldrich UK) 
2x10-3 M L-Glutamine (Sigma-Aldrich UK) 
The 293T cell line was maintained in 10 mL of culture medium in 75mL tissue 
culture flasks (Nunc, Denmark) at a cell density of 0.5x106 cells per flask, incubated 
at 37°C/5%CO2, in a humidified incubator. After the cells were confluent the culture 
medium was aspirated and the cells were gently washed once with 10 mL of 1X PBS 
and then trypsinized with 3 mL of 1% trypsin (Lonza, UK) by incubating for 3 min at 
room temperature. The sides of the tissue culture flask was gently tapped to dislodge 
the cells, following which 7 mL of culture medium was added and cells were washed 
by centrifuging at 300g (Heraeus-Multifuge 3S-R) for 5 min. The cells were then 
          Chapter 2 
    59 
seeded at 0.5x106 cells per 75mL tissue culture flask (Nunc, Denmark) in 10 ml of 
fresh culture medium.  
Lentivirus production in 293 T cells 
To generate lentivirus 4.5 x 106 293T cells were plated in culture medium containing 
10% FCS without any antibiotics in 10 cm tissue culture plates (Nunc, Denmark). 
The following day a DNA mixture containing 4.5µg of envelope protein, pMDG2- 
VSV-G, 11.5µg of psPAX2, packaging plasmid and 16µg of viral vector resuspended 
in 562.5µL of TE buffer and 62.5µL of CaCl2 (2.5M stock) solution was prepared. 
The DNA/ CaCl2 solution was quickly mixed with 625µL of 2X HBS (section 2.1.7) 
by vortexing. The DNA/ CaCl2/ HBS solution was immediately added onto the cells. 
After overnight incubation the medium was changed to fresh medium containing 
10mM sodium butyrate (Sigma, stock solution prepared at 10µM). This medium was 
collected 30 h later and spun at 4000g (Heraeus-Multifuge 3S-R) for 5min to remove 
cell debris. The virus supernatant was either used fresh or was concentrated by 
centrifugation, using a 45Ti rotor (Beckman Coulter) for 2h at 50,000g. The viral 
pellet was resuspended in 50µL medium at 4°C and aliquots (50µL) were snap frozen 
in liquid nitrogen and stored at -80°C. 
Lentivirus Titration  
To titrate lentivirus batches, 1x105 3T3 cells were plated in 24-well tissue culture 
plate (Nunc, Denmark) one day prior to infection. 10µL of concentrated lentivirus 
was added to 1mL of medium and then serially diluted 10 fold.  24 h post infection 
the supernatant was aspirated and the cells were washed with PBS once and then 
transferred into 12*75mm FACS tubes (BD biosciences, UK). The percentage of 
GFP+ cells was evaluated by a MACSQuant (Miltenyi, Germany) flow cytometer 
and lentiviral titer was calculated using the following formula: 
!"#$%!!"!#$ ! !"! !"!!!!!!"##$!!"#$%&!! !!"#!!"#$%$&'!!"##$!"#$%"&'!!"!!"#$%!!"#$ !!!!""" 
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2.7 Lentivirus transduction of activated T cells 
To transduce in vitro generated polyclonal or OT-I cytotoxic T-lymphocytes (CTLs), 
the activated T cells were washed, by centrifugation at 300g (Heraeus-Multifuge 3S-
R) for 5 min and the cell pellet was resuspended, at 106 cells per 1 mL of viral 
supernatant with 20ng mL-1 recombinant human IL2 (rhIL2; Peprotech, UK) and 
4µg polybrene (Sigma-Aldrich, UK). Control cells were resuspended at the same 
density in culture medium containing the concentration of rhIL2 and polybrene. 1mL 
of the cell suspension was added to each well of a 24-well plate and the cells spin-
infected by centrifuging at 500g for 45 min at 32°C. Following the centrifugation the 
medium was gently removed, without disturbing the cell pellet and replaced with 
1mL of complete culture medium containing 20ng mL-1 rhIL2 followed by 
incubation at 37°C/5%CO2 in a humidified incubator. The efficiency of transduction 
efficiency was assessed by expression of GFP by flow cytometry.  
2.8 Amaxa nucleofactor transfection of T cells  
Designed based on kind advice from Dr. Jessica Borger 
Prior to transfection, 1mL of Mouse T cell Nucleofactor medium (supplemented with 
20ng mL-1 rhIL2, 5% FCS, 2mM glutamine, 1mL of component A and 10µL of 
component B) supplied with the Mouse T cell Nucleofector kit (Lonza, Switzerland) 
was aliquoted into a 12-well plate (Nunc, Denmark) and incubated at 37°C for a 
minimum of 30 min. The in vitro generated CTLs, were density separated on 
lympholyte (Cedarlane, UK), to remove dead cells, counted and washed once with 
1X PBS to remove the medium containing serum proteins. The cells were then 
resuspended at a concentration of 1x107 cells in 100µL of Mouse T cell nucleofector 
solution (supplied with Nucleofector kit) containing 10µg plasmid, then transferred 
to a cuvette and electroporated using the CD8+ T cell parameter, X-001 of the Amaxa 
Nucleofector Device (Lonza, Switzerland). The cells were transferred immediately to 
the pre-warmed aliquoted medium (described above) and incubated for 4 h at 
37°C/5% CO2, in a humidified incubator. Following 4 h of incubation, the cells were 
resuspended in 12 mL of complete IMDM culture medium (supplemented with 20ng 
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mL-1 of rhIL2) before aliquoting 4 mL of the cell suspension to each of 3 wells of a 
12-well plate and incubated for further 4 h.  
2.9 Molecular Biology Techniques 
2.9.1 Plasmid DNA Constructs  
The cDNA encoding mouse PTPN22 was cloned from the full-length image clone: 
30077916. PTPN22R619W variant was generated by site directed mutagenesis at base 
1858, where a C>T mutation conferred the change of Arg (R) at aa 619 to a Trp (W). 
Dr Jessica Borger kindly provided the full-length cDNA PTPN22WT, PTPN22R619W, 
PTPN22WT-YFP and PTPN22R619W-YFP fusion protein constructs cloned in CMV 
promoter vectors (pCMV- Sport6 and pMAX for YFP, respectively). The bicistronic 
lentiviral vector pLVX-EF1! was purchased from Takara Clonetech, UK. 
2.9.2 Agarose Gel Electrophoresis 
Electrophoresis of DNA was performed on standard horizontal electrophoresis 
apparatus (Biorad, UK). Depending on the size of the DNA to be visualised, 0.75% 
to 1% w/v DNA grade agarose gels were prepared in 1X TAE (section 2.1) and 
stained by incorporation of 0.5µg mL-1 of ethidium bromide. Prior to loading, DNA 
was mixed in with 1"L of DNA loading buffer (Thermo Scientific; 10mM Tris-HCl 
pH 7.6, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol and 60mM 
EDTA pH 8.0) and electrophoresed at 100V until optimal band separation was 
achieved. DNA was visualized with ultra-violet light and photographed using a Gel-
documentation system (Syngene). Molecular weights of DNA bands were estimated 
by the relative electrophoretic mobility of DNA ladders Hyperladder 1 (Bioline,UK) 
and 1kB ladder (New England Biolabs, UK). 
2.9.3 Restriction Endonuclease Digestion 
A total of 5µg of DNA diluted in sterile distilled water and 5µL 1X NEBuffer 
(supplied with variable MgCl2 concentrations, New England Biolabs, UK), with 
100µg mL-1 of BSA and 1U of appropriate restriction endonuclease was digested in a 
final volume of 50µL restriction digestion mixture reaction in 0.5 mL eppendorf 
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tubes (Fisher-Scientific, UK). The samples were incubated at 37°C for 1 h, unless 
specified otherwise and where advised the enzyme was heat inactivated by 
incubating at 65°C for 5 min.  
2.9.4 Gel Extraction of DNA  
The restriction digested DNA fragments were separated by gel electrophoresis 
(described in 2.9.2) and DNA fragments of required molecular weight were excised 
from the gel using a scalpel. Using the GeneClean III kit (qBiogene) according to 
manufacturer’s protocol, the gel slice was weighed and 3 volumes of NaI solution 
(supplied with kit) was added and incubated at 55°C to melt the gel slice. Depending 
on the final volume of the mixture, GLASSMILK (silica beads) were added to the 
NaI/DNA solution, mixed well and incubated at room temperature for 5 min 
following which the DNA bound to the beads were pelleted by centrifuging at 
16060g (Biofuge Fresco, Heraeus) for 1 min. The pellet was washed twice with 
0.5mL of wash buffer and air-dried. The DNA pellet was then resuspended in equal 
volume of TE buffer as that of added silica beads.  
2.9.5 Ligation  
Ligation of insert and vector DNA was generally performed at 3:1 equimolar ratio, 
thus approximately 600ng insert DNA to 200ng of vector DNA, was ligated in a total 
volume of 10µL containing 1µL of 10X ligase buffer (New England Biolabs, UK; 
50mM Tris-HCl, 10mM MgCl2, 1mM ATP, 10mM DTT, pH 7.5 @ 25°C) and 1U T4 
ligase (New England Biolabs, UK). Cohesive-end ligation were incubated at 16°C 
for 1 h and blunt-end ligation reaction at 4°C overnight.  
2.9.6 Transformation  
Competent DH5! cells (Life-Technologies UK) were thawed on ice for 10 min prior 
to incubation with 50ng plasmid DNA or 400ng of ligation mixture at 4°C for 20 
min. Following which the cells were heat shocked at 42°C for 30s and immediately 
incubated on ice for 2 min. Pre-warmed SOC medium (Invitrogen, UK) was added to 
each transformation reaction and incubated for 1 h at 37°C with constant shaking. 
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50µL and 100µL of cells were spread onto LB agar plates containing appropriate 
antibiotic selection and incubated at 37°C overnight.  
2.9.7 Cloning of PTPN22-StrepTAG into lentiviral vector 
Sequences of oligonucleotides designed for generation of C terminal double Streptag 
separated by glycine-serine linker (WSHPQFEK-GGGSGGGSGGGS-WSHPQFEK) 
are listed in Table 2.2. PCR overlap extension was performed on PTPN22WT or 
PTPN22R619W template cDNA using Phusion High- Fidelity DNA polymerase 
(Finnzymes, New England Biolabs, UK) and oligonucleotides StrepTAG 1F, 
OnestrepTAG -1F (listed in Table 2.2). The following thermal cycling conditions; an 
initial denaturation step at 98°C for 1 min followed by 3 cycles of 98°C denaturation 
for 30 s, 47°C annealing for 30 sec, 72°C for 30 s for nucleotide extension and then 
27 cycles of 98°C denaturation for 30 s, 65°C annealing for 30 s and 72°C for 1 min 
nucleotide extension, and a final incubation at 72°C for 10 min was used. The second 
round PCR reaction to amplify 470 bp fragment used 1µL of first reaction PCR 
product as DNA template with oligonucleotides StrepTAG 1F and 3’ overlapping 
primer OneStrepTAG-1R (listed in Table 2.2) using the same thermal cycling 
conditions. The PCR product was cloned back using unique restriction site XcaI and 
NotI restriction enzyme site encoded within the OneStrepTAG-1R oligonucleotide 
(Table 2.2 underlined) into PTPN22 cDNA cloned in Sport 6 vector. The clones 
were confirmed by DNA sequencing. The full-length cDNA PTPN22WTStreptag or 
PTPN22R619WStreptag fusion protein tagged constructs were subsequently subcloned 
into bicistronic GFP reporter lentiviral vector using unique restriction enzyme sites 
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Table 2.2 Sequences of Oligonucleotides used for generation of PTPN22 StrepTAG fusion 
lentiviral constructs 
Primer1 Oligonucleotide Sequence2 
StrepTAG 1F (F1) 3’-TCTCCCAGAAAGAACTCTAG-5’ 
Onestrep TAG-1F (R1) 5’CTTTCTCGAACTGCGGGTGGCTCCAAGCGCTCA
TATT CCAAGCTGATGGC-3’ 




1 The sense of the oligonucleotide is indicated in parentheses. 
2 NotI restriction enzyme site is underlined, stop codon is shown in bold (black) and 
the overlapping between primers is highlighted.  
2.9.8 Sequencing  
The generated recombinant PTPN22-Streptag clones were confirmed by commercial 
sequencing carried out by GenePool (University of Edinburgh, Edinburgh, UK).  
Table 2.3 shows the details of primer sequences used for sequencing. The raw 
sequencing files was analysed using the free online sequence analysis program 
(BioEdit Sequence Alignment Editor) (Hall, 1999). The pair-wise sequence 
alignment was performed in BioEdit software between the obtained sequencing 
results and construct clones. This program was also used to view chromatograms 
generated by GenePool sequencing results.  
Table 2.3 Oligonucleotides used for the sequencing of generated PCR products 
Primer Sequence1 
M-13 F 5’-GTAAAACGACGGCCAGT-3’ 
PTPN22 cDNA R2 3’-TCTTCGAATCAGCACTATTCGG-5’ 
StrepTAG 1F 3’-TCTCCCAGAAAGAACTCTAG-5’ 
1 The sense of the oligonucleotide is indicated in parentheses. 
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2.9.9 Miniprep for Plasmid DNA Isolation 
E.coli containing the plasmid DNA were cultured overnight in 2mL of LB medium 
with antibiotic selection. The bacteria was pelleted at 10000 rpm for 10 min and 
resuspended in 200µL of buffer P1. An equal volume of buffer P2 was added, gently 
mixed and incubated on ice for 5 min. 200µL of chilled buffer P3 was added and the 
tube was inverted several times followed by 10 min incubation on ice. The tubes 
were then centrifuged at 16060g (Biofuge Fresco, Heraeus) for 10 min at 4°C and the 
supernatant was transferred to another tube and 600µL of isopropanol was added and 
incubated on ice for 1 h. The plasmid DNA was pelleted by centrifuging at 16060g 
(Biofuge Fresco, Heraeus) for 10 min at 4°C, washed once with 70% ethanol, air 
dried for 5 min and resuspended in 30µL of TE buffer. 
2.9.10 Large Scale Plasmid Isolation 
Plasmid DNA was purified from E. coli cultures using the NucleoBond® Xtra Midi 
Plus purification kit protocol (MACHEREY- NAGEL, Germany). Briefly, E.coli 
harbouring the gene of interest were cultured overnight in 200mL of LB medium 
with selection antibiotic. The bacteria were pelleted at 42205g (RC56 Sorvall, rotor 
SLA3000) for 10 min at 4°C and resuspended in 8mL of RES buffer. An equal 
volume of LYS buffer was added, gently mixed followed by addition of 8mL of 
NEU buffer, mixed by inverting 5-10 times. After incubation the cells were 
centrifuged at 4347g (Heraeus-Multifuge 3S-R) for 5 min.  The supernatant was 
passed over an equilibrated NucleoBond® Xtra Column Filter and washed once with 
the buffer EQU following which the filter was discarded and column was washed 
with WASH buffer. The plasmid DNA was eluted from the column with 5mL of 
ELU buffer and 3.5ml of isopropanol was added, vortexed and incubated at room 
temperature for 5 min. The mixture was then passed through the NucleoBond 
Finalizer filter. The filter was washed once with 2mL of ethanol and air dried by 
expelling air through the filter (n !5). The DNA was eluted from the filter with 400 - 
800µL of TE buffer (Section 2.1).  
 
          Chapter 2 
    66 
2.9.11 Concentration of DNA by Ethanol Precipitation 
To concentrate plasmid DNA, one- tenth volume of 3M Sodium acetate (pH 5.2) was 
added to the DNA solution, followed by two volumes of 95% ethanol and allowed to 
incubate for 10 min at room temperature. The DNA was pelleted by centrifuging at 
16060g (Biofuge Fresco, Heraeus) for 10 min. The pellet was then washed once with 
70% ethanol air-dried and resuspended in TE buffer. 
2.10 Western Blot (WB) 
2.10.1 Sample Preparation  
The cells were pelleted by centrifugation 300g (Heraeus-Multifuge 3S-R) for 5 min 
and supernatant discarded. The pellet was resuspended at 1x108 cells per 1 mL of 
lysis buffer (described in 2.1.8) with freshly added protease inhibitors and incubated 
for 30 min on ice. The lysates were subsequently microfuged at 16060g (Biofuge 
Fresco, Heraeus) for 10 min at 4°C to separate the nuclear fraction. The post-nuclear 
supernatants were transferred to clean 1.5mL eppendorf tubes (Fisher-Scientific, UK) 
and if not used immediately were labeled and stored at -20°C. For whole cell lysates, 
the samples were defrosted and an 10µL aliquot of 2x106 cells was mixed with 2µL 
of distilled water and 4µL of 4X sample buffer (section 2.1) and boiled for 5 min at 
95°C on a heat block. The samples were briefly centrifuged prior to loading it on a 
gel.  
2.10.2 Immunoprecipitation with Streptactin magnetic beads 
Streptactin magnetic beads were prepared by taking an aliquot of 50µL of beads and 
were washed twice by addition of 500µL of lysis buffer (containing protease 
inhibitors) and retaining the beads by magnetic separation in each wash by placing 
against the magnet. The beads were finally resuspended in 100µL of lysis buffer and 
stored at 4°C until use. 15µL of the washed beads were added to 100µL of cell lysate 
and incubated overnight at 4°C with constant rotation. The beads were microfuged 
very briefly at low speed (95g for 30 sec) and were separated from the supernatant by 
placing the eppendorf tubes against the magnet. The supernatant was discarded and 
the beads were washed thrice with lysis buffer containing protease inhibitors by 
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placing against the magnet, removing the supernatant each time and retaining the 
beads. After the final wash step, the beads were resuspended in 20µL of 4X reducing 
sample buffer (section 2.1) and processed as explained in the section above.  
2.10.3 Gel running 
NuPage Novex Bis-Tris 4-12% (Life Technologies, USA) was placed in an 
electrophoresis system (BioRad, UK) with running buffer (Novex, Life 
Technologies,USA). The protein ladder (Precision Plus Protein Standards All Blue, 
Bio-Rad, US) and samples were loaded and the gel was run at 100V for 1 h in cold 
cabinet with constant stirring.  
2.10.4 Transfer protocol  
The resolved proteins were transferred onto PVDF membranes (Millipore, USA) 
using wet transfer apparatus from (BioRad, UK). Firstly the PVDF membrane was 
activated by soaking in 100% ice-cold methanol for 30 s and then equilibrated in ice-
cold transfer buffer (section 2.1). Two pieces of filter paper (Whatman Ltd, UK) and 
two sponges were immersed in the transfer buffer. The gel was removed from the 
running cassette and equilibrated in the transfer buffer by shaking for 10 min on the 
shaker (Stovall, lifesciences) at room temperature. The transfer sandwich was set-up, 
comprising the outer sponge, filter paper, gel and the PVDF membrane layered 
sequentially from the negative cathode of the transfer cassette, care was taken to 
remove any air bubbles while placing the gel and the PVDF membrane. The transfer 
was performed at 100V for 105 min at 4°C. The blotted membrane was blocked for 
1h at room temperature in Odyssey blocking buffer (Li-Cor, UK). The blot was 
incubated with the primary antibodies (listed in table 2.4) in Odyssey blocking buffer 
containing 0.1% Tween 20 overnight at 4°C. Subsequently the membrane was 
washed in wash buffer thrice for 15 min and then incubated with appropriate 
secondary antibody (listed in table 2.4) in 20 mL wash buffer containing 0.1% SDS 
for 45 min at room temperature. The membrane was washed again three times for 15 
min with wash buffer and acquired in PBS using the Odyssey Scanner (Li-Cor, UK). 
All incubation and washing steps were carried out under continuous shaking.  
          Chapter 2 
    68 
2.10.5 WB analysis and Quantification  
All the western blots were quantified using the Odyssey infrared fluorescence 
imaging systems. The advantages of using the Odyssey are that the fluorescent signal 
is directly proportional to the amount of target protein over a wide range of 
concentrations and two different targets can be identified simultaneously on a single 
blot with spectrally distinct secondary fluorescent antibodies (Table 2.4). Following 
the acquisition the relative band intensities were compared by densitometry using 
Image Studio Lite (Li-Cor Odyssey software). The software calculates the 
background by taking the median values of the background above and below the 
drawn rectangle, which is then subtracted from the final reading. The resulting 
integrated intensity (counts per mm2) was recorded. 
Table 2.4 Antibodies for Western Blot 
Specificity Conjugated Clone Host Usage conc. Manufacturer 
Primary Antibody  
Human 
PTPN22 








Rabbit 1:1000 (stock 
5mg mL-1) 
Genentech 
ZAP-70  29/Zap70 
Kinase 




Actin   13E5 Rabbit 1:5000 Cell signaling 
Secondary Antibody 
Anti-goat Alexa Fluor 
680 
 Donkey 1:5000 
(stock 2mg 
mL-1)  
Cat. A21084, Life 
Technologies, USA 
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Specificity Conjugated Clone Host Usage conc. Manufacturer 





Anti-mouse  Alexa Fluor 
680 
 Goat 1:5000 
(stock 2mg 
mL-1) 
Cat. A21058, Life 
Technologies, USA 
Anti-rabbit Alexa Fluor 
680 
 Goat 1:5000 
(stock 2mg 
mL-1) 
Cat. A21109, Life 
Technologies, USA 
 
2.11 Enzyme Linked Immuno-Sorbant Assay  
Cytokine ELISAs were performed on supernatants that were previously harvested 
from culture plates and stored at -20ºC. IL-2 production was measured with mouse 
IL-2 Ready-Set-Go Kit (Cat 88-7024). The kit was used according to the 
manufacturer’s protocol. Briefly, capture antibody (provided by the kit) was coated 
onto 96 well plate (NUNC, maxisorp, Denmark) in 50µL/well of the supplied coating 
buffer by incubating at 4°C overnight. The following day the plates were blocked for 
1 h at room temperature with 100µL of blocking buffer (supplied with the kit). 
Optimum dilutions of supernatant along with doubling dilution of recombinant 
protein standards were added in a total volume of 50µL/well of blocking buffer. The 
standards were always assayed in duplicates and the supernatants were assayed in 
triplicates. The plates were then incubated on an oscillatory shaker (Stovall, 
lifesciences) for 2 h at room temperature. 50µL of the secondary-biotinylated 
antibody (supplied with the kit) diluted in the blocking buffer were added to each 
well and plates were incubated for 1 h at room temperature. Streptavidin-peroxidase 
(supplied with the kit) was added in 50µL/well in blocking buffer and incubated for 
45 min at room temperature. 50µL of 3, 3, 5, 5-Tetramethylbenzidine (TMB), the 
colorimetric substrate of peroxidase was added (supplied with kit). When the blue 
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color change was noted (or maximum 10 min), the reaction was stopped by addition 
of 0.18M H2SO4 (Carl Roth, UK) and the plates were read at 450nm on microplate 
reader (Fluoroscan II, Labsystems) within 30 min. The plates were washed 
vigorously 3-5 times after every subsequent step with ELISA wash buffer (Section 
2). 
2.12 T cell based functional assays  
2.12.1 In vitro T cell activation  
For antigen-specific stimulation, single cell suspension of lymph node cells and/or 
splenocytes were incubated at density of 5x106 cell mL-1 in 5 mL of complete 
medium, in 6-well tissue culture plate (Nunc, Denmark) containing either 2.5µg mL-1 
of concanavalin A (for polyclonal T cells) (Sigma-Aldrich, stock 10mg mL-1) or 
10nM of SIINFEKL (N4) peptide (for OT-I transgenic T cells) (Cambridge peptides 
stock 1x 10-3M) at 37°C/5%CO2 in a humidified incubator.  
2.12.2 In vitro generation of CTLs 
Ptpn22+/+ and Ptpn22-/- OT-I CTLs were generated by incubating 3x107 total 
splenocytes in 25mL filtered capped tissue culture flasks (Nunc, Denmark) with 
10nM SIINFEKL (N4) peptide at 37°C/5%CO2 in a humidified incubator for 2 days. 
Following 2 days of incubation the cells were washed twice with 1X sterile PBS and 
then incubated for another 2 days with complete culture medium containing 20ng 
mL-1 rhIL2 (PeproTech, UK) in 75mL tissue culture flasks (Nunc, Denmark) at cell 
density of 2.5x106 cells mL-1. A similar procedure was followed for in vitro 
generation of polyclonal CTLs, except that the cells were activated with 2.5µg mL-1 
of concanavalin A, as described above.  
2.12.3 Ex vivo cytokine production  
5x105 cells of ex-vivo lymphocytes were plated in each well of a 96-well round 
bottom plate and were stimulated in a final volume of 200µL of culture medium 
containing a final concentrations of 0.05µg mL-1 phorbol 12,13-dibutyrate (PDBu) 
(Sigma-Aldrich, stock 1mg mL-1) and 0.5µg mL-1 of ionomycin (Sigma) in the 
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presence of 5µg mL-1 Brefeldin A (Sigma) by incubation for 4 h at 37°C 5%/ CO2, in 
a humidified incubator. Unstimulated controls were incubated in 200µL of culture 
medium containing only 5µg mL-1 Brefeldin A. Following 4 h of incubation the cells 
were washed and stained with Live/Dead Aqua (Molecular Probes, Life 
Technologies, UK) dye in PBS for 10 min at room temperature and the cells were 
then fixed and permeabilised for intracellular detection of cytokines (see 2.14.2). 
2.12.4 Cell Proliferation  
Labelling with Cell trace Violet  
For the measurement of in vitro proliferation, single cell suspension of FACS sorted 
CD4+T cells were labelled with Cell Trace Violet (Molecular Probes, Life 
Technologies, UK) according to the manufacturer’s protocol. Briefly, the cells were 
resuspended at 3x106 cells mL-1, in pre-warmed PBS and Cell Trace was added at a 
concentration of 2.5µM with continuous gentle mixing followed by incubation in the 
dark for 20 min at 37°C 5%/ CO2 in a humidified incubator. Excess dye was 
quenched by adding an equal volume of pre-warmed culture medium and incubating 
for 5 min at room temperature. The cells were then centrifuged 300g, and 
resuspended in culture medium at a final concentration of 1x106 cells mL-1. 100µL of 
labelled cells were pipetted into each well of a round-bottomed 96-well plate and 
prepared for stimulation. An aliquot of labelled cells was checked by flow cytometry 
to ensure uniform labelling.  
Activation of T cells using irradiated splenocytes 
Irradiated splenocytes from BALB/c Rag2-/- mice (kindly provided by Prof. Judith 
Allen, University of Edinburgh) were used as a source of antigen presenting cells. 
Briefly, a single cell suspension of splenocytes was prepared and the red blood cells 
were lysed with ACK red cell lysis buffer and the cell suspension was irradiated at 
30Gy (Cs137, Gamma Service Medical, GmBH). Irradiated splenocytes were washed 
thrice with culture medium and then counted and resuspended at a final 
concentration of 2x106 cells mL-1. The cells were mixed with 0, 0.04, 0.2 and 1µg 
mL-1 of anti-mouse CD3! antibodies (eBiosciences, UK) and were added in 2:1 ratio 
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to the Cell Trace labelled CD4+ cells (described above) and the plate was incubated 
at 37°C 5%/ CO2, in a humidified incubator. The cell proliferation was assessed by 
doubling reduction of Cell Trace Violet dye fluorescence at day 3 by flow cytometry  
2.12.5 Ca2+ Flux Assay 
N.B: This assay is very temperature sensitive and during the entire assay 
including harvest of organs, buffers were maintained at room temperature at all 
times unless otherwise specified.  
We wanted to compare the ability to detect Ca2+ flux in thymocytes or lymphocytes 
from three different strains of mice. Therefore, in order to avoid the bias in 
measurement of Ca2+ Flux, the cells from the different strains of mice were 
stimulated simultaneously in a single 5mL round bottom FACS tube (BD 
biosciences, USA). The different cell populations were identified by staining them 
with a varying concentration of Carboxyfluorescein diacetate N-succinimidyl ester 
(Vybrant CFDA-SE, Invitrogen, UK), a commonly used intracellular dye as a marker 
for cell proliferation.  
Single thymocyte cell suspension resuspended at 3x107 cells mL-1, in pre-warmed 1X 
PBS was labelled with CFDA-SE dye at final concentration of either 0.02µM or 
0.012µM, by incubating for 10 min in the dark at 37°C 5%/ CO2. Cells from third 
strain left unlabelled but incubated as above. The excess dye was quenched by 
addition of an equal volume of pre-warmed culture medium containing 10% FCS and 
washed by centrifugation at 300g. The cells were counted using an automated cell 
counter, CASY-1 and mixed in 1:1:1 ratio at final cell concentration of 3x107 cells 
mL-1. An aliquot of cells were checked for proportions by acquisition on a 
MacsQuant (Milltenyi, Germany) flow cytometer. The cells were then resuspended 
at 1x107 cells mL-1 and loaded with 2µM of the ratiometric Indo-1 dye (Life 
Technologies, USA) in pre-warmed PBS. The samples was incubated at 37°C/5% 
CO2 for 40 min after which the excess dye was quenched by addition of culture 
medium containing 1% FCS and washing. At this point, the sample was split into 
three groups for labelling with biotinylated (bio) antibodies (10µg mL-1) (e.g. Group 
1: TCR-bio, Group 2: TCR-bio with CD4-bio and Group 3:CD3-bio with CD4-bio) 
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(eBiosciences, UK) in 100µL of 1% cell culture medium and incubated for 20 min at 
room temperature in dark. Thereafter, the samples were washed and resuspended in 
600µL of culture medium containing 1% FCS, and supplemented with 2.5mM CaCl2 
and 2.8mM MgCl2 for acquisition on LSR II flow cytometer (BD Biosciences, USA). 
The filter configurations for the assay on LSRII are 530/30 PMT A (Indo-1-blue) and 
405/20 PMT B (Indo-1) on the UV trigon. After 45 s of running the samples, 1µg 
mL-1 of Streptavidin-PE was added to induce surface protein crosslinking via the 
bound biotinylated antibodies. The sample was then acquiring for 8 min, before 
stimulating the cells were with 1µg mL-1 of ionomycin (Sigma-Aldrich, UK) that 
served as a positive control. 
The detection of cellular levels of Ca2+ is calculated based on the ratio of the Indo-1 
bound to calcium (emitted at 420nm, violet) and free calcium (emitted at 510nm, 
blue) which is displayed as a parameter over time. Hence before activation the 
presence of excess dye within the cell population gives a predominant violet signal 
and hence low ratio value, whereas upon activation the dye changes from violet to 
blue and hence the Indo-1 ratio increases over time.  
2.12.6 Analysis of pERK phosphorylation  
Different populations of ex vivo thymocytes were labelled with varying concentration 
of Cell Trace Violet (0, 0.1 and 0.012 µM) and mixed in 1:1:1 ratio. The cells 
resuspended at 1x107 cells mL-1 in serum-free culture medium were stained with 
10µg mL-1 of biotinylated anti-mouse CD3 and CD4 antibodies by incubating for 20 
min on ice in the dark. The samples were washed by addition of 200µL FACS buffer 
and centrifuging at 300g from 3 min once, the cells were then resuspended at 
1x107cells mL-1 in FACS buffer and split by aliquoting 100µL of cells in round 
bottomed FACS tubes (BD Biosciences, USA), in triplicates were possible. Tubes 
were then placed in a 37°C water bath and stimulated by crosslinking with 1µg mL-1 
of streptavidin conjugated fluorophore (PE or FITC) antibody for different lengths of 
time (0, 2, 5 and 10 min). The controls included were unstimulated cells, PDBu and 
UO126 inhibitor. The unstimulated control received an equivalent amount of serum-
free culture medium. The reaction was stopped at the desired time point by addition 
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of 2% v/v paraformaldehyde (PFA) (Acros, USA) and incubated for minimum of 15 
min at RT. Amongst the various fix/permeabilisation methods PFA/methanol 
(described in 2.14.2) showed best results for the pERK intracellular staining. 
ERK phosphorylation was monitored in OT-I CTLs by stimulating with 1x10-7 M G4 
peptide. A similar procedure was followed except that the cells were not pooled and 
different time points (0, 2.5, 7.5 and 22.5 min) were considered for the assay. 
2.13 Induction and scoring of arthritis  
Six to eight week-old mice were injected intraperitoneally with 50mg mannan in 
reconstituted in sterile PBS once. Mice were weighed and observed for clinical signs 
weekly for 4 weeks. Signs of arthritis was assessed by visual scoring where 0 = no 
joint swelling, 1 = mild to moderate swelling, 2 = substantial swelling of wrist or 
ankle and 3 = severe swelling of wrist or ankle. Scores for all the wrists and ankles 
were combined for each mouse.  
2.14 Cell treatments 
Depending on the kind of functional assay carried out, the cells were treated with 
various reagents to either inhibit or serve as a positive control for the assay.  
PP2 treatment for inhibition of SFK  
Cells at a concentration of 1x107/mL were incubated in complete medium 
supplemented with 10µM PP2 (Gibco BRL, UK) for 15 min at 37°C/5%CO2 and 
were then fixed with 2% PFA by incubating at room temperature for 20 min 
Sodium Orthovanadate (Na3VO4) treatment to inhibit cellular phosphatases 
Cells at a concentration of 1x107/mL were incubated in complete medium 
supplemented with 100mM Na3VO4 (Sigma-Aldrich, UK) for 15 min at 
37°C/5%CO2 and then fixed with 2% PFA by incubating at room temperature for 20 
min. 
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Phorbol 12,13 – dibutyrate (PDBu) treatment 
Cells at a concentration of 1x106/mL were incubated in complete medium 
supplemented with 0.1µM PDBu (Sigma-Aldrich, UK) for 10 min at 37°C/5%CO2 
and then fixed with 2% PFA by incubating at room temperature for 20 min. 
U0126 treatment for MEK Inhibition 
Cells at a concentration of 1x106/mL were incubated in complete medium 
supplemented with 20µM U0126 (Calbiochem-Novabiochem, UK) for 10 min at 
37°C/5%CO2 and then fixed with 2% PFA by incubating at room temperature for 20 
min. 
2.15 Flow cytometry and Antibodies 
2.15.1 Surface Staining  
The expression of cell surface markers both ex vivo and in in vitro activated T or 
treated cells was assessed using flow cytometry. A minimum of 0.5-1x106 cells were 
pipetted into a conical bottomed 96-well plate (Greiner Bio-One, Germany), 
centrifuged (300g, 5 min) and resuspended in 30µL of PBS containing a 1:750 
dilution of Live/Dead Aqua Stain (Molecular Probes, Life Technologies, UK). The 
cells were stained in the dark by incubating at room temperature for 10 min. The 
excess stain was washed off by addition of 100µL FACS buffer and centrifuging 
(300g, 5 min). The samples were then subsequently stained with fluorescence or 
biotin-conjugated antibodies (listed in Table 2.5) by incubating for 30 min on ice in 
30µl of FACS buffer antibody mix followed by a wash step. For biotinylated primary 
antibodies, a secondary incubation for 15 min on ice with either streptavidin-
conjugates (BD-Biosciences, UK) (listed in Table 2.5) or Alexa Fluor (Molecular 
probes, Life Technologies, UK) (listed in Table 2.4) was performed. Finally the 
samples were washed in FACS buffer and resuspended in 50-300µL of FACS buffer 
and acquired on either LSR II (BD, Biosciences, USA), Canto II (BD Biosciences, 
USA) or MacsQuant (Miltenyi, Germany) flow cytometers.  
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2.15.2 Intracellular Staining  
Cell surface staining protocol was performed as normal. Importantly, the live/dead 
viable staining was always done prior to fixing. Following the final wash of the 
surface stains, intracellular staining with antibodies (listed in Table 2.6) was 
performed with one of the following protocols depending on the application.  
Foxp3 Intracellular staining Kit (Cat. 00-5523-00, eBioscience, 
USA) 
This kit was used specifically for intracellular staining of Foxp3 transcription factor, 
according to the manufacturer’s recommendations. Briefly, cells were resuspended in 
100µL of diluted fixation/permeabilisation buffer (supplied with the kit) and the 
samples were incubated for 20 min at room temperature (or left overnight at 4°C if 
required). Thereafter the samples were centrifuged (600g, 3 min), buffer was 
removed and the pellet fully resuspended, washed twice with 1X permeabilisation 
buffer (600g, 3 min), after which the samples were stained by incubating in 30µL of 
permeabilisation buffer containing the antibody for minimum 30 min at 4°C in dark. 
The samples were finally washed with permeabilisation buffer and resuspended in 
100µL of FACS buffer for acquisition on either LSR II (BD, Biosciences, USA) or 
MacsQuant (Miltenyi, Germany) flow cytometers. 
BD Cytofix/ CytoFix Fixation Permeablisation Kit (Cat. 
555023, BD Bioscience, UK) 
This kit was used when assessing ex vivo cytokine production and for intracellular 
staining of Streptag, as the FoxP3 buffer completely quenched the GFP reporter 
expression. Intracellular staining was performed with one of the following protocols 
depending on the application Briefly, cells were resuspended in 100µL of diluted 
fixation/ permeabilisation buffer and the samples incubated for 20 min at 4°C (or left 
overnight at 4°C if required). Thereafter the samples were centrifuged (600g, 3 min), 
buffer was removed and the samples were incubated with 1X BD permeabilisation 
buffer for 30 min at 4°C and washed (600g 3 min), after which the resuspended 
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samples were stained by incubating in 30µL of permeabilisation buffer containing 
the antibody for a minimum 30 min (and maximum overnight at 4°C) at 4°C in dark. 
The samples were finally washed with permeabilisation buffer and resuspended in 
100µL of FACS buffer for acquisition on MacsQuant (Miltenyi, Germany) flow 
cytometer.  
Paraformaldehyde (PFA) and Methanol procedure for 
Phospho-stainings.  
This intracellular staining protocol was followed for phospho-staining assays (pERK) 
and provided the best results compared to other intracellular protocols. The samples 
were fixed in 2% final concentration of PFA for 20 min at room temperature, washed 
once with 1X PBS by centrifuging at 600 g for 3 min and permeabilized in 90% ice-
cold methanol for 30 min on ice. The samples were then washed in FACS buffer by 
centrifuging at 600 g for 3 min and then stained for 30 min by incubation on ice in 
the dark with the respective intracellular antibodies. Samples stained with 
biotinylated antibodies were subsequently stained with a secondary streptavidin-
conjugated fluorophore (BD-Biosciences, UK) or Alexa Fluor (AF) (Molecular 
probes, Life Technologies, UK) (listed in Table 2.4 & 2.5) for 30 min on ice in dark. 
After staining the samples were washed and resuspended in 100µL FACS buffer on 
either LSR II (BD, Biosciences, USA) or MacsQuant (Miltenyi, Germany) flow 
cytometers.  
2.15.3 Flow Cytometry Data Analysis 
Flow cytometry data was analysed with FlowJo software v.9.6 (TreeStar Inc.). All 
samples were first gated on intact lymphocytes, thymocytes or splenocytes using the 
side scatter (SSC) versus the forward scatter (FSC). The dead cells were excluded 
from analysis, by gating the live/ dead stained cells against forward scatter, following 
which doublet or aggregated cells were removed from analysis by gating for single 
cells through FSC-area (FSC:A) versus FSC-height (FSC:H) or FSC width (FSC:W) 
depending on optimal profile discrimination. Subsequent gating was dependant on 
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population distribution profiles and appropriate antigen-fluorophore marker 
fluorescence intensity used in the particular experiment.  
Table 2.5 Flow Cytometry Antibodies 
Surface Staining 
Primary Antibodies  
Figure Specificity Clone Host Conjugate Supplier 




Biotin  eBioscience, 
USA 
4.5, 4.6 Anti-Mouse 
CD4 








RM4-5 Rat Pacific blue Biolegend, 
USA 
5.2; 5.3 Anti-Mouse 
CD4 











4.5; 4.6 Anti-Mouse 
CD4 






53-7.3 Rat APC BD 
Biosciences, 
USA 
3.4; 3.5 Anti-Mouse 
CD8a 
53-6.7 Rat BV421 Biolegend, 
USA 








53-6.7 Rat PE eBioscience, 
USA 
4.5; 4.6 Anti-Mouse 
CD8a 
53-6.7 Rat PerCP Biolegend, 
USA 
          Chapter 2 
    79 
4.8; 4.9 Anti-Mouse 
CD8a 























104 Rat PE Biolegend, 
USA 
4.13, 5.2 Anti-Mouse 
CD45RB 
C363.16A Rat PE eBioscience, 
USA 
3.8; 4.12 Anti-Mouse 
CD62L 








H1.2F3 Hamster Biotin Biolegend, 
USA 















UC10-4B9 Rat PE Biolegend, 
USA 
4.8; 4.9 Anti-Mouse 
TCR V!3 
KJ25 Mouse  FITC eBioscience, 
USA 
4.8; 4.9 Anti-Mouse 
TCR V!5 
MR9.4 Mouse  PerCP eBioscience, 
USA 
4.8; 4.9 Anti-Mouse 
TCR 
V!8.1/8.2 
KJ16 Mouse  PE eBioscience, 
USA 
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4.8; 4.9 Anti-Mouse 
TCR V!11 
CTVB11 Mouse FITC eBioscience, 
USA 
Secondary Reagents and Antibodies 
4.3 Streptavidin   PerCP Biolegend, 
USA 
4.5, 4.6 Streptavidin    PE Biolegend 
USA  
 
Table 2.6 Flow Cytometry Antibodies-Intracellular staining 
Intracellular Primary Antibodies  
Figure Specificity Clone Host Conjugate Supplier 











































Rat PeCy7 Biolegend, 
USA 
5.11;5.12 Anti- Mouse IL-
17 
Ebio17B7 Rat  APC eBioscience, 
USA 
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2.16 Statistical analysis 
Statistical analyses were done using Prism 6 software (GraphPad Software Inc, 
USA). When comparing two samples significance was calculated using the 
parametric student’s t-test, unpaired, and two-tailed. Significance was denoted with 
the following cutoffs: *P<0.05, **P<0.01, ***P<0.001. Multiple samples were 
compared using one-way ANOVA with post-ANOVA Holm-Sidak or Tukey’s 
methods for multiple t-tests with the following cutoffs: * p ! 0.05. 
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Chapter 3: Role of PTPN22 and its variant 
R619W in T cell signalling 
3.1 Introduction 
Autoimmune diseases are characterized by dysfunction of the immune system 
resulting in the failure to remain tolerant to ‘self’ antigens thus causing aberrant 
attack against self-tissues and organs. Autoimmunity is a consequence of both 
genetic predisposition and environmental factors. Alleles of PTPN22 have emerged 
as the strongest common genetic risk factor for human autoimmunity outside of the 
major histocompatibility complex (Bottini et al., 2006). Studies implicating a 
PTPN22 allelic variant, R620W, in susceptibility to numerous autoimmune diseases 
attests the biological importance of its immune regulatory role (Begovich et al., 
2004; Bottini et al., 2004; Kyogoku et al., 2004). 
PTPN22 shares a similar structure, bearing 89% sequence homology in the catalytic 
domain, and 61% homology in the C-terminal domain between man and mouse 
(Cohen et al., 1999). Given the high degree of homology (70%) between the 
phosphatases, the role of human PTPN22 is likely to be analogous to that of murine 
PTPN22 protein. It is therefore perplexing that studies involving the PTPN22R620W 
(PTPN22R619W in mouse) polymorphisms, which disrupts the association of PTPN22 
with Csk, present conflicting results with regards to the functional consequences of 
the polymorphism in humans and comparable knock-in (KI) mouse model which 
phenotypically resembles the PTPN22 KO mouse and is a loss-of-function mutation 
(Dai et al., 2013; Zhang et al., 2011). 
An early study conducted using peripheral T cells isolated from type-1 diabetes 
patients with heterozygous expression of the PTPN22 R620W polymorphism showed 
reduced IL-2 production after stimulation with CD3/CD28 (Vang et al., 2005), 
suggesting that the variant was a gain-of-function allele. Additionally over 
expression of PTPN22R620W in primary human T cells resulted in significant 
inhibition of TCR induced tyrosine phosphorylation of Lck at Tyr394, TCR-CD3! 
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chain, LAT and demonstrated a more efficient reduction in calcium mobilisation and 
phosphorylation of ERK as compared to expression of the more common variant 
PTPN22 allele (Vang et al., 2005). Likewise, Aarnisalo et al observed a significant 
decrease in IL-2 secretion by PTPN22R620W CD4+ T cells relative to PTPN22 
expressing CD4+ T cells from T1D patients (Aarnisalo et al., 2008). In addition, 
CD4+ T cells from the PTPN22R620W carriers showed a profound decrease in calcium 
flux in response PHA stimulation (Aarnisalo et al., 2008). Collectively, these data 
supported the idea that PTPN22R620W is a gain-of-function mutation that inhibited T 
cell signalling more potently than PTPN22. In support, another study reported a 
reduced TCR-induced calcium mobilisation in memory T cells, among homozygous 
PTPN22R620W carriers (Rieck et al., 2007). TCR-stimulated IL-10 was significantly 
reduced in PTPN22R620W T cells, production of IL-2, IFN-! and TNF-" and 
proliferation of CD4+CD25- T cells were similar to that of PTPN22 controls 
suggesting that the variant is associated with alteration in cytokine balance (Rieck et 
al., 2007). More support for a PTPN22R620W gain-of-function model in T cell 
activation came from a study of SLE, wherein patients expressing the PTPN22R620W 
variant demonstrated a skewing of cytokines profiles towards higher IFN-" serum 
levels (Kariuki et al., 2008). 
The effects of PTPN22R620W polymorphism is not only limited to T cells, healthy 
cohorts expressing PTPN22R620W showed a significant decrease in number of 
memory B cells with impaired calcium flux compared to PTPN22 controls in 
response to stimulation via the BCR (Rieck et al., 2007). Recent studies by Arechiga 
et al. further identified the role of PTPN22R620W in BCR signalling pathway wherein 
it reduced Syk, PLC! and Akt phosphorylation compared to cells expressing the 
common variant PTPN22 allele (Arechiga et al., 2009).  
In contrast to the numerous studies indicating that PTPN22R620W is more efficient at 
suppressing T cell signalling compared to PTPN22, a recent study conducted in a 
group of patients with myasthenia gravis found elevated IL-2 production by 
stimulated PBMCs in PTPN22R620W carriers (Lefvert et al., 2008) thus supporting a 
loss-of-function effect for the PTPN22R620W variant in opposition to the previous 
studies. Further support for the loss-of-function model came from two groups that 
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independently reported the generation of knock-in mice expressing the analogous 
mutation R619W in the murine ortholog of PTPN22. Both groups found that the 
variant exhibited increased TCR signalling with enhanced T cell proliferation and 
expansion of the effector/memory T cell pool (Dai et al., 2013; Zhang et al., 2011). 
Furthermore, peripheral CD4+ T cells carrying the homozygous PTPN22R620W 
substitution from both healthy donors and rheumatoid arthritis patients exhibited 
augmented ERK phosphorylation and proliferation in response to anti-CD3/CD28 
stimulation (Zhang et al., 2011). 
Clearly, whether the disease predisposing variant PTPN22R620W is a gain or loss-of-
function still needs to be resolved. We therefore chose to investigate the functional 
consequence of the mouse ortholog of PTPN22R620W, PTPN22R619W in T cell 
signalling by expressing it in vitro into primary PTPN22-deficient murine T cells. 
3.2 Results  
3.2.1 Generation of C-terminal Streptag PTPN22WT and 
PTPN22R619W lentiviral constructs  
The strategy used to generate the PTPN22WT and PTPN22R619W Streptag fusion 
proteins is outlined in Figure 3.1. The Streptag construct was incorporated in the 
carboxyl terminal of PTPN22WT or PTPN22R619W cDNA using 3’ oligonucleotide 
overhang extension PCR. The overhang extension PCR was generated during two 
rounds of PCR as shown in Figure 3.1A. In the first round, amplification of a 370 bp 
fragment with primer pair F1 and R1 was carried out (listed in Table 2.2) The PCR 
fragment spanned a region between an amino-terminal XcaI restriction site and an 
elongated 3’ end with one copy of Streptag. The 3’ primer was designed such that it 
removed the stop codon and original NotI restriction site from the resulting PCR 
product, thus producing a PTPN22-Streptag fusion protein. Utilising the first PCR 
product as template DNA, a second round of PCR reaction was carried out with 
primer pair F1 and R2 producing a 450 bp PCR product. Primer R2 contained a 3’ 
overlapping sequence with primer R1 and the sequence for a second copy of Streptag 
separated by a glycine serine linker sequence, it also incorporated a stop codon and 
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NotI restriction site. The two PCR products were identified by agarose gel 
electrophoresis as shown in lanes 2,3 and 4, 5 (Fig 3.1B). The final PCR product was 
digested with XcaI and NotI restriction enzymes to produce a 382 bp product, which 
was inserted back into the full-length cDNA clone contained in pCMV-Sport6 vector 
utilising the same restriction sites. To generate PTPN22WT and PTPN22R619W 
lentiviral expression constructs, cDNA encoding the PTPN22WT or PTPN22R619W 
Streptag fusion protein was excised by digestion with EcoRI and NotI restriction 
enzymes and subcloned in an EF1! promoter driven GFP reporter based bicistronic 
lentiviral vector between the EcoRI and NotI restriction sites as depicted in Figure 
3.1C 
3.2.2 Generation of recombinant virus in 293T producer cell 
line and characterization of PTPN22 lentiviral 
constructs by transient transfection. 
Use of the recombinant lentiviral system is a preferred method of gene transfer as it 
results in stable integration into mammalian cells and directs high level gene 
expression. Figure 3.2 illustrates the generation of replication incompetent 
recombinant lentiviral particles by co-transfection, into the producer cell line 293T, 
of plasmids coding for viral envelope proteins from vesicular stomatitis virus 
glycoprotein (VSV-G), viral structural proteins (gag, pol) and the high quality 
lentiviral plasmid DNA containing either PTPN22WTStreptag or 
PTPN22R619WStreptag. The recombinant viral vector is then replicated and assembled 
into complete pseudotype virus particles that are secreted into the culture medium by 
the 293T producer cells. 
The lentiviral vector is bicistronic and the reporter GFP is encoded downstream of an 
IRES sequence. Thus PTPN22 and GFP were transcribed from a single transcript but 
were translated independent of each other; the expression of PTPN22WT and 
PTPN22R619W was confirmed in transfected 293T by intracellular staining for the 
fusion tag, Streptag by flow cytometry. Vector only transfected 293T cells served as 
negative control (Fig. 3.3A). Given that ~99% of the cells were positive for GFP 
expression with either of the constructs, it was surprising that we only detected about 
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32% and 48% of the 293 T cells expressing Streptag (Fig. 3.3A). As Streptag is 
designed for affinity purification of proteins it is possible that detection by flow 
cytometry could be inefficient, suggesting a problem with signal detection rather 
than expression of the construct. The expression of PTPN22 in transfected 293T cells 
was further assessed and confirmed by western blotting, where cell lysates were first 
immunoprecipitated with streptactin magnetic beads and then subjected to 
immunoblotting with Goat Anti-Human PTPN22 antibody (Fig. 3.3B). In these 
experiments, the lentiviral-containing supernatant from 293T cells was tested by 
transducing the murine 3T3 embryonic fibroblast cell line. Figure 3.3C shows that, 
in comparison to the untransfected controls, nearly 99% and 98% of cells were 
transduced with vector only control and PTPN22WT generated supernatant 
respectively, whereas 89% of 3T3 cells were transduced with PTPN22R619W as 
assessed by the expression of GFP. Taken together, these results show that the 293T 
cell supernatant contained sufficient lentiviral particles to efficiently infect the target 
3T3 fibroblast cells and, subsequently, that Streptag-PTPN22WT and Streptag-
PTPN22R619W fusion proteins are similarly expressed.  
3.2.3 Efficient lentiviral-induced expression of PTPN22WT and 
PTPN22R619W in primary PTPN22-deficient T 
lymphocytes. 
Following the initial characterisation of the PTPN22-Streptag fusion lentiviral 
constructs in 3T3 cell line (Fig. 3.2A), we next wanted to test if we could express 
PTPN22WT and PTPN22R619W in primary Ptpn22-/- T lymphocytes. We used the 
Ptpn22-/- OT-I mouse model, which was generated by back-crossing H-2Kb-restricted 
OT-I mice with global deletion of Ptpn22 (described in section 2.3). 
Primary murine lymphocytes are not only difficult to transduce but the efficiency of 
transduction is very low in comparison to the human lymphocytes (Zhang et al., 
2003). Several studies have established the capacity of lentiviruses to transduce 
various kinds of non-proliferating cells both in vitro and in vivo, however some cell 
types such as early progenitor hematopoietic stem cells and resting T lymphocytes 
are refractory to transduction unless dividing (Frecha et al., 2010). Furthermore, the 
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efficiency of lentivirus-mediated gene transfer into T cells depends on a combination 
of various factors such as cycling status of the cells, high viral titers and optimal 
timing of transduction (Zhang et al., 2003). 
Fig 3.4A outlines the summary of optimised protocol utilised for the transduction of 
in vitro generated Ptpn22-/- OT-I CTLs with PTPN22WT and PTPN22R619W lentiviral 
constructs. For the transduction of in vitro generated Ptpn22-/- OT-I CTLs two 
strategies were employed: (1) co-culturing activated Ptpn22-/- OT-I T cells with 
transfected 293T packaging cells (Fig. 3.4 B) or (2) by “spin infection” with the 
produced lentiviral supernatant from transfected 293T (Fig. 3.4 C). Both the 
strategies showed similar transduction efficiency, of up to 70% at 24 hours post 
transduction, as assessed by GFP expression by flow analysis. Therefore all 
subsequent experiments were done using spin-infection technique. Cell viability of 
the transduced cells was determined by staining with TO-PRO-3, an impermeant dye 
that intercalates into DNA in necrotic and apoptotic cells. The flow cytometry plots 
(Fig. 3.4) show that cell death in transduced Ptpn22-/- T cells expressing either 
phosphatase was similar, as determined by the percentage of TO-PRO-3 positive 
cells. Furthermore, in the TO-PRO-3 negative population, the expression profile for 
GFP expression was similar for both PTPN22WT and PTPN22R619W transduced cells 
(~70%). These results demonstrate that both PTPN22WT and PTPN22R619W can be 
expressed with high efficiency in primary mouse Ptpn22-/- OT-I CTLs cells. 
Successful expression of both PTPN22 proteins in Ptpn22-/- OT-I CTLs cells was a 
promising result which allowed us to further address the functional effect of 
expression of PTPN22WT and PTPN22R619W in Ptpn22-/- OT-I CTLs.  
3.2.4 Effects of re-expression of PTPN22WT and PTPN22R619W 
on cytokine production by Ptpn22-deficient cells. 
To investigate the effects of PTPN22R619W on the functional consequences of T cell 
activation, we examined the in vitro production of cytokines by Ptpn22-/- OT-I CTLs 
expressing either PTPN22WT or PTPN22R619W. A recent study from our group 
showed that CD8+ effectors from Ptpn22-/- OT-I TCR transgenic mice had higher 
levels of cytokine expression in response to stimulation with lower affinity peptides 
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compared to Ptpn22+/+ CD8+ cells both in vitro and in vivo (Salmond et al., 2014). 
Therefore, we sought to determine if re-expression of either PTPN22WT or 
PTPN22R619W in in vitro generated Ptpn22-/- OT-I CTLs had any affect on cytokine 
production in response to re-stimulation through the TCR.  
Briefly, in vitro generated Ptpn22+/+ and Ptpn22-/- OT-I CTLs (described in detail in 
section 2.12 and outlined in Fig 3.4A) were transduced with vector only, 
PTPN22WTStreptag or PTPN22R619WStreptag constructs. After 24 h of transduction, 
the cells were re-stimulated with the weak agonist SIITFEKL (T4), and very weak 
agonist SIIGFEKL (G4) peptides at varying concentration (10-8, 10-7,10-6 M) for 4 
hours in presence of Brefeldin A, and the GFP positive cells were assessed for their 
expression of IFN! and TNF" by flow cytometry.  
Firstly to ensure that the results obtained were not affected by the transduction 
procedure, cytokine production from GFP+ (transduced) and GFP- (untransduced) 
Ptpn22+/+ and Ptpn22-/- OT-I CTLs was compared, after transduction with empty 
lentiviral vector construct. In response to re-stimulation with the T4, and G4 
peptides, more untransduced control CD8+ effectors from Ptpn22-/- mice expressed 
IFN! and TNF than their wild-type counterparts (left panel, Fig 3.5A). Similarly, a 
higher proportion of GFP+ Ptpn22-/- cells produced IFN! and TNF than vector only 
transduced GFP+ wild-type cells upon stimulation with either 10-6 M of G4 or T4 
(right panel, Fig 3.5A). Of note, the fewer cells displayed in the GFP gated plots is 
because the fixing and permeabilisation protocol resulted in loss of GFP expression 
so some of the GFP positive cells were lost from the analysis (right panel, Fig 3.5A). 
Nonetheless, these results are in agreement with our recently published data showing 
that Ptpn22-/- OT-I CTLs produced more cytokines than wild-type OT-I CTLs cells 
in response to re-stimulation with low affinity peptide (Salmond et al., 2014).  
Having established that the process of transduction did not impact upon the 
differences observed in cytokine production between the wild-type Ptpn22+/+and 
Ptpn22-/- mice, we next examined the cytokine production in transduced Ptpn22-/- 
OT-I CTLs expressing either vector only, PTPN22WT or PTPN22R619W. The 
efficiency of transduction determined 24 h post transduction by analysis of GFP 
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expression was 70% for both PTPN22WT and PTPN22R619W transduced cells (Fig. 3.4 
C). The GFP positive cells from both PTPN22WT and PTPN22R619W transduced OT-I 
CTLs cells were assessed for their expression of IFN! and TNF by flow cytometry. 
PTPN22 has been previously demonstrated to act as a negative regulator of TCR 
signalling and shown to reduce cytokine production in primary human T cells 
following stimulation via TCR (Aarnisalo et al., 2008; Arechiga et al., 2009; Vang et 
al., 2005). Therefore, it was surprising that expression of either PTPN22WT or 
PTPN22R619W in CD8+ effectors did not result in a decrease in cytokine expression, 
with the percentages of IFN!+ and TNF"+ cells comparable to the vector transduced 
control Ptpn22-/- cells (Fig. 3.5B). These results suggest that the lentiviral induced 
expression of either PTPN22WT or PTPN22R619W in differentiated Ptpn22-/- CTLs was 
not sufficient to significantly temper TCR-induced cytokine production, with similar 
amounts of cytokines been produced as the control Ptpn22-/- T cells.  
3.2.5 Comparison of effects of PTPN22R619W and PTPN22WT 
expression in PTPN22-deficient cells on lymphopenia-
induced T cell expansion 
PTPN22-deficient mice on a C57BL/6 background have increased numbers of 
effector and memory cells (Brownlie et al., 2012; Hasegawa et al., 2004). The 
increase in the effector and memory cell population in PTPN22-deficient mice has 
been attributed to a disruption of T cell homeostasis as demonstrated by the increased 
ability of naïve Ptpn22-/- T cells to proliferate when co-transferred into a 
lymphopenic host compared to their Ptpn22+/+ counterparts (Brownlie et al., 2012). 
In support, recent work from our group has shown that the increased homeostatic 
proliferation in both naïve polyclonal and OT-I Ptpn22-/- T cells was driven by low 
affinity interactions with MHC molecules loaded with self-peptide (Salmond et al., 
2014). As two independent studies have confirmed that the phenotype of T cells from 
PTPN22R619W the knock-in mouse is similar to that of Ptpn22-/- mice (Dai et al., 
2013; Zhang et al., 2011), we hypothesised that we might see differences in the 
homeostatic proliferation between PTPN22R619W and PTPN22WT transduced T cells. 
In order to compare the effects of PTPN22R619W and PTPN22WT on lymphopenia-
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induced proliferation, we performed adoptive T cell transfer experiments. In vitro 
generated CD8+ CTLs from Ptpn22-/- OT-I mice (CD45.2+) were transduced with 
vector only, PTPN22WTstreptag or PTPN22R619Wstreptag plasmids. Wild-type CD8+ 
CTLs (CD45.1+) transduced with vector only served as control. Following 24 hours 
of transduction the control wild-type Ptpn22+/+ CD8+ CTLs were mixed 1:1 with 
Ptpn22-/- CD8+ CTLs transduced with vector, or with PTPN22WTStreptag or with 
PTPN22R619WStreptag and a total of 2x106 cells were injected intravenously into 
RAG KO mice (n=3) as illustrated by the schematics in Figure 3.6. The transduction 
efficiency of each population was comparable before injection (Figure 3.7). After 30 
days, the mice were sacrificed and the LNs and spleens were harvested and analysed 
for the presence of CD45.1+GFP+ (Ptpn22+/+) and CD45.2+GFP+ (Ptpn22-/-) cells. 
Very few cells were recovered in any of the three groups (Figure 3.8A). Although 
not statistically significant, decreased numbers of Ptpn22-/- CD8+ T cells were 
recovered from all three groups (i.e. transduced either with vector, PTPN22WT or 
PTPN22R619W) compared to the Ptpn22+/+ vector transduced control (Figure 3.8B) 
suggesting either that Ptpn22-/- did not expand as well as the wild-type Ptpn22+/+ 
cells or that they did not survive as well. Additionally analysis of the Ptpn22+/+ and 
Ptpn22-/- T cells within the different groups for the proportions of effector 
(CD62LloCD44hi) or central memory (CD62LhiCD44hi) as assessed by expression for 
CD44 and CD62L markers showed no difference (Figure 3.8 C and D). 
To our surprise, there was no expression of GFP in either Ptpn22+/+ or Ptpn22-/- 
CD8+ T cells recovered from any of the groups suggesting that either the transferred 
transduced cells were outcompeted by untransduced cells or that the transduced cells 
lost the expression of the GFP reporter (Figure 3.9). As the recovery Ptpn22+/+ or 
Ptpn22-/- OT-I T cells from either of the groups was very low, failure to survive or 
low level of expansion due to homeostatic proliferation cannot be ruled out. Indeed a 
previous report found that naïve TCR transgenic donor T cells expand to a lesser 
extent than polyclonal C57BL/6 T cells in RAG KO hosts (Kieper et al., 2005). 
Therefore, based on the findings of this study and our results we decided to 
adoptively transfer activated polyclonal T cells transduced with the PTPN22WT or 
PTPN22R619W phosphatase constructs into RAGKO hosts. 
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As before, in vitro activated polyclonal T cells from Ptpn22-/- mice (described in 
section 2.3) were transduced with vector only, PTPN22WTstreptag or 
PTPN22R619Wstreptag plasmids whereas wild-type Ptpn22+/+ activated T cells were 
transduced with vector only control. The level of transduction efficiency of wild-type 
Ptpn22+/+ and   Ptpn22-/- T cells transduced with vector only was comparable and 
expression of either phosphatase in Ptpn22-/- T cells assessed by GFP expression was 
similar (Figure 3.10). The cells were mixed as before and are detailed in schematic 
figure 3.6 with additional control groups of recipient mice injected with 
untransduced in vitro activated Ptpn22+/+ and Ptpn22-/- T cells and untransduced ex 
vivo wild-type Ptpn22+/+ and Ptpn22-/- T cells (Figure 3.11A). Of note, the previous 
study examined homeostatic proliferation by adoptive transfer of naïve T cells 
(Kieper et al., 2005), however due to limitation of lentiviral transduction technique, 
we transferred activated T cells and therefore the additional ex vivo untransduced 
group served as a positive control for the assay. In case the loss of GFP expression in 
the previous experiment was due to length of time (30d) the cells were in the 
recipient, mice were sacrificed 10 days post cell transfer and LNs and spleens were 
analysed. Even though we recovered increased total cell numbers in both LNs and 
Spleen within all the groups in this experiment compared with the previous 
experiment suggesting adoptively transferred cells did expand (Figure 3.11B), once 
again there was complete loss of GFP expression in the adoptively transferred cells 
in all the groups even at this earlier time point (Figure 3.11A). 
Overall the transduced T cells either from the polyclonal or TCR transgenic wild-
type or Ptpn22-/- mice harbouring the lentiviral constructs did not maintain the 
transgene expression in vivo, suggesting there was silencing of the introduced 
transgene or deletion of gene modified cells in vivo. Indeed, examination by PCR for 
the presence of the Streptag in DNA extracted from the lymph nodes of these mice 
showed no bands for the incorporated tag compared to positive control suggesting 
loss of the transduced cells. Disappointingly, therefore, it cannot be concluded from 
these data if there are any differences in the ability of expressed PTPN22WT and 
PTPN22R619W to affect homeostatic proliferation of Ptpn22-/- T cells.  
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3.2.6 Transient transfection of PTPN22 and PTPN22R619W YFP 
fusion constructs showed reduced ERK 
phosphorylation 
To address the functional effects of the allelic variant in TCR signalling, Ag-induced 
phosphorylation of ERK was assessed in Ptpn22-/- OT-I T cells transiently 
transfected with constructs encoding PTPN22WT-YFP or PTPN22R619W-YFP fusion 
proteins by electroporation. The advantage of using fusion proteins was that, unlike 
the bicistronic lentiviral vector where expression of GFP reporter protein was 
independent of PTPN22 protein expression, YFP expression was a direct indication 
of PTPN22 protein expression.  
To optimise and determine the effects of DNA transgene expression in Ptpn22-/- T 
cells, in vitro generated CD8+ CTLs from Ptpn22-/- OT-I mice were transfected with 
increasing concentration of DNA (2.5 µg, 5µg, 10µg per 5x106 cells) using the 
Amaxa transfection system (described in section 2.8). The expression of PTPN22 
was assessed by analysis of YFP expression by flow cytometry following incubation 
for 8 hours post transfection (Fig. 3.12). Figure 3.12 shows expression of a titration 
of different concentrations of PTPN22-YFP fusion proteins 8 hours after 
electroporation. YFP expression was detected in cells transfected with all 
concentrations of DNA tested with an increase of YFP expression proportional to the 
increasing amount of DNA. The frequency of YFP+ cells and the relative level of 
YFP expression gauged by MFI, was much lower in PTPN22WT as compared to 
PTPN22R619W transfected cells at all DNA concentrations (Fig. 3.12). Cell death 
assessed by staining with TO-PRO3 was similar in cells transfected with either 
PTPN22WT or PTPN22R619W (Fig. 3.12). It was therefore determined that a 10µg 
DNA dose resulted in maximal cell transfection efficiency without resulting in 
excessive cell death.  
To investigate the effect of PTPN22WT and PTPN22R619W on TCR signalling, the 
time-course of ERK phosphorylation (pERK) was assessed in PTPN22WT and 
PTPN22R619W transfected Ptpn22-/- cells following stimulation with 10-7M of G4 
(low affinity) peptide for 2.5, 7.5 and 22.5 minutes, stimulation was terminated at 
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respective time points by addition of PFA followed by staining with pERK specific 
antibody and pERK was quantified at a single cell level by flow cytometry (Fig 
3.13).  
Figure 3.13A illustrates the gating strategy employed to permit assessment of pERK 
based on the different amount of expression of YFP. As the PTPN22WT-YFP 
construct was never expressed as brightly as the other two constructs, three gates 
were applied: YFP-, YFPlo and YFPhi, based on GFP control vector expression while 
the untransfected cells served as negative control. Expression of either phosphatase 
construct reduced the proportions of pERK+ cells following TCR stimulation in 
comparison to Ptpn22-/- transfected with GFP only vector (Fig 3.13B). As noted 
earlier the expression of PTPN22WT was lower than that of PTPN22R619W so the 
YFPlo population was compared between all samples (Fig 3.13 C, middle panel). 
Furthermore the data show that the decrease in pERK was dependent on the levels of 
PTPN22R619W-YFP expression, with proportionally fewer pERK+ cells present in 
YFPhi compared to the YFPlo population. The difference in pERK in PTPN22WT or 
PTPN22R619W transfected cells was not significantly different from Ptpn22-/- cells at 
low levels of PTPN22 expression. However high levels of expression of 
PTPN22R619W (assessed by YFPhi) showed a significant three-fold decrease in levels 
of ERK phosphorylation compared to Ptpn22-/- transfected with GFP only vector 
(Fig. 3.13C right panel). Unfortunately lack of YFPhi population in PTPN22WT 
transfected cells prevented a comparison of whether the variant reduced pERK 
activation more or less than PTPN22WT. Taken together, these data show that re-
expression of both PTPN22WT and PTPN22R619W inhibits ERK phosphorylation but 
whether PTPN22R619W is a more or less potent inhibitor of TCR mediated signalling 
than PTPN22WT remains to be determined.  
3.3 Discussion  
In this chapter we aimed to address the functional consequences of PTPN22R619W 
expression and characterise the role of this disease predisposing variant on 
lymphocyte activation. We first optimized the expression of PTPN22WT and 
PTPN22R619W in Ptpn22-/- T cells using lentiviral transduction technology (Fig. 3.4) 
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and studied the subsequent effect of expression on cytokine production from   
Ptpn22-/- T cells in response to stimulation. The transduction efficiency of either 
phosphatase, evaluated by GFP expression was similar and very efficient (Fig. 3.4). 
Restimulation of these cells with varying doses of different affinity peptides led to 
production of IFN! and TNF. However the re-expression of either PTPN22WT or 
PTPN22R619W into Ptpn22-/- T did not alter the percentage of IFN!+ and TNF+ cells 
compared to control Ptpn22-/- T lymphocytes transduced with vector (Fig 3.5B). This 
result was surprising, as PTPN22 has been previously demonstrated to act as a 
negative regulator of TCR signalling and that loss of expression of PTPN22 
primarily impacts effector T cell activation (Brownlie et al., 2012; Hasegawa et al., 
2004).  
There are several possible interpretations of these data. One is that PTPN22 
expression in differentiated CTLs is not important as these cells are intrinsically 
rewired to function without PTPN22. A way to test this possibility would be to treat 
the wild-type Ptpn22+/+ CTLs with chemical inhibitors against PTPN22 and assess 
the cytokine production compared to uninhibited controls. However it is unclear 
whether any of the available inhibitors are specific enough and it would be difficult 
to rule out that they may be affecting other phosphatases. If indeed PTPN22 has no 
effect in differentiated CTLs the level of cytokine expression should remain the 
same. The expression level of PTPN22 in both mouse and human is upregulated 
upon T cell activation (Arimura and Yagi, 2010). It is possible that the lentiviral-
induced expression of both PTPN22WT and PTPN22R619W into Ptpn22-/- T cells is 
insufficient to impact upon cytokine production. In support of this latter view, is the 
observation that decrease in phosphorylation of ERK following TCR stimulation was 
directly proportional to the levels of PTPN22 expression and at low level of 
expression, both PTPN22WT and PTPN22R619W showed similar levels of inhibition of 
ERK phosphorylation (3.13 C). In addition, the comparison of endogenous levels of 
PTPN22 expression with the lentiviral induced expression of PTPN22WT and 
PTPN22R619W by western blot could not be done at the time due to lack of detection 
antibody and would be worth pursuing in future studies.  
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Work from our group has established that PTPN22 is particularly important in 
controlling responses to weak antigens, whereas responses to strong agonist peptides 
are often comparable in the presence or absence of PTPN22 (Salmond et al., 2014). 
Therefore we analysed the ability of Ptpn22-/- OT-I CTLs transduced with 
PTPN22WT and PTPN22R619W construct to expand following adoptive transfer into a 
lymphopenic hosts. These assays were performed by directly comparing expansion 
of transduced Ptpn22-/- cells with control wild-type Ptpn22+/+ OT-I CTLs transduced 
with vector and transferred together into a single host. As transduction efficiency of 
both wild-type Ptpn22+/+ and Ptpn22-/- OT-I CTLs was consistently 50-80% of cells 
(Fig 3.7), we transferred the cells directly without sorting. In contrast to the 
published literature showing increased homeostatic proliferation of Ptpn22-/- T cells 
than their wild-type Ptpn22+/+counterparts (Brownlie et al., 2012; Salmond et al., 
2014) we recovered proportionally fewer Ptpn22-/- cells than wild-type Ptpn22+/+ 
OT-I CTLs within all groups although total cell recovery was extremely poor (Fig 
3.8B). Of note, the published studies addressed the homeostatic proliferation of naïve 
T cells whereas, due to limitation of the transduction procedure, we adoptively 
transferred activated cells, which resembled effector cells. Unlike the naïve T cells, 
the survival and proliferation of antigenic-specific memory cells are largely 
independent of MHC and driven by cytokines (Surh and Sprent, 2000) and it is likely 
that Ptpn22-/- CTLs, which were generated in vitro with IL-2, underwent activation 
induced cell death due to cytokine withdrawal to a greater extent than the wild-type 
Ptpn22+/+ CTLs (Schluns and Lefrancois, 2003).  
Another complication with the interpretation of data from the adoptive transfer 
experiments was the inability to recover GFP+ cells within any of the groups for both 
the Ptpn22+/+ or Ptpn22-/- T cells. The loss of GFP reporter could be possibly due to 
either transgene silencing or competitive outgrowth of untransduced population over 
the transduced cells. Lentiviruses are emerging as a promising tool for gene transfer 
due to their ability to transduce both dividing and non-dividing cells at high 
efficiencies. Whether lentiviruses are also subjected to transgene silencing, however, 
is still controversial (He et al., 2005; Ma et al., 2003; Pfeifer et al., 2002). The 
molecular basis for gene silencing in lentiviruses has been attributed to cytosine 
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methylation of DNA and chromatin structure modification (He et al., 2005). In 
contrast a recent report comparing the ability of different lentiviral promoters to 
maintain in vivo gene expression in murine T cells showed that the expression of the 
reporter was most efficiently maintained in an EF-1alpha promoter lentiviral vector 
in adoptively transferred cells for 2 weeks (Gilham et al., 2010). If loss of GFP 
expression was due to transcriptional repression rather than transgene deletion, use of 
methylase inhibitors could be a way to retrieve the expression. Also it is difficult to 
ascertain whether the loss of reporter expression correlates with loss of transgene as 
GFP protein expression was independently driven by IRES. The inability to detect 
the presence of the Streptag sequence by PCR in DNA recovered from the cells 
suggested that the transferred transduced GFP+ cells either died upon transfer or were 
outgrown by untransduced cells with time as the cells were not sorted before 
adoptive transfer. 
It is difficult to draw any conclusion from the adoptive transfer experiments given 
the loss of reporter expression and generation of bone marrow chimeras may be a 
better approach at understanding the function of PTPN22 in the biological context. I 
generated some preliminary results from naïve T cells recovered from RAGKO 
chimeras reconstituted with Ptpn22-/- bone marrow transduced with vector only, 
PTPN22WT and PTPN22R619W retroviral constructs, which showed that either 
construct reduced T cell activation compared to Ptpn22-/- T cells. PTPN22WT 
appeared to be more suppressive of T cell responses than variant PTPN22R619W 
consistent with the idea that PTPN22R619W was a partial loss of function allele. 
However we then switched from retrovirus to lentivirus transduction hoping for more 
efficient gene transfer and further repeats with the retrovirus system were not 
obtained to consolidate the preliminary results. 
Finally to circumvent the problem of loss of reporter expression in transduced cells, 
Ptpn22-/- OT-I CTLs were transfected with PTPN22WT and PTPN22R619W YFP fusion 
proteins using an Amaxa nucleofection technique. To assess the functional effect of 
PTPN22 in signalling, phosphorylation of ERK was tested in the cells transfected 
with PTPN22WT and PTPN22R619W in response to a time course of stimulation with 
G4, a low affinity peptide recognized by the OT-I TCR. We found that ERK 
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phosphorylation was decreased by expression of either PTPN22WT or PTPN22R619W 
constructs when compared to vector only transduced Ptpn22-/- control cells (Fig 
3.13B middle). No difference in the percentage of pERK+ cells was seen between 
cells expressing PTPN22WT and PTPN22R619W at low levels, but high levels of 
PTPN22R619W showed less ERK phosphorylation than Ptpn22-/- control cells 
suggesting a dose dependent response in inhibition (Fig 3.15C right panel). 
As up to 25 - 50% of PTPN22 has been shown to be bound to 5% Csk in a resting 
mouse T cell (Cloutier and Veillette, 1996), it is likely that when PTPN22 is 
expressed alone in cells, it might alter the PTPN22/Csk complex stoichiometry and 
potentially lead to mislocalisation, resulting in off target effects in respect to 
dephosphorylation. To address this possibility Weiss and colleagues co-expressed 
PTPN22 along with Csk in Jurkat cells and showed that when analysing the different 
populations of GFP expressing cells (from low, intermediary and high) there was a 
dose dependent effect on ERK phosphorylation following TCR signalling 
(Zikherman et al., 2009). Furthermore, the authors show that Jurkat cells transfected 
with either PTPN22R620W or its mouse ortholog PTPN22R619W showed greater levels 
of ERK phosphorylation compared to wild-type controls when expressed alone or in 
combination with Csk, thus concluding that PTPN22 R620W is in fact a loss-of-
function allele, arguing that overexpression levels of the protein must be carefully 
controlled for and also studied in the context of Csk (Zikherman et al., 2009). In 
addition, since multiple TCR signalling regulators are known to interact with Csk-
SH3 domain in T cells (Davidson et al., 1997), some of these phosphatases might 
exist in equilibrium and overexpression of PTPN22 may effect the relative affinity of 
various protein-protein interaction therefore the interpretation of result showing 
expression of PTPN22R619W decreased ERK phosphorylation needs to be considered 
carefully. 
In conclusion it remains contentious whether the R619W substitution increases or 
decreases functional capacity of PTPN22. Studies from two groups independently 
reporting generation of PTPN22 R619W KI mice, a model for a disease-associated 
PTPN22 single-nucleotide polymorphism (Dai et al., 2013; Zhang et al., 2011) 
showed that the effect of the KI mutation on T cells was very similar to that reported 
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for the knock-out (KO) mice therefore suggesting that the SNP acts, in mice at least, 
as a loss-of-function allele. The observed discrepancy resulting in different 
functional consequences of the mutation in human and mice could be attributed to 
the species-specific difference.   
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3.4 Figures  
 
 
Figure 3.1 Generation of PTPN22WT and PTPN22R619W Streptag fusion lentiviral constructs 
Illustration of the PCR-based epitope tagging method employed to generate the Streptag fusion 
PTPN22 constructs. (A) Linear representation of the amplification region of the template plasmid 
along with the primers and restriction sites. The Streptag was introduced at the 3’ terminal by overlap 
extension PCR, first round amplifying 370 bp region between primer pair P1 and R1 spanning across 
XcaI restriction sites and abrogating the stop codon and NotI restriction site and the second round 
further extending the 3’ end of first PCR product with 3’ overlapping primer R2 (overlapping primer 
sequence region on R2 shown in orange) to generate a 450 bp PCR product complete with a stop 
codon and NotI restriction site. The PCR product was cloned back into the pCMV Sport6 vector using 
XcaI and NotI restriction sites in the 3’ to 5’ orientation (indicated as red). (B) The PCR products 
produced were verified by visualization with agarose gel electrophoresis. Lane 1 shows the 10 kb 
ladder while lanes 2 and 3 show the first PCR product (370 bp) for PTPN22WT and PTPN22R619W 
respectively and lanes 4 and 5 show the second PCR product (450 bp) for PTPN22WT and 
PTPN22R619W with two copies of Streptag. (C) The wild-type and the R619W full length C-terminal 
Streptag PTPN22 cDNA were ligated into the pLVX-EF1!-IRES-ZsGreen1pLVX Vector using the 
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Figure 3.2 Production of recombinant lentiviral particles in 293T cells 
Lentiviral construct containing full-length cDNA of PTPN22 was (1) transfected into 293T cells 
along with viral packaging elements using calcium phosphate. The DNA is (2) transcribed into RNA 
and along with the viral structural proteins it is (3) packaged into replication incompetent pseudo 
virus particles that are (4) released in the culture medium, which is collected and used to (5) infect 
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Figure 3.3 Characterisation of PTPN22 Streptag constructs and lentivirus mediated transfection 
of 3T3 cell line.  
 (A) 293T cells were transiently transfected with indicated cDNAs, 2 days following transfection, the 
cells were harvested and intracellular staining for the fusion Streptag was performed following which 
it was analysed by flow cytometry. The FACS histogram shows expression of GFP (top panel) or 
Streptag (bottom panel) in 293T cell lines transfected with either vector alone (black line), PTPN22WT 
(blue line) or PTPN22R619W (red line) compared to untransfected cells (grey shaded). The percentage 
and MFI of GFP+ and Streptag+ population is indicated on the graphs. (B) Streptag tagged PTPN22WT 
and PTPN22R619W 293T transfected lysates were recovered by immunoprecipitation with streptactin 
magnetic beads and determined by immunoblotting with Goat Anti-Human PTPN22 antibody (C) The 
3T3 cell line was infected with lentiviral supernatant generated from either vector alone (black line), 
PTPN22WT (blue line) and PTPN22R619W (red line), efficiency of transfection determined by 
expression of GFP by flow cytometry compared to untransduced cells (grey shaded). 
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Figure 3.4. Lentiviral transduction of primary murine Ptpn22-/- OT-I T cells. 
(A) Summarised protocol for lentiviral mediated transduction (steps of lentivirus generation in 293T 
shown in blue text on scheme) of in vitro generated Ptpn22-/- OT-I CTLs (described in 2.12 and 
shown in red text on the scheme) either by (B) co-culture with transfected 293T cells or (C) by 
incubation with generated lentiviral supernatant. The histogram shows expression of GFP in 
transduced CD8+ T cells either with vector only (black dotted line), PTPN22WT (blue line) or 
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Figure 3.5 Intracellular cytokine production in PTPN22WT and PTPN22R619W transduced 
Ptpn22-/- OT-I CTLs  
(A) Cytokine expression was assessed in untransduced (left panel) or vector only transduced GFP+ 
(right panel) Ptpn22+/+ and Ptpn22-/- OT-I CTLs following stimulation with either 10-6 M T4 or G4 
peptide. (B) The bar chart shows average percentages ± SD of IFN! and TNF" expressing GFP 
positive Ptpn22-/- cells transduced either with vector only (black line), PTPN22WT (green line), or 
PTPN22R619W (red line) following re-stimulation with varying concentration (10-8, 10-7,10-6 M) of 
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Figure 3.6 Adoptive transfer of lentivirally transduced PTPN22WT and PTPN22R619W Ptpn22-/- 
OT-I CTLs into RAGKO mice  
In vitro generated OT-I CTLs (described in 2.12) from wild-type Ptpn22+/+ (CD45.1+) mice were 
transduced with vector only and Ptpn22-/- (CD45.2+) cells were transduced with either vector only, 
PTPN22WT or PTPN22R619W. Transduced CD45.1+ wild-type Ptpn22+/+ and CD45.2+ Ptpn22-/- cells 
were mixed and injected intravenously into Rag1!/! recipient mice (n = 3) at an ~1:1 ratio (2x106 cells 
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Figure 3.7 In vitro transduction efficiency of wild-type Ptpn22+/+ and Ptpn22-/- OT-I CTLs 
The histograms (top panel) show expression of GFP in wild-type Ptpn22+/+ OT-I CTLs transduced 
with vector only (blue line), and Ptpn22-/- T cells transduced with either vector only, PTPN22WT or 
PTPN22R619W (red line) compared to the untransduced control (grey shaded). The percentage of GFP+ 
cells and MFI of GFP population are indicated on the plots. The FACS plots (bottom panel) shows the 
respective ratios of wild-type (CD45.1+) and Ptpn22-/- (CD45.2+) T cells in the three groups before 
injection; of note groups 2 and 3 did not receive 1:1 ratio of wild-type and Ptpn22-/- CD8+ T cells but 
received ~1.5 fold more Ptpn22-/- CD8+ T cells than wild-type Ptpn22+/+ CD8+ T cells. 
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Figure 3.8 Adoptively transferred transduced Ptpn22+/+ and Ptpn22-/- OT-I CTLs did not expand 
in RAGKO hosts 
Lymph nodes and spleen were harvested from the mice 30 days post adoptive transfer (A) The graph 
shows total cell numbers recovered post transfer in each group (B) Total numbers of CD8+ wild-type 
Ptpn22+/+ transduced with empty vector (clear circles) and CD8+ Ptpn22-/- T cells transduced either 
with vector only (black squares), PTPN22WT (green square) or PTPN22R619W (red square) cells 
recovered from the mice in the three groups. No difference was observed in the proportions of (C) 
effector or (D) central memory populations between the wild-type and Ptpn22-/- T cells within any of 
the groups. Each point represents an individual animal (n=3) and the error bars show standard error 
mean 
 
Figure 3.9 Loss of GFP expression following the adoptive transfer  
The histograms show the expression of GFP wild-type Ptpn22+/+ (grey fill) and Ptpn22-/- (red line) 
CD8+ T cells recovered from recipient mice 30 days post adoptive transfer in all the three groups. The 
gates were drawn based on an untransduced control.  
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Figure 3.10 In vitro transduction efficiency of polyclonal wild-type and Ptpn22-/- CTLs 
The histograms show expression of GFP in Ptpn22+/+ T cells transduced with vector only (blue line), 
and Ptpn22-/- T cells transduced with either vector only, PTPN22WT or PTPN22R619W (red line) 
compared to the untransduced control (grey shaded). The percentage of GFP+ cells and MFI of GFP 
population are indicated on the plots. 
 
Figure 3.11 Adoptively transferred transduced wild-type Ptpn22+/+ and Ptpn22-/- polyclonal 
activated T cells expanded in RAGKO hosts but still lost GFP expression.  
Lymph nodes and spleen were harvested from the mice 10 days post adoptive transfer. (A) The 
histograms show expression of GFP in wild-type Ptpn22+/+ T cells transduced with vector (grey 
shaded) and Ptpn22-/- T cells transduced with either vector only, PTPN22WT or PTPN22R619W within 
the different groups (B) The graph shows absolute total cell numbers from LN and spleen recovered 
post transfer in each group.  
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Figure 3.12 Transient transfection of PTPN22WT-YFP and PTPN22R619W-YFP fusion proteins in 
Ptpn22-/- CTLs.  
5x106 CD8+ CTLs from Ptpn22 deficient OT-I mice were transfected with Amaxa® nucleofection 
technology with indicated amounts of (2.5µg, 5µg and 10µg) of PTPN22WT YFP (top panel) or 
PTPN22R619W YFP (bottom panel) DNA and incubated at 37°C/5% CO2 for 8 hours. As shown by 
flow cytometry plots the expression levels of recombinant YFP protein increased proportionally to 
DNA concentration with either phosphatase construct. The histograms shows the level of YFP 
expression in transfected cells as compared to no DNA electroporated control (grey shaded) with 
2.5µg (blue line), 5µg (green line), 10µg (red line) DNA for either PTPN22WT or PTPN22R619W YFP 
fusion protein. MFIs of YFP+ cells are indicated on the plots and shows that PTPN22WT level in 
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Figure 3.13 High-levels of PTPN22R619Wexpression inhibit TCR-induced ERK phosphorylation 
PTPN22WT and PTPN22R619W transfected Ptpn22-/- OT-I CTLs were stimulated for 2.5, 7.5 and 22.5 
min with 1x10-7 M G4 peptide. Medium only treated cells were analysed as negative controls. (A) 
Illustration of the gating strategy devised to examine the different levels of YFP expression (YFP-, 
YFPlo, YFPhi) in PTPN22WT and PTPN22R619WYFP fusion protein transfected cells. (B) Representative 
FACS plots showing with proportion of pERK in vector alone, PTPN22WT and PTPN22R619W YFP 
constructs at 22.5 min post stimulation (C) Bar graph shows the relative percentages of pERK+±SD 
within the different YFP expressing populations in response to peptide stimulation over the time 
course. Data is representative of two independent experiments. Statistical significance calculated in 
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Chapter 4: What is the effect of Ptpn22 
deficiency on the SKG phenotype?  
4.1 Introduction  
The fate of developing thymocytes is dependent on the strength of signals originating 
from the interaction of T cell receptors with self-peptide/MHC ligands expressed on 
thymic stromal cells. Cells with overly low self-reactivity die of apoptosis; highly 
self-reactive clones are eliminated by negative selection while the ones with 
appropriate self-reactivity are retained through positive selection (Starr et al., 2003). 
Thus, thymic development ensures the generation of a diverse repertoire of mature 
CD4+ and CD8+ T cells capable of responding to a wide array of foreign pathogens.  
ZAP-70, a Syk family tyrosine kinase that associates with the TCR CD3 and ! 
subunits plays a critical role in thymocyte development and mature T cell activation 
(Chan et al., 1992). Loss of ZAP-70 protein expression in humans leads to severe 
immunodeficiency characterized by the complete absence of CD8+ T cells and 
unresponsive mature CD4+ T cells (Chan et al., 1994; Elder et al., 1994). Similarly, 
ZAP-70-deficient mice present a complete block at double positive (DP) selection 
stage of thymocyte development resulting in the complete absence of CD4 and CD8 
single positive (SP)  thymocytes, which could be reconstituted within the thymus 
following re-expression of ZAP-70 (Negishi et al., 1995). By contrast, single-
nucleotide substitutions affecting ZAP-70 and other TCR signalling proximal 
molecules show partial defects in TCR signalling and are associated with 
autoimmunity. In SKG mice, a spontaneously-occurring hypomorphic W163C 
mutation within the carboxyl terminal SH2 domain of ZAP-70 reduces the amount of 
ZAP-70 protein expression and results in decreased TCR signalling and impaired 
thymocyte development compared to wild-type BALB/c mice (Sakaguchi et al., 
2003). Furthermore, when maintained under conditions where they are exposed to 
microbes, i.e. not under SPF condition, these mice are prone to spontaneously 
develop CD4+ T cell-mediated autoimmune arthritis that closely resembles 
rheumatoid arthritis in humans (Sakaguchi et al., 2003). 
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Another hypomorphic ZAP-70 mutant mouse strain, ZAP-70 YYAA, which has 
“knock in” alanine substitutions of tyrosine residues 315 and 319 in the interdomain 
B of ZAP-70 protein show similar aberration in T cell development to that of SKG 
mice (Hsu et al., 2009). However, T cells from the YYAA mice are less 
hyporesponsive to in vitro TCR signalling as compared to SKG mice, as shown by 
slight increases in Ca2+ flux and ERK phosphorylation in thymocytes and peripheral 
T cells (Hsu et al., 2009). Interestingly, unlike SKG mice which develop both 
spontaneous arthritis and rheumatoid factor autoantibodies, YYAA mice also 
developed rheumatoid factor antibodies but failed to develop autoimmune arthritis 
due to differential sensitivity to negative selection in YYAA mice (Hsu et al., 2009).  
Graded changes in TCR signalling was first studied by taking advantage of two 
hypomorphic ZAP-70 mutants, murdock (mrd), mrtless (mrt), each with partial 
defects in TCR signalling because of amino acid substitutions within the catalytic 
site of ZAP-70 (Siggs et al., 2007). The mrd mutation, which substituted an 
isoleucine for phenylalanine (I367F) within the kinase catalytic domain, had a 
modest effect on TCR signalling and thymocyte development, whereas the ZAP-70 
mrt mutation, arising due to W405R codon change within the catalytic site, 
completely arrested T cell development at CD4+CD8+ double positive stage. Neither 
of the alleles resulted in autoimmunity individually, however autoimmunity arose 
when these two Zap-70 gene variants were intercrossed (Siggs et al., 2007) revealing 
a threshold effect in which partial, but neither mild nor severe, T cell 
immunodeficiency was sufficient to break tolerance.  
The differences in autoimmune syndromes in SKG, YYAA and ZAP-70mrd/mrt mice 
could be attributed to either the genetic backgrounds or to the differences in TCR 
signaling resulting from the quantitative and qualitative impairments in ZAP-70. An 
informative allelic series of ZAP-70 hypomorphic mutants containing increments of 
Skg allele and/or Zap-70 null allele described recently, provides a model to study 
how genetic anomaly of T cell signalling contributes to autoimmunity (Tanaka et al., 
2010). The study showed a step wise decrease in signalling from +/+, skg/+, skg/skg 
to skg/- in response to stimulation via the TCR which correlated with graded 
alterations in positive and negative selection of T cells in the thymus, thus resulting 
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in an altered repertoire with accumulation of self-reactive autoimmune T cell clones 
in a gene-dosage dependent fashion (Tanaka et al., 2010). 
Collectively, these studies show that TCR affinity for MHC/peptide ligands play a 
central role in shaping the peripheral TCR repertoires that is further influenced by 
TCR signalling thresholds. An association of PTPN22 dysfunction with 
autoimmunity fits well with the known roles of phosphatases in attenuating 
signalling pathways integral to immune cellular reactivity (Rhee and Veillette, 2012). 
However, several key issues need to be addressed which include the substrates of 
PTPN22, the signalling cascades in which PTPN22 acts and finally the underlying 
molecular mechanism by which it regulates the adaptive immune responses to 
maintain or break tolerance.  
To further our understanding of the effects of PTPN22 on T cell signalling, we 
generated double mutant SKG Ptpn22 deficient mice (SKG Ptpn22-/-) by            
back-crossing SKG mice with mice containing global deletion of Ptpn22. Substrate 
trap experiments conducted in vitro in Jurkat T cells show that ZAP-70 is one of the 
substrates of PTPN22, which dephosphorylates the activating Tyr493 residue on 
ZAP-70 (Wu et al., 2006). The combination of these two mutations provides a 
unique opportunity to determine the effects of PTPN22 on proximal TCR signalling 
molecules in the context of an autoimmune disease with a well characterised 
signalling disruption. We wanted to ask if increasing signalling by loss of a negative 
regulator would compensate for the decrease in the function of ZAP-70 (positive 
regulator) in SKG Ptpn22-/- mice and whether the two molecules function by 
affecting similar signalling pathways. 
4.2 Results: Thymic development in SKG and SKG 
Ptpn22-/- mice 
4.2.1 Impaired T cell development in SKG Ptpn22-/- mice  
To investigate the effect of Ptpn22 deficiency on SKG phenotype, we generated 
ZAP70skg/skg Ptpn22-/- double-mutant (hereafter described as SKG Ptpn22-/-) mice. 
Previous studies have shown that homozygous expression of the hypomorphic 
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W163C ZAP70 SKG mutation results in decreased signalling through the TCR 
complex. In developing thymocytes, this decreased signalling results in defective 
positive and negative thymic selection (Sakaguchi et al., 2003). By contrast, Ptpn22-
deficiency has no major impact on thymic selection on mice of the C57BL/6 
background (Brownlie et al., 2012) and results only in a marginal increase in positive 
selection in some TCR transgenic strains (Hasegawa et al., 2004). Therefore, we 
investigated the impact of Ptpn22 deficiency on thymocyte development in         
SKG Ptpn22-/- mice. As initial experiments, broad phenotypic analysis of the thymus 
from SKG Ptpn22-/- mice was performed. 
Previously published data estimated the amount of ZAP-70 protein in thymocytes 
from SKG mice to be 20 to 25% of wild-type BALB/c levels (Hsu et al., 2009). 
Assessment of ZAP-70 protein by western blotting from thymi of age matched 
BALB/c, SKG and SKG Ptpn22-/- mice, showed that thymocytes from SKG and 
SKG Ptpn22-/- mice scanned respectively at ~18% and ~24% of BALB/c levels (Fig 
4.1A). These data suggest that lack of Ptpn22 does not affect expression of ZAP-70 
protein, with the amount of ZAP-70 protein in SKG Ptpn22-/- thymocytes similar to 
that of SKG thymocytes.  
Comparison of thymus lobes taken from SKG Ptpn22+/- and SKG Ptpn22-/- mice 
showed no gross phenotypic abnormalities in size or morphology compared to 
control SKG or BALB/c thymi (Figure 4.1B). The total thymocyte cell numbers 
from SKG Ptpn22+/- and SKG Ptpn22-/- were similar to those of SKG mice, however 
there was a trend for a decrease in thymic cell numbers when compared to BALB/c 
wild-type mice, which, although not statistically significant, was consistent with an 
impairment of positive selection (Fig. 4.1C). These results are in agreement with 
published data, which showed no significant difference in total number of 
thymocytes and thymic architecture between SKG and BALB/c mice (Sakaguchi et 
al., 2003). Moreover, there was no significant difference observed in thymocyte 
number from SKG and SKG Ptpn22+/- mice. Therefore, all subsequent analysis 
compared only SKG with SKG Ptpn22-/- mice. 
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The development process of thymocytes can be further examined by analysis of CD4 
versus CD8 expression by flow cytometry (Fig 4.2A). Three distinct stages of thymic 
T cell development are defined based on the expression of CD4 and CD8: the 
double-negative (DN) stage (CD4-CD8-), the DP stage (CD4+CD8+) and the SP stage 
(CD4+CD8- or CD4-CD8+). Analysis of DN thymocytes from SKG and               
SKG Ptpn22-/- mice showed no significant difference either in proportion (Fig 4.2A) 
or absolute DN cell numbers (Table 4.1) in comparison to the wild-type BALB/c DN 
thymocytes. Additionally examination of the various subsets of DN; DN1, DN2, 
DN3 and DN4, facilitated by staining for CD25 and CD44, showed no striking 
difference in percentages between BALB/c, SKG and SKG Ptpn22-/- (Fig 4.2B); the 
only discernable differences was a marginal decrease in frequency of DN1 subset in 
SKG Ptpn22-/- mice. Overall these results show that there was no block in the 
progression of thymocytes from DN to DP stage in SKG and SKG Ptpn22-/- mice. 
This is in line with published literature showing that ZAP-70 expression is not 
crucial in transition of thymocytes from DN to DP (Negishi et al., 1995).  
As previously reported for SKG mice (Sakaguchi et al., 2003), the proportions, but 
not the numbers, of DP cells were significantly increased, whereas both the 
proportions and the absolute numbers of CD4+ SP and CD8+ SP thymocytes were 
significantly reduced compared to the wild-type BALB/c control (Fig 4.2A, Table 
4.1). Loss of Ptpn22 did not significantly affect these parameters, with similar 
increase in percentages of SKG Ptpn22-/- DP cells (92.6% ± 0.79) to that of SKG 
(91.6% ± 0.92) cells. The proportion of SKG Ptpn22-/- DP cells was increased 
compared to BALB/c DP cells (77.63% ± 4.27), which correlated with the slight 
increment observed in DP thymocyte absolute cell numbers (Fig 4.2A, Table 4.1). 
As observed in SKG thymocytes, the absolute numbers of CD4+ SP and CD8+ SP 
cells was profoundly reduced in SKG Ptpn22-/- mice (Table 4.1). Further analysis of 
the CD8 SP thymocytes, revealed that some of the CD8 SP thymocytes in both SKG 
and SKG Ptpn22-/- mice were immature, TCR-negative cells (Table 4.1).  
Therefore, thymocyte development in SKG Ptpn22-/- mice and SKG mice was 
similarly affected, in that proportionally fewer DP thymocytes from SKG Ptpn22-/- 
and SKG mice matured into either CD4+ SP or CD8+ SP in comparison to wild-type 
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BALB/c control (~5 fold less than BALB/c). These data indicate that, in the context 
of the SKG mutation, Ptpn22 expression does not have a major influence on overall 
thymocyte differentiation (Fig 4.2A, Table 4.1).  
4.2.2 Positive selection is partially rescued in SKG Ptpn22-/- 
thymocytes 
Thymocyte development is an extremely orchestrated process, which is highly 
dependent on receptor signalling. Signals via TCR are critical for determining 
positive versus negative selection at the DP stage of development to generate a 
refined self-restricted and self-tolerant T cell repertoire in the periphery (Gascoigne 
and Palmer, 2011). The importance of ZAP-70 for T cell development is emphasized 
by the fact that loss of ZAP-70 completely arrests T cell development at DP stage 
with the complete absence of CD4+ and CD8+ SPs (Negishi et al., 1995). Partial loss 
of ZAP-70 as seen in SKG mice, results in defective thymic positive and negative 
selection which leads to failure in deletion of autoreactive T cells that cause arthritis 
(Sakaguchi et al., 2003). To determine the effect of Ptpn22 deficiency on thymocyte 
differentiation in SKG Ptpn22-/- mice a more detailed examination of positive 
selection in thymocytes was carried out. 
Thymocytes undergoing positive selection can be identified by staining for the early 
activation marker CD69 together with the TCR (Yamashita et al., 1993). Fig 4.3A 
shows the gating strategy for identification of the distinct stages of thymocyte 
differentiation stages from total live thymocytes. The CD69-TCR- cells in gate 1 
(purple) represent mostly pre-selection CD4+CD8+ cells. As the thymocytes initiate 
positive selection, they express intermediate levels of CD69 and TCR, shown by gate 
2 (green) while cells undergoing positive selection expressed high levels of both 
CD69 and TCR as denoted by gate 3 (orange) and finally as the thymocytes mature 
into CD4 or CD8 SP cells they stop expressing CD69 and retain high levels of TCR 
expression as indicated by gate 4 (blue). Fig 4.3B shows the proportions of BALB/c, 
SKG and SKG Ptpn22-/- thymocytes in these 4 distinct development stages. The table 
shows the average proportion of cells in the different positive selecting gates for 
individual strains with 6-9 mice for each genotype (Fig 4.3C). In comparison to 
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BALB/c, both SKG and SKG Ptpn22-/- thymocytes showed a significant increase 
(p<0.0001) in proportion and numbers of thymocytes, within gate 1 indicating that 
more thymocytes were retained in the pre-selection stage. Significantly decreased 
frequencies of SKG and SKG Ptpn22-/- thymocytes in comparison to BALB/c 
thymocytes were noted for all the subsequent stages of progression (gate 2, gate 3) 
with fewer thymocytes finally maturing into SPs (gate 4). A trend in the increased 
frequency of cells in gates 2 – 4 is noted in the SKG Ptpn22-/- thymocytes compared 
to SKG but only the increase in frequency within gate 2 was significant (p<0.01) 
(Fig 4.3 B and C) 
This observation suggested that Ptpn22 deficiency might potentially affect positive 
selection in SKG Ptpn22-/- thymocytes. To further dissect the impact of loss of 
Ptpn22 on thymic differentiation, the expression of TCR! and CD5 in DP 
thymocytes was assessed. The level of TCR signalling directly correlates with and 
quantitatively influences levels of CD5 surface expression in DP thymocytes (Azzam 
et al., 1998). The TCR levels of SKG and SKG Ptpn22-/- DP thymocytes were 
indistinguishable and were substantially lower than wild-type Balb/c cells (Fig 
4.4A). By contrast, the levels of CD5 expression in SKG Ptpn22-/- DP thymocytes 
were markedly increased above that of SKG DP thymocytes (Fig 4.4A), reflecting 
that the loss of Ptpn22 enhanced the intensity of TCR signalling.  
The levels of both TCR and CD5 are developmentally regulated in thymus and 
increase from DN to DP to SP stages of development, therefore thymocytes at 
temporally distinct stages of maturation could be distinguished by gating for CD5 
versus TCR (Azzam et al., 1998). The DP population can be subdivided into three 
subsets on the basis of CD5 versus TCR staining: DP1 (TCRloCD5lo), DP2 
(TCRintCD5hi) and DP3 (TCRhiCD5int) (Saini et al., 2010). Saini et al. showed that 
the timing of CD4-CD8 lineage commitment is determined by ZAP-70 dependent 
TCR signals and the development of CD4+ and CD8+ T cells were temporally 
separated and originated from these distinct subsets, with CD4+ SP population arising 
from the DP2 subset at ~48h and the CD8+ SP population emerging about one day 
later from the DP3 subset following induction of ZAP-70 expression (Saini et al., 
2010). Fig 4.4B shows the representative dot plots of CD5 versus TCR in DP 
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thymocytes from BALB/c, SKG and SKG Ptpn22-/-. The proportion of cells in each 
gate from individual mice is tabulated and shown in Fig 4.4C. The abundance of 
both CD5 and TCR depends on the levels and function of ZAP-70 (Otsu et al., 2002) 
and given that the amount of ZAP-70 protein is reduced due to the W163C point 
mutation, therefore as expected, the proportion of thymocytes in DP2 and DP3 
subsets was significantly reduced in both SKG and SKG Ptpn22-/- thymocytes when 
compared to wild-type BALB/c. Comparison of the proportion of thymocytes within 
the three subsets indicated comparable proportions in DP1 subset but a significant 
two fold increase in the proportion of thymocytes over SKG was noted in               
DP2 (p = 0.0001) and DP3 subsets (p = 0.016) in SKG Ptpn22-/- (Fig 4.4C).  
Taken together, Ptpn22 deficiency increased the frequency of cells within the DP2 
subset (Fig 4.4C) with a trend towards a modest increase in the absolute numbers of 
CD4+SP thymocytes (Table 4.1) in SKG Ptpn22-/- mice compared to SKG mice, 
suggesting a subtle enhancement of positive selection. 
4.2.3 Ptpn22 deficiency enhances signalling through the TCR 
in SKG thymocytes 
Ca2+ flux initiated by the activation of PLC! is an early consequence of TCR 
signalling and results in NFAT translocation to the nucleus (Masuda et al., 1998). 
Initial experiments were undertaken to establish whether there was a difference in 
Ca2+ signalling between Ptpn22-deficient and wild-type thymocytes on a C57BL/6 
background i.e. when normal ZAP-70 was present. Cells from Ptpn22-/- thymus was 
labelled with low concentration of CFSE and mixed with wild-type Ptpn22+/+ 
thymocytes in 1:1 ratio and loaded with the Ca2+ sensitive fluorescent dye indicator 
Indo 1. Thymocytes were stimulated by incubating with biotinylated antibodies that 
were cross-linked by addition of streptavidin. Calcium flux measurement was carried 
out by assessing the ratio of bound calcium (emitted at 390nm Violet) or unbound 
calcium (emitted at 500nm Blue) to the Indo-1 dye by flow cytometry. In contrast to 
a previous study, which showed that CD3 stimulation resulted in greater increase in 
Ca2+ flux in the double positive thymocytes of PTPN22-deficient mice compared 
with that of wild-type mice (Maine et al., 2012), we found no differences in Ca2+ flux 
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in double positive thymocytes of PTPN22 KO and wild-type mice following 
stimulation via crosslinking of CD3 with CD4 (Fig 4.5). 
As increased expression of CD5 at the DP stage is associated with enhanced TCR 
signalling (Azzam et al., 2001; Azzam et al., 1998), we sought to determine whether 
the lack of Ptpn22 in SKG thymocytes increased the sensitivity to TCR signalling. If 
so this might explain why DP thymocytes from SKG Ptpn22-/- had increased levels of 
CD5 expression compared to SKG thymocytes (Fig 4.4A). Cells from BALB/c, SKG 
and SKG Ptpn22-/- thymus were labelled with different concentration of CFSE to 
distinguish each population (Fig 4.6A). As described above, the cells were mixed in 
1:1:1 ratio, loaded with the Indo 1 and the thymocytes were stimulated by cross-
linking. Cross-linking TCR with CD4 or CD3 with CD4, but not TCR alone, induced 
a robust peak of intracellular Ca2+ flux in wild-type BALB/c DP thymocytes whereas 
Ca2+ flux in SKG thymocytes was impaired, as has been reported previously 
(Sakaguchi et al., 2003). The absence of Ptpn22 partially restored the ability of TCR 
with CD4 or CD3 with CD4 crosslinking to induce Ca2+ flux in SKG DP cells, 
although it was lower than wild-type BALB/c control (Fig 4.6B). 
Mitogen activated protein kinase (MAPK) pathways are major pathways induced by 
TCR stimulation and are critical for T-cell responses (Smith-Garvin et al., 2009). In 
particular, the ERK cascade is reported to play an important role in the regulation of 
T cell activation and can be differentially regulated based on TCR signal strength 
(Daniels et al., 2006). Thymocytes from BALB/c, SKG and SKG Ptpn22-/- were 
labelled with different concentration of Cell trace dye and mixed in ~1:1:1 ratio (Fig 
4.7A). The extent of ERK phosphorylation stimulated by antibody-mediated 
crosslinking of CD3 and CD4 was determined at various time points by FACS 
analysis using a phospho-Erk antibody (Fig 4.7B). As reported previously, 
phosphorylation of ERK was markedly reduced in SKG compared to wild-type 
BALB/c thymocytes (Sakaguchi et al., 2003). SKG Ptpn22-/- thymocytes displayed 
marginally increased ERK phosphorylation compared to SKG thymocytes as shown 
by increased percentage and MFI of pERK+ cells at 2 mins but the response of both 
SKG and SKG Ptpn22-/- thymocytes declined more rapidly than that of BALB/c 
thymocytes (Fig 4.7C). In response to PdBU stimulation, levels of ERK 
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phosphorylation were comparable in all 3 mouse strains (Fig 4.7C). This control 
indicated that there were no intrinsic defects in the ERK MAPK pathway in SKG and 
SKG Ptpn22-/- cells and that the major differences arose from defects in TCR- 
dependent activation of the pathway. 
Collectively, these data showed that Ptpn22 deficiency improved signalling 
downstream of the TCR in developing SKG thymocytes, although this seemed 
stronger for the Ca2+ rather than the ERK pathway. These data complement the 
results obtained in Fig 4.4A that showed increased levels of CD5 expression in SKG 
Ptpn22-/- DP thymocytes with comparable TCR! expression to SKG DP thymocytes, 
therefore, indicating an increased signalling potential due to lack of Ptpn22. These 
data are also in agreement with published literature showing Ptpn22 deficiency has 
direct effects on T cell signal transduction (Brownlie et al., 2012; Hasegawa et al., 
2004). 
4.2.4 Ptpn22 deficiency does not alter the TCR repertoire 
compared to SKG mice 
In BALB/c mice, thymocytes expressing TCR V!3, V!5, V!11 and V!12 chains are 
reactive with endogenous viral superantigens encoded by Mtv-8 and Mtv-9, and are 
subsequently deleted (Matsutani et al., 2006). It has been noted that there is an 
increased frequency of thymocytes bearing these TCR V! subfamilies in SKG mice 
indicating a failure in negative selection (Hsu et al., 2009). Furthermore, a recent 
study showed that a graded decrease in TCR signal strength by the expression of 
aberrant ZAP-70 led to alteration of TCR repertoire due to failure of deletion of self 
reactive autoimmune clones in the thymus (Tanaka et al., 2010). Therefore we sought 
to determine if there was any effect of Ptpn22 deficiency on expression of particular 
TCR V! families.  
FACS analysis showed that the frequency of mature CD4+CD5+ thymocytes 
expressing TCR V!3, V!5 or V!11 chains was increased in SKG as compared to 
wild-type BALB/c thymi (Fig 4.8). Additionally a compensational decrease in the 
proportion of TCR V!8.1/8.2+ cells which are normally positively selected was noted 
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in SKG cells. This is in line with published literature (Hsu et al., 2009). Despite 
increased expression of CD5 and signalling in SKG Ptpn22-/- compared to SKG 
thymocytes, there was no significant difference in the TCR V! repertoire 
representation in either mature CD5+ CD4+ SP or CD5+ CD8+ SP SKG Ptpn22-/- 
thymocytes (Fig 4.9). Furthermore, compared to T cells from SKG mice, SKG 
Ptpn22-/- T cells showed no significant differences in the repertoire of peripheral 
CD4+ or CD8+ T cells expressing particular V!s except for V!11 (Fig 4.9) which 
could be attributed to very few cells that were acquired.  
These data indicate that Ptpn22 deficiency does not significantly increase negative 
selection in SKG Ptpn22-/- mice compared to SKG mice and the increase in TCR 
signalling caused by loss of Ptpn22 is insufficient to cause significant alteration in 
V! repertoire usage. This result is supported by previous studies reporting that 
Ptpn22 has minimal role in negative selection (Hasegawa et al., 2004). 
4.2.5 Ptpn22 deficiency does not change the total cell 
numbers in the periphery in comparison to SKG mice.  
Collectively, studying the thymic development in SKG Ptpn22-/- mice demonstrated 
that the loss of Ptpn22 in SKG Ptpn22-/- mice partially rescued positive selection and 
increased the sensitivity of signalling in thymocytes. We next assessed whether it 
altered the composition or function in the resulting pool of peripheral T cells.  
Previous reports have shown that Ptpn22-/- mice of the C57BL/6 background develop 
splenomegaly and lymphoadenopathy suggesting a dysregulation of the lymphoid 
compartment (Brownlie et al., 2012; Hasegawa et al., 2004). Fig 4.10 shows an 
image of lymph nodes and spleen taken from a 7-week old SKG Ptpn22-/- mouse 
compared to age matched SKG and BALB/c wild-type control mice. The size of the 
lymphoid organs is similar in all 3 mouse strains, which is further reflected by no 
significant differences in the total cell numbers in SKG Ptpn22-/- compared to SKG 
and BALB/c wild-type control mice. These data are consistent with published reports 
of a lack of effect of the SKG mutation on LN and spleen cellularity (Sakaguchi et 
al., 2003).  
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4.2.6 Increase in proportion of effectors with age in           
SKG Ptpn22-/- mice.       
FACS analysis of peripheral T cells in SKG Ptpn22-/- mice showed a similar 
decrease in proportions of CD4+ and CD8+ T cells as that of SKG mice (Fig 4.11). 
Numbers of CD4+ and CD8+ T cells in lymph nodes (Table 4.2) and spleen      
(Table 4.3) from SKG mice were reduced compared with wild-type BALB/c mice as 
previously reported (Sakaguchi et al., 2003). Consistent with the trend towards an 
increase in the absolute numbers of CD4+ SP thymocytes (Table 4.1), there was an 
increase in the absolute numbers of CD4+ T cells in LN from SKG Ptpn22-/- mice as 
compared to SKG mice, with numbers similar to that of BALB/c mice (Table 4.2). 
In contrast, there was no increase in the number of CD4+ T cells in the spleen  
(Table 4.3). Additionally SKG Ptpn22-/- also showed similar relative increase in B 
cell numbers as observed in SKG mice and compared to wild-type BALB/c mice 
(Table 4.2).  
Naïve T cells generated under lymphopenic conditions acquire memory-phenotype, 
showing higher level expression of memory marker CD44 due to extensive 
homeostatic proliferation (Sprent and Surh, 2011). SKG mice show a lymphopenia 
induced increase in the effector population in the periphery due to reduced thymic 
output of CD4+ and CD8+ T cells (Sakaguchi et al., 2003), whereas the 
effector/memory population is increased in Ptpn22-/- deficient mice due to lack of 
homeostatic regulation (Brownlie et al., 2012; Salmond et al., 2014). We wanted to 
assess if the deficiency of Ptpn22 on the SKG background increased the effector and 
memory cell population in the periphery of SKG Ptpn22-/- mice. Although young (6 
week old) SKG Ptpn22-/- mice showed no difference in effector/memory T cell pools 
compared to SKG mice as characterised by CD44 and CD62L expression in CD4+ 
and CD8+ T cells by FACS. Further examination of the CD4+ and CD8+ T cells in 
the LN of older SKG Ptpn22-/- mice (> 5 months) showed increased proportions, but 
not cell numbers, of effector memory T cell pools compared to SKG mice as 
determined by CD44hiCD62Llo (Fig. 4.12) and CD45RBlo population (Fig. 4.13). 
Additionally, the increase in effector/memory phenotype was accompanied by a 
decrease in the frequency of naïve cell (CD44loCD62Lhi) (Fig 4.12). By contrast, the 
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proportions of CD44hiCD62Lhi central memory population were similar in SKG and 
SKG Ptpn22-/- mice. These data show that CD4+ T cells from SKG Ptpn22-/- have a 
significant increase in proportions of CD44hiCD62Llo and CD45RBlo populations, 
suggestive of T cells responding to endogenous autoantigens or to the lymphopenic 
environment.  
4.2.7 Ptpn22 deficiency increased the numbers of Tregs in 
SKG Ptpn22-/- mice 
Decrease in TCR signal strength due to deficiency of ZAP-70 results in a decrease in 
the proportion of thymic Tregs in SKG mice, however, in contrast to the thymus, the 
ratios of Tregs are substantially increased in the lymph nodes and spleen of the SKG 
mice in comparison to BALB/c mice due to lymphopenia (Tanaka et al., 2010). Our 
data indicated that the loss of Ptpn22 in SKG mice altered the signal intensity in the 
thymocytes of SKG Ptpn22-/- mice (Fig 4.4A). TCR signal strength is crucial in 
development of Tregs, which can develop either in the thymus (natural Tregs; 
nTregs) or in the periphery upon T cell activation (induced Tregs; iTregs) 
(Josefowicz and Rudensky, 2009). The increase in number could be explained by the 
increased number of thymic nTregs, increased induction of iTregs in the periphery, 
or increased survival/expansion of either or both of these populations. We examined 
if Ptpn22 deficiency in SKG mice led to changes in proportions of thymic and 
peripheral Tregs. The percentages and the absolute cell numbers of FoxP3+ cells 
were not increased in thymi of young (~7-week-old) SKG Ptpn22-/- mice compared 
to those in SKG mice (Fig 4.14) thus suggesting comparable selection of nTregs in 
both strains. We noted a mild increase in the percentages and the cell numbers of 
CD25+FoxP3+ Tregs in both the lymph nodes and spleen in SKG Ptpn22-/- mice 
compared to SKG mice (Fig 4.15).  
Taken, together these data suggest that loss of Ptpn22 enhances T cell signalling in 
SKG mice leading to the subtle increase in numbers of Tregs. This is line with 
previously published literature showing Ptpn22-/- mice presented with increased 
proportion and numbers of peripheral Tregs (Brownlie et al., 2012).  
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4.3 Discussion  
The aim of the work presented in this chapter was to determine the impact of Ptpn22 
deficiency on T cell development and signalling in context of SKG background. To 
this end we compared the SKG Ptpn22-/- mice with SKG mice, which contains a 
spontaneous W163C mutation in the C-terminal domain of ZAP-70 and results in 
reduced levels of ZAP-70 protein (Sakaguchi et al., 2003) (Fig 4.1A).  
PTPN22 is a negative regulator of early TCR signalling that tempers the activity of 
SFKs, including Lck by dephosphorylation of the activatory tyrosine residue on 
LckY394 (Cloutier and Veillette, 1999; Gjorloff-Wingren et al., 1999). Moreover, 
PTPN22 may also attenuate signals via the TCR by dephosphorylating ZAP-70, 
CD3!/" and Vav (Wu et al., 2006). ZAP-70 plays a critical role in TCR signalling 
both during thymocyte maturation and in mature T cell responses (Chan et al., 1992). 
Thymocyte development and TCR signalling is significantly impaired in SKG mice 
leading to decreased numbers of CD4+ and CD8+ SP thymocytes and diminished 
signalling (Sakaguchi et al., 2003; Sakaguchi et al., 2006). Phenotyping of Ptpn22-/- 
mice suggested that Ptpn22 deficiency may augment positive selection in Ptpn22-/- 
mice, either polyclonal or TCR transgenic, displayed increased fractions and 
numbers of CD4 SP cells (Hasegawa et al., 2004) and similar results were found in 
two independently generated PTPN22R619W mice (Dai et al., 2013; Zhang et al., 
2011). In another study, Zikherman et al described subtle TCR hyperresponsiveness 
and evidence of increased TCR signal strength among Ptpn22-/- immature 
thymocytes, suggesting that altered antigen receptor thresholds in comparison to 
wild-type counterparts might contribute to the observed enhancement of positive 
selection (Zikherman et al., 2009). Thus we focussed initially in the thymus to study 
the effect of loss of Ptpn22 on selection and development of SKG mutant mice.  
Overall, thymic development was quite similar to SKG mice in the combined SKG 
Ptpn22-/- mice, with reduced numbers of CD4+ SP and CD8+ SP thymocytes and 
similar distribution of the major thymocytes subpopulations. However, there were 
subtle changes that indicated that loss of Ptpn22 partially rescued signalling in 
developing thymocytes, in particular the increased surface expression of CD5 in 
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SKG Ptpn22-/- as compared to SKG DP thymocytes (Fig 4.4A). Detailed 
investigation of the distinct maturation stages of DPs by examining the levels of 
expression of CD5 and TCR revealed significantly greater percentages of DP2 
thymocytes in SKG Ptpn22-/- relative to SKG (Fig 4.4B). A recent report showed 
that CD4+ SP T cells originate from the DP2 subset (Saini et al., 2010). These results 
suggest that while Ptpn22 deficiency did not result in a significant quantitative 
increment in SP cell numbers but it showed a subtle changes in immature thymocyte 
populations in SKG Ptpn22-/- mice compared to SKG mice. In vivo experiments, 
which tuned proximal TCR signalling by manipulating Src family kinases suggest 
that “strong” signals promote the development of CD4+ T cells (Hernandez-Hoyos et 
al., 2000; Legname et al., 2000). This could explain the trend towards an increase in 
CD4+ SP numbers observed in SKG Ptpn22-/- thymocytes (Table 4.1). 
Consistent with increased levels of CD5 expression, DP thymocytes from            
SKG Ptpn22-/- mice showed increased sensitivity compared to SKG thymocytes in 
signalling through the TCR as seen by improved calcium flux (Fig 4.6) and more 
moderately, ERK phosphorylation (Fig 4.7). However, the SKG Ptpn22-/- 
thymocytes still showed diminished TCR signalling in comparison to the control 
BALB/c thymocytes, suggesting that Ptpn22 deficiency could not completely 
compensate for the reduced signalling capacity of SKG cells. Alteration in the 
expression and function of ZAP-70, as shown by expression of aberrant ZAP-70, 
results in graded attenuation in TCR signalling strength (Tanaka et al., 2010) thus 
supporting our findings that removal of a PTPN22, a negative regulator, is 
compensating for decreased function of ZAP-70.  
CD5 expression has been shown to be associated with TCR affinity (Kassiotis et al., 
2003), therefore the increase in CD5 MFI expression in SKG Ptpn22-/- DP 
thymocytes may be indicative of a change in repertoire selection due to loss of 
Ptpn22. Given the subtle changes in positive selection and the improved signals 
through the TCR, we anticipated differences in the negative selection of the TCR V! 
repertoires. Surprisingly, the data show minimal effect of Ptpn22 deficiency in 
negative selection with frequencies of the select autoreactive V! members 
comparable between the two mouse strains both in the thymus (Fig 4.8) as well as in 
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the periphery (Fig 4.9). These findings suggest many possible implications, first that 
Ptpn22 is less important in negative selection, which is in line with previous study 
showing Ptpn22 deficiency had no effect on negative selection (Hasegawa et al., 
2004) and second, that the increase in signalling due to loss of Ptpn22 was not 
sufficient to further shift the window of thymic selection seen in the SKG mice 
(Sakaguchi et al., 2003). Third the strength and kinetics of both Ca2+ and ERK 
signalling are extremely important in positive versus negative selection (Gascoigne 
and Palmer, 2011). In support of this view is the result showing that the 
phosphorylation of ERK was less moderately affected in SKG Ptpn22-/- mice 
compared to SKG mice (Fig 4.7). Mariathasan et al. showed that low level but 
sustained extracellular signal related kinase (ERK) signaling downstream of MAPK, 
promoted positive selection, but strong and transient ERK activation led to negative 
selection (Mariathasan et al., 2001). Higher affinity interactions of thymocyte TCR 
with self-antigen are thought to be required for differentiation of Treg in thymus, 
suggesting that alteration of TCR signalling might determine the amount of Tregs 
(Hsieh et al., 2012). However, we did not find any changes in the thymic output of 
Tregs providing further evidence that Ptpn22 deficiency did not grossly affect thymic 
development in SKG Ptpn22-/- (Fig 4.14). 
We noted an increase in the number of CD4+ T cells, which paralleled the CD4+ T 
cell numbers in BALB/c mice however such a difference was only noted in the 
lymph nodes and not in spleen. Of importance is the increased proportion of effector 
cells characterized as CD44hi CD62Llo or CD45RBlo seen in the periphery of               
SKG Ptpn22-/- mice (Fig 4.12 and 4.13) suggesting greater lymphopenia induced 
expansion early on in development due to decreased thymic output, which was 
further exacerbated by loss of Ptpn22. The increase in effector cells was not 
surprising as studies conducted in Ptpn22 deficient mouse model showed increased 
expansion and function of effector/memory T cell pool, which may stem from loss of 
the homeostatic regulation of naïve T cells by low affinity self-antigens (Brownlie et 
al., 2012; Salmond et al., 2014). Furthermore, consistent with our previous study 
showing that increase in the effector population is counteracted by increased 
regulatory T cells in periphery of PTPN22-deficient mice (Brownlie et al., 2012) we 
          Chapter 4 
    126 
also noted a subtle increase in the proportion and the numbers of Tregs in the LNs 
and spleen (Fig 4.15).  
Overall, this chapter highlighted that Ptpn22 deficiency did not overtly affect thymic 
development but showed subtle effects on positive selection in SKG Ptpn22-/- mice 
as evident by increased TCR signal strength in immature thymocytes compared to 
SKG mice. These results show that removal of PTPN22 can compensate, at least 
partially, for the deficient ZAP-70 activity in the SKG mice, thus linking PTPN22 
and ZAP-70 to a common signalling pathway in vivo. 
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4.4 Figures 
 
Figure 4.1. Ptpn22 deficiency does not alter the reduced levels of ZAP-70 on SKG background 
and total thymic numbers are comparable between SKG and SKG Ptpn22-/- mice. 
(A) Abundance of ZAP-70 protein in thymocytes from age matched (7week) BALB/c, SKG and     
SKG Ptpn22-/- were analysed by western blotting (pre-cast gel). The blot was sequential blotted for 
anti-ZAP-70 (BD biosciences) and anti-Actin antibodies overnight at 4°C and for 1 hour at room 
temperature respectively, and then blotted with anti-mouse (for ZAP-70) and anti- rabbit (for Actin) 
fluorescent secondary antibodies for 1 hour. The blot was scanned using Li-Cor systems. Relative 
expression of ZAP-70 was calculated by normalising fluorescence of bands to BALB/c band 
fluorescence. Experiment is only done once. (B) Representative thymi from 7 week old BALB/c, 
SKG, SKG Ptpn22+/- and SKG Ptpn22-/- mice. (C) Total cell numbers were counted using CASY 
counter. Data shown are pooled from 3 independent experiments representing BALB/c (black fill 
circles), SKG Ptpn22+/+ (green fill circles), SKG Ptpn22+/- (blue fill circles) and SKG Ptpn22-/- (red 
fill circles). Dot plots shows group means indicated by the horizontal bars ± SD with each point 
representing individual mouse. Statistical significance was calculated in Prism using Student’s t – test 
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Figure 4.2 Thymic development is impaired in SKG Ptpn22-/- mice  
 (A) Single-cell suspensions from thymi of age matched (7 week) BALB/c, SKG and SKG Ptpn22-/- 
mice were assessed for the proportions of DN (CD4-CD8-), DP (CD4+CD8+), CD4SP (CD4+CD8-) 
and CD8SP (CD4-CD8+) by staining for CD4 versus CD8 by flow cytometry. (B) Contour plots 
depicting the sub-stages of the DN population; DN1 (CD44+CD25-) DN2 (CD44+CD25+), DN3 
(CD44-CD25+), DN4 (CD44-CD25-) were identified by staining for CD44 versus CD25. Numbers on 
the plots denotes the averages ± SD of a minimum of 3 individual mice per group. Numbers in bold 
blue font represent significant difference calculated in prism with One-Way ANOVA, P<0.001. Data 
are representative of 4 independent experiments with minimum of 3 mice per group. Three replicate 
experiments conducted with 7 week old mice, and one with 11 week old mice showed similar results.  
 














































































Genotype Total DN DP CD4 SP CD8 SP CD8 SP TCR+ 
BALB/c (n=9) 125.2 ± 13.8 7.0 ± 2.7 98.1 ± 8.8 11.5 ± 2.0 4.0 ± 2.3 3.4 ± 1.9 
SKG (n=9) 113.3 ± 3.2 4.7 ± 1.5  102.5 ± 3.5  2.7 ± 0.7  0.8 ± 0.3 0.34 ± 0.1 
SKG Ptpn22-/- (n=12) 112.1 ± 10.4 4.7 ± 3.0 100.8 ± 9.6 3.3 ± 0.5 0.8 ± 0.2  0.45 ± 0.18 
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Figure 4.3 Positive selection is partially restored in SKG Ptpn22-/- mice. 
(A) CD69 together with TCR! on total live thymocytes was used to distinguish the stages of positive 
selection. Gate 1: pre-selection DPs thymocytes denoted by CD69-TCR-; Gate 2: DPs thymocytes 
initiating positive selection denoted by CD69+TCR+; Gate 3:Thymocytes undergoing positive 
selection denoted by CD69hiTCRhi; Gate 4: SPs denoted by CD69loTCRhi (B) Representative flow 
cytometry plots show the CD4 versus CD8 profile for the 4 selecting gates for BALB/c, SKG and 
SKG Ptpn22-/- thymocytes. (C) Table shows the proportions of thymocytes within the four stages of 
positive selection for indicated strains of mice. Data represents the average of 6-9 mice per genotype 
(±SD) from three independent experiments. Numbers in bold represent significant difference 
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Gated on live thymocytes 
C. Genotype Gate 1 Gate 2 Gate 3 Gate 4 
BALB/c 73.1 ± 2.4 7.3 ± 0.5 10.4 ± 2.6 5.4 ± 0.8 
SKG 93.5 ± 1.7 1.8 ± 0.3 1.9 ± 0.8 1.2 ± 0.3 
SKG Ptpn22-/-  90.8 ± 2.1 2.8 ± 0.4  2.6 ± 0.9 1.8 ± 0.3 
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Figure 4.4 SKG Ptpn22-/- DP thymocytes show increased expression of CD5 compared to DP 
thymocytes from SKG mice  
(A) FACS histogram plots showing the surface expression of CD5 and TCR gated on CD4+CD8+ 
double positive thymocytes from BALB/c, SKG and SKG Ptpn22-/- mice. Gray filled histogram 
represents BALB/c, SKG is shown by black line overlay while SKG Ptpn22-/- is shown by red line. 
Mean fluorescence of CD5 and TCR is indicated on the FACS plots for the strains. (B) Example of 
dot plots showing the profile of CD5 versus TCR! gated on DP thymocytes which distinguishes the 
stages of DP maturation; DP1 (TCRloCD5lo), DP2 (TCRintCD5hi) and DP3 (TCRhiCD5int) in BALB/c, 
SKG and SKG Ptpn22-/- DP thymocytes. (C) Bar chart shows the proportions of thymocytes in in 
DP1, DP2 and DP3 gate. Data represents the average of 6-9 mice per genotype (±SD) from three 
independent experiments. Statistical significance calculated with One-Way ANOVA and post-
ANOVA Holm-Sidak test for multiple comparison, *P<0.05, **P<0.01, ***P<0.001 
Fig. 2. Mature CD4+ SP and CD8+ SP cells develop with distinct kinetics.
Dox-free TetZap70 mice (n = 3 or more mice per day) were fed dox-
containing food, and their thymi were characterized by flow cytometry on
the indicated days. (A) Density plots of CD4 against CD8 are shown for
total live huCD2+ (upper row) and CD5hiTCRhi gated populations (lower
row) at the indicated days. (B) Density plots of CD5 against TCR are shown
for DP cells gated from huCD2+ thymocytes from TetZap70 mice at the in-
dicated days after dox feeding. The lower row of plots of CD5 against TCR
show magnifications of the areas depicted in the boxes indicated on each
of the dot plots above. (C) Density plots of HSA against TCR for CD4+ SP
and CD8+ SP cells at the indicated days. (D) Graph shows the frequency of
induced huCD2+ thymocytes from TetZap70 mice that were TCRhi CD4+ SP
cells (filled circles) or TCRhi CD8+ SP cells (white diamonds) over time
compared with the frequencies of TCRhiCD4+ or CD8+SP cells in thymi
from WT mice (far right). (E) Graph of the ratio of TCRhiCD4+ SP cells to
TCRhiCD8+ SP cells against time after the induction of Zap70 expres-
sion in TetZap70 thymi. (F) Density plot of TCR against CD5 on DP thymo-
cytes from WT mice. Gates show the three subsets of DPs, namely, DP1
(TCRloCD5lo), DP2 (TCRintCD5hi), and DP3 (TCRhi CD5int). Data shown in
(A) to (F) are representative of four or more independent experiments.
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Figure 4.5 No difference in Ca2+ Flux in wild-type C57BL/6 and PTPN22 KO CD4+CD8+ 
thymocytes  
Single cell suspension of thymocytes from PTPN22KO mice were labelled with 0.012µM CFSE and 
mixed in 1:1 ratio with unlabelled wild-type C57BL/6 thymocytes (left panel). The cells were then 
loaded with 2µM indo-1, followed by staining with biotin-conjugated anti-TCR! and anti CD3 + CD4 
(clone RMA 4.4). Basal levels of Ca2+ were determined for 45 seconds and induction of Ca2+ flux was 
achieved by crosslinking of anti TCR! (top right) or anti CD3 + CD4 (bottom right) with streptavidin 
phycoerythrin conjugates.  Arrows on the histogram indicate the time of addition of streptavidin (45 
sec) and ionomycin (8min). Wild-type Ptpn22+/+ is represented in black and Ptpn22-/- in red line. 
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Figure 4.6 Thymocytes from SKG Ptpn22-/- show enhanced TCR induced calcium mobilisation 
compared to SKG mice  
Thymocytes from BALB/c, SKG and SKG Ptpn22-/- mice were labelled with 2µM indo-1, followed 
by staining with biotin conjugated antibody anti-TCR! ± CD4 (clone 145 2C11) and anti CD3 + CD4 
(clone RMA 4.4). Additional fluorescently conjugated CD8 and CD4 (clone RMA 4.5 does not 
compete with clone RMA 4.4 used for crosslinking) Abs were used to identify thymocyte populations 
and Ca+2 flux was analysed by flow cytometry (A) Single cell suspension of thymocytes from 
BALB/c, SKG and SKG Ptpn22-/- mice were labelled with different concentration of CFSE: 0µM, 
0.012µM, 0.002µM respectively and mixed in 1:1:1 ratio. Ca2+ traces were analysed in the DP gate for 
each genotype as shown on the CD4 versus CD8 dot plot. (B) Basal levels were determined for 45 
seconds and induction of Ca2+ was achieved by addition of crosslinking anti TCR! ± CD4 and anti 
CD3 + CD4 with streptavidin phycoerythrin conjugates. Arrows on the histogram indicate the time of 
addition of streptavidin (45 sec) and ionomycin (8min) BALB/c is represented in black, SKG in green 
and SKG Ptpn22-/- in red line. Data are representative of three independent experiments. 
B. 
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Figure 4.7 Ptpn22 deficiency results in moderate increase in phosphorylation of ERK on SKG 
background 
(A) Single cell suspension of thymocytes from BALB/c, SKG and SKG Ptpn22-/- mice were labelled 
with different concentration of Cell Trace Violet: 0µM, 0.012 µM, 0.1µM respectively and mixed in 
1:1:1 ratio. Cells were stained with biotinylated anti-CD3 and CD4 antibodies and stimulated by 
crossing linking with streptavidin-allophycocyanin for 0, 2, 5 and 10 minutes. Cells were fixed at end 
of the time points by addition of 4% PFA, permeabilised with 90% methanol and stained with 
phospho-ERK specific antibody. (B) Representative histograms show overlays of intracellular pERK 
2, 5 and 10 min after cross-linking. Filled histogram depicts BALB/c treated with UO126, MEK 
inhibitor that serves as negative control. pERK levels is shown for BALB/c by black line, SKG in blue 
overlay line while SKG Ptpn22-/- is indicated by red line. Bar graph shows average percentages of 
pERK+ cells ± SD, over the time course. Data are representative of two independent experiments. 
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Figure 4.8 Ptpn22 deficiency does not alter the TCR V! repertoire in mature thymocytes 
compared to SKG mice 
The bar charts show the percentage expression of V!3, V!5, V!11 and V!8 TCR chains in mature 
CD4+ CD5+ (left) and in mature CD8+ CD5+ (right) thymocytes for BALB/c (black), SKG (green) and 
SKG Ptpn22-/- (red). The data are representative of three independent experiments and are shown as 
averages of n=4 for each strain ± SD. Statistical significance was calculated in Prism: One way 
ANOVA, *P<0.05, **P<0.01, ***P<0.001.  
 
Figure 4.9 Peripheral CD4+ and CD8+ T cells from SKG Ptpn22-/- showed no differences in 
selection of TCR V! subfamilies.  
The bar charts shows the percentages of expression indicated TCR V! chains in CD4+ (left) and CD8+ 
(right) T lymphocytes for BALB/c (black), SKG (green) and SKG Ptpn22-/- (red). The data is from 
only one experiment and is shown as average of n=4 mice for each strain ± SD. Statistical significance 
was calculated in Prism: One way ANOVA, ***P<0.001. 
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Figure 4.10 Total numbers of LNs and spleen cells were comparable between SKG and SKG 
Ptpn22-/- mice 
(A) Representative spleen, inguinal and brachial LNs from 7 week old BALB/c, SKG and SKG 
Ptpn22-/- mice. (B) Total cell numbers were counted using CASY counter. Data shown are pooled 
from 2 independent experiments representing BALB/c (black fill circles), SKG Ptpn22+/+ (green fill 
circles) for SKG Ptpn22+/- (blue fill circles) and SKG Ptpn22-/- (red fill circles). Dot plots shows group 
means indicated by the horizontal bars ± SD with each point representing individual mice. Statistical 
significance was calculated in Prism: One way ANOVA, ns - non significant, *P<0.05, **P<0.01, 
***P<0.001. 
 
Figure 4.11 The proportions of T cells in LN and spleen on SKG background are not altered by 
Ptpn22 deficiency  
Representative FACS dot plots showing the CD4 versus CD8 expression in LN (top panel) and spleen 
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Table 4.2 Absolute T cell numbers in LN from 7 week old mice (x106) 
 
 




Figure 4.12 SKG Ptpn22-/- mice have an expansion of effector/memory T cells than increases 
with age compared to SKG mice 
Single cell suspension from LNs was evaluated for the proportions of naïve (CD44loCD62Lhi) and 
effector (CD44hiCD62Llo) cells within the CD4+ T cells from young (6 week), 11week and 21 week 
old BALB/c, SKG and SKG Ptpn22-/- mice.  
Genotype Total CD4 CD8 B220 
BALB/c 33.3 ± 10.7 19.7 ± 6.7 7.1 ± 2.6 4.1 ± 1.2 
SKG 27.2 ± 11.3 13.3 ± 6.3 3.0 ± 1.2 9.1 ± 4.1 
SKG Ptpn22-/- 42.3 ± 5.7 19.6 ± 5.9  4.5 ± 1.0 13.4 ± 1.9 
Genotype Total CD4 CD8 B220 
BALB/c 89.6 ± 8.8 24.1 ± 8.7 7.9 ± 1.8 33.1 ± 2.2 
SKG 91.7 ± 5.4 13.4 ± 4.1 1.8 ± 0.3 43.7 ± 11.2 
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Figure 4.13 Increased proportions of CD4+ CD45RBloT cells in SKG Ptpn22-/- mice compared to 
SKG mice 
Top panel shows representative histograms of CD4+ T cells from 20 week BALB/c (grey shaded), 
SKG (black overlay line) and SKG Ptpn22-/- (red line) for expression of CD45RB. Graph below 
shows tabulated frequencies and absolute numbers of CD45RBlo population calculated from the FACS 
plots. Data represents the average of n=6 for BALB/c and SKG mice and n= 12 for SKG Ptpn22-/-
mice (±SD) from three independent experiments. Statistical significance was calculated in Prism with 
One-Way ANOVA and Tukey’s post-ANOVA multiple comparison test, ns – non significant, 
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Figure 4.14 Proportion and absolute numbers of thymic Tregs were similar in SKG and            
SKG Ptpn22-/- mice 
(A) Representative dot plot showing the thymi from 7 week old BALB/c, SKG and SKG Ptpn22-/- 
mice were examined for the proportions of FoxP3+ CD4+ Tregs (B) Graph showing the percentages 
and the absolute number of Tregs. Data represent the average of 6-9 mice per genotype (±SD) from 
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Figure 4.15 SKG Ptpn22-/- mice show a subtle increase in proportion and numbers of peripheral 
Tregs than SKG mice 
T cells recovered from LN and spleen from wild-type BALB/c (black), SKG (green) and               
SKG Ptpn22-/- (red) mice were analysed by ex vivo intracellular staining for Tregs (FoxP3+CD25+) 
within the CD4+ T cell population. Example dot plots are shown as well as graphs representing the 
proportions and absolute cell numbers of CD4+ FoxP3+CD25+ Tregs. Data represents the average of 6-
9 mice per genotype (±SD) from three independent experiments. Statistical significance was 
calculated in Prism: One-Way ANOVA and Tukey’s post-ANOVA multiple comparison test, ns-non 
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Chapter 5: Effect of Ptpn22 deficiency on 
susceptibility to arthritis in SKG Ptpn22-/- mice 
5.1  Introduction 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, which 
predominantly affects the synovial membranes of the primary joints. Although 
autoreactive CD4+ T cells and dysregulated B cell homeostasis are prime mediators 
of RA, the precise aetiology remains unknown (Burmester et al., 2014). Both genetic 
and environmental factors contribute to the development of RA. Recent genome 
wide association analyses identified several HLA and non-HLA disease 
susceptibility genes among which HLA-DRB1 and PTPN22 are robustly linked to 
disease predisposition (Choy, 2012). 
There are several animal models of RA (Asquith et al., 2009). Here we took 
advantage of the SKG mouse strain that contains a homozygous W163C mutation in 
C-terminal SH2 domain of ZAP-70 due to which these mice spontaneously develop 
CD4+ T-cell-mediated autoimmune arthritis when maintained in conventional 
environments (Sakaguchi et al., 2003). Arthritis can also be elicited in animals held 
under SPF conditions either through antigen non-specific activation of innate 
immunity, e.g. by administration of crude or purified fungal extracts or by provoking 
homeostatic proliferation of self-reactive T cells upon transfer to the T cell-deficient 
environment of nude mice (Yoshitomi et al., 2005). Importantly, PTPN22 directly 
affects ZAP-70 signalling (Wu et al., 2006). Given the association of PTPN22 
polymorphisms with an increased susceptibility of developing RA, it was of interest 
to assess the impact of the phosphatase in the SKG arthritis model.  
Arthritis in SKG mice is characterized by symmetric swelling of small joints that 
later progress to larger joints accompanied by severe joint destruction (Sakaguchi et 
al., 2003). Serologically, SKG mice develop high titers of rheumatoid factors (RF), 
autoantibodies specific for type II collagen, antibodies reactive with heat shock 
protein of Mycobacterium tuberculosis potentially because of cross-reaction with its 
conserved epitope, severe hypergammaglobulinemia and high concentrations of 
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circulating immune complexes (Sakaguchi et al., 2003). In addition, cells within the 
affected joints produce abundant proinflammatory cytokines such as IL-1, IL-6 and 
TNF and the incidence and severity of arthritis in SKG mice has shown to be 
significantly reduced by genetic deficiency of these cytokines (Hata et al., 2004).  
The underlying mechanism for development of arthritis in SKG mice is decreased 
signalling downstream of the TCR due to expression of aberrant ZAP-70 which leads 
to alteration of the thymic selection thresholds resulting in production of autoreactive 
T cells that would otherwise be deleted due to negative selection (Sakaguchi et al., 
2003). As shown in chapter 4, our results illustrate that although both SKG Ptpn22-/- 
and SKG mice exhibit a similar extent of impairment in thymocyte development, 
SKG Ptpn22-/- mice show subtle effects in positive selection and have increased TCR 
mediated signalling in comparison to SKG mice. These results suggest that both 
ZAP-70 and PTPN22 act by affecting similar signalling pathways.  
In the light of the genetic predisposition to developing autoimmune arthritis in SKG 
mice, we next set out to investigate whether the increased TCR signalling observed 
in SKG Ptpn22-/- mice influenced their susceptibility in developing autoimmune 
arthritis. Figure 5.1 summarises the effect of T cell signalling on the development 
and immune phenotypes of SKG and PTPN22 KO mouse models. Several 
possibilities were considered for the impact of Ptpn22 deletion on the severity of 
disease in the SKG model of autoimmune arthritis. The increase in the signalling 
capacity could perhaps balance the “thymic selection shift” and coupled with 
enhanced peripheral signalling in absence of Ptpn22 could decrease severity of 
disease. Alternatively, the increase in signalling capacity might not be sufficient to 
shift the selection window to avoid release of autoreactive T cells in periphery and 
with a cumulative lack of negative regulation due to Ptpn22 deficiency could 
exacerbate the phenotype resulting in increased severity of disease. In support, of the 
latter view is the observation that we did not see any differences in the deletion of 
endogenous provirus-specific TCR V! clones in SKG Ptpn22-/- mice (Fig 4.9) along 
with increase in ratio of effector/memory T cells (Fig 4.12) compared to SKG mice. 
The Ptpn22 deficient mouse is a global knock out, therefore there is a third 
possibility of creating a balanced situation wherein we have augmented thymic 
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threshold and simultaneously caused a similar increase in the peripheral T cell 
activation thus having no affect on incidence or severity of arthritis in SKG Ptpn22-/- 
mice and a fourth possibility where the effect of PTPN22-deficiency on non-T cells 
may influence the T cell responses directly.  
5.2 Results 
5.2.1 Increased proliferation of naïve SKG Ptpn22-/- CD4+ T 
cells in response to TCR stimulation 
PTPN22 is an inhibitor of TCR signalling (Bottini and Peterson, 2014). In line with 
previous studies from Ptpn22-/- mice showing TCR signalling is enhanced in the 
absence of PTPN22 (Brownlie et al., 2012; Hasegawa et al., 2004), we showed in the 
previous chapter that loss of Ptpn22 improved TCR signalling defects in SKG 
Ptpn22-/- thymocytes compared to SKG thymocytes (Fig 4.6 and 4.7) and SKG 
Ptpn22-/- CD4 T cells presented with increased proportions of effector memory cells 
(Fig 4.12). Therefore, for analysis of TCR-induced proliferation it was important to 
sort naïve CD4+ T cells, as CD44hi memory-phenotype cells contribute differently 
than naïve T cells in an immune response (Surh and Sprent, 2002). Naïve CD4+ T 
cells, gated as CD45RBhiCD25- were sorted from LNs of young BALB/c, SKG and 
SKG Ptpn22-/- mice (Fig. 5.2). Subsequently the cells were labelled with Cell Tracer 
Violet and stimulated in vitro by co-culturing with irradiated splenocytes from a 
BALB/c RAG-/- mouse in the presence of varying doses of anti-CD3 mAb. 
Proliferation was measured at day 3 by assessing the dilution of Cell Tracer dye by 
flow cytometry.  
As previously reported, there was decreased proliferation of SKG CD4+ cells 
compared with that of wild type BALB/c in response to all doses of anti-CD3 after 
72h of stimulation in vitro (Fig 5.3A) (Sakaguchi et al., 2003). Interestingly, 
although the proliferation of SKG Ptpn22-/- cells was lower compared to BALB/c 
CD4+ T cells (Fig 5.3A), SKG Ptpn22-/- cells partially overcame the proliferative 
defect seen in SKG cells in response to stimulation with anti-CD3, showing that 
Ptpn22 deficiency enhanced the proliferative capacity of CD4+ SKG Ptpn22-/- cells 
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(Fig 5.3A). The proliferation index is a quantitive analysis calculated by FlowJo 
software (from the cell violet dilution peaks shown in Fig 5.3B) and represents the 
average number of divisions of the dividing population. Therefore the proliferation 
index measures only the response of cells that underwent at least one division. Fig 
5.3C shows that SKG Ptpn22-/- CD4+ T cells proliferated more than SKG CD4+ T 
cells at all concentrations of anti-CD3 in vitro. Additionally, more SKG Ptpn22-/- 
cells went into division which is further quantified in FlowJo by the divison index 
function, which calculates the average number of cell division that a cell in the 
original population has undergone and takes into consideration the undivided peak 
(Fig 5.3C, right panel). As shown in Figure 5.3C, both SKG and SKG Ptpn22-/- cells 
show very similar proliferation index, however the division index is much lower in 
SKG cells compared to SKG Ptpn22-/- cells suggesting that SKG T cells are less 
likely to reach the threshold of proliferation than SKG Ptpn22-/- T cells, but those 
SKG cells which do overcome the threshold, undergo similar numbers of cell 
divisions on an average. 
5.2.2 IL-2 production was enhanced in SKG Ptpn22-/- T cells  
Upon activation, both CD4+ and CD8+ T cells produce IL-2, the latter to lesser extent 
(Malek and Castro, 2010). Ca2+ signalling has also been shown to be important for 
IL-2 production (Rao et al., 1997; Smith-Garvin et al., 2009). Our results show that 
Ptpn22 deficiency results in increased calcium mobilisation in the thymus (Fig 4.6) 
as well enhanced proliferation in SKG Ptpn22-/- T cells (Fig 5.3). IL-2 has an 
important role in augmenting T cell expansion, differentiation and effector functions 
(Boyman and Sprent, 2012) therefore we assessed the capacity of CD4+ T cells from 
SKG and SKG Ptpn22-/- mice to produce IL-2. To this end naïve sorted CD4+ T cells 
from BALB/c, SKG and SKG Ptpn22-/- mice were stimulated with different amounts 
of anti-CD3! for 72h and the amount of IL-2 produced was measured by ELISA. 
BALB/c T cells were used as a positive control. Consistent with increased in vitro 
proliferation (Fig. 5.3), SKG Ptpn22-/- CD4+ cells produced more IL-2 in a dose 
dependent manner in response to stimulation with anti-CD3 than SKG CD4+ cells 
(Fig. 5.4). Nonetheless, the levels of IL-2 were greatly reduced in SKG Ptpn22-/- 
CD4+ cell cultures as compared to wild type CD4+ BALB/c controls. These data need 
          Chapter 5 
    144 
to be interpreted with caution, as at 72h the data may be biased by differences in the 
IL-2 consumption and also depend on the number of cells present in the culture. 
As seen in Chapter 4 increased signalling strength observed in the thymus correlated 
with elevated responses in the peripheral pool of T cells with increased in vitro 
proliferation and IL-2 production of CD4+ T lymphocytes from SKG Ptpn22-/- 
relative to SKG, but as noted earlier, in the thymus, the SKG Ptpn22-/- cells did not 
reach the levels of responses seen in BALB/c cells. 
5.2.3 Ptpn22  deficiency results in development of less severe 
arthritis in SKG Ptpn22-/- mice. 
Despite production of arthritogenic autoimmune T cells due to imbalances in thymic 
selection, SKG mice fail to develop arthritis when maintained in a SPF animal 
facility. However, severe arthritis can be triggered by a single intraperitoneal (i.p.) 
injection of zymosan, a crude yeast wall extract or purified ! glucan, such as 
laminarin (Yoshitomi et al., 2005). Additionally SKG mice stimulated with mannan, 
a fungal wall polysacharride, presented a higher arthritis score than mice stimulated 
with zymosan A (Keller et al., 2013). Therefore, we decided to use mannan to induce 
arthritis in SKG and SKG Ptpn22-/- mice. 
The frequency and clinical score of spontaneous arthritis in SKG mice is dependent 
on the cleanliness of the environment and microbial colonisation. In our animal 
facilities, SKG mice up to the age of 6 months did not develop any spontaneous 
arthritis or any systemic inflammation such as interstitial pneumonitis as previously 
reported (Sakaguchi et al., 2006). Additionally, unlike previously demonstrated, 
SKG mice, those maintained in our facility failed to develop any signs of arthritis 
with published doses of mannan (0.2, 2 and 20 mg) (Hashimoto et al., 2010). 
Furthermore, even a 2mg zymosan boost or doubling the amount of highest dose 
used in literature either showed no disease or only about 50% disease incidence 
respectively. Therefore we used a higher dose of 50mg/mouse to provoke arthritis in 
SKG mice (Figure 5.5). 
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SKG and SKG Ptpn22-/- mice were challenged with mannan and monitored for the 
development of arthritis. A single i.p. injection of 50 mg mannan triggered joint 
inflammation in the mice as seen by increased paw swelling compared to untreated 
control (Fig 5.6). Interestingly, Ptpn22 deficiency delayed the onset and severity of 
arthritis in SKG mice. In addition, the incidence of disease was decreased in        
SKG Ptpn22-/- mice with one out of the six SKG Ptpn22-/- mice failing to develop 
any clinical signs of arthritis, while there was 100% incidence in the SKG group (Fig 
5.7). At the end of the 4-week observation period, arthritic joints from the mannan 
treated SKG and SKG Ptpn22-/- mice (n=3) were collected and were evaluated for 
histology. The mice were not scored for arthritis by histology and it would be 
interesting to conduct blinded histological scoring with bigger cohort in future 
experiments. Consistent with the arthritis scores, SKG Ptpn22-/- mice showed less 
synovial hyperplasia compared to the SKG mice (Fig 5.8). Collectively, these data 
show that loss of Ptpn22 reduced the severity of arthritis in SKG Ptpn22-/- mice.  
5.2.4 Increase in total LN and spleen cell number after 
mannan treatment 
Examination of the SKG and SKG Ptpn22-/- mice for other evidence of dysregulation 
of the T cell compartment following mannan administration revealed that more cells 
were recovered from LNs of SKG mice relative to SKG Ptpn22-/- mice. Overall 
increased total cell numbers were recovered from LNs and spleen in mannan treated 
SKG and SKG Ptpn22-/- mice compared to untreated SKG control mice (Fig 5.9 A). 
A decrease in frequency of both CD4+ and CD8+ T cells in LNs was noted in mannan 
treated SKG and SKG Ptpn22-/- mice compared to the untreated BALB/c or SKG 
controls (Fig 5.9B), possibly due to infiltration of T cells into the sub synovial tissue, 
a cardinal feature in SKG arthritis (Keller et al., 2013; Kobayashi et al., 2006; 
Sakaguchi et al., 2003; Sakaguchi et al., 2006). The proportions of CD4+ T cells 
recovered from the LNs were similar in both mannan treated SKG and SKG Ptpn22-/- 
mice but decreased proportions of CD8+ T were detected in SKG Ptpn22-/- compared 
to SKG mice (Fig 5.9B left panel). Furthermore, no significant difference in the 
ratio of CD4+ and CD8+ T cells was observed in the spleen between SKG and     
SKG Ptpn22-/- (Fig 5.9B right panel) suggesting that the increase noted in the total 
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cell numbers from LNs and spleen were not primarily because of the expansion of T 
cell compartment. Furthermore the percentages of activated/memory CD44hiCD62Llo 
were significantly (p<0.0001) increased for both CD4+ and CD8+ T cells in SKG 
Ptpn22-/- compared to SKG mice following mannan challenge (Fig 5.10). 
5.2.5 IL17 production is decreased in SKG Ptpn22-/- mice 
Numerous studies have provided evidence that cytokines are directly involved in the 
pathogenesis of arthritis (Hata et al., 2004; Hirota et al., 2007a; Kobayashi et al., 
2006). Of importance is a recent report showing that the development of arthritis in 
SKG mice is dependent on IL-17-producing arthritogenic Th17 cells, which are 
promoted by IL-6, secreted by either activated APCs or T cells (Hirota et al., 2007a). 
Deficiency of either IL-6 or IL-17 completely inhibited the arthritis, while lack of 
IFN-! exacerbated the disease (Hirota et al., 2007a). Collectively, these data suggest 
that both IL-6 and IL-17 are important in the differentiation of Th17 and IFN-! plays 
a critical role in maintenance of immunological self-tolerance, as IFN-! deficiency 
can break tolerance facilitating differentiation/expansion of arithogenic Th17 cells 
(Hirota et al., 2007a). 
As SKG Ptpn22-/- mice developed less severe arthritis in comparison to SKG mice, 
we compared ex vivo cytokine production in CD4+ T cells from mannan treated SKG 
and SKG Ptpn22-/- mice following stimulation with phorbol ester and ionomycin. As 
shown in Fig 5.11A, a significant fraction of LN CD4+ cells from untreated control 
SKG mice produced IL-17 compared to BALB/c mice and this proportion was 
further increased on treatment with mannan in both SKG and SKG Ptpn22-/- mice. 
Importantly, the proportion of CD4+IL-17 producing cells was 2-fold higher in LN 
cultures from SKG as compared to SKG Ptpn22-/- mice (Fig 5.11B). We asked 
whether there was a direct correlation between the increase in proportions of IL-17 
positive cells and severity of arthritis in individual animals in both SKG and SKG 
Ptpn22-/- mice, but no such correlation was observed in two independent arthritis 
induction experiments (Fig 5.11C). Therefore, these results show that the expansion 
or differentiation of Th17 cells occurs in both SKG and SKG Ptpn22-/- mice, albeit to 
a much lesser degree in SKG Ptpn22-/- mice. Additionally SKG Ptpn22-/- CD4+ T 
cells produced more IFN! and less TNF relative to SKG CD4+ T cells (Fig 5.11C). 
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5.2.6 Increased production of IL-10 in SKG Ptpn22-/- CD4+ T 
cells 
IL-10 is a pleiotropic cytokine made by variety of hematopoietic cells, which 
modulates both the innate and adaptive immune response. Broadly, in CD4+ T cells it 
exerts its effects by induction of Tregs and by suppressing production of 
inflammatory Th1 cytokines (Mege et al., 2006). The balance of Th1 and Th17 
cytokines play a pivotal role in the pathogenesis of RA (Andreakos et al., 2002). 
Indeed, the immunosuppressive effects of IL-10 were shown in a study in which    
IL-10-/- SKG mice had a consistently higher incidence and mean arthritis score than 
IL-10 sufficient mice (Hata et al., 2004). In line with the reported effect of IL -10 on 
Th1 cells, we sought to determine, if there was any difference in production of IL-10 
from CD4+ T cells from SKG and SKG Ptpn22-/- mice following stimulation with 
Phorbol ester and ionomycin. As shown previously, a higher proportion of CD4+ T 
cells from SKG as compared to BALB/c mice produced IL-10, which was further 
increased upon treatment of mice with mannan (Hata et al., 2004; Hirota et al., 
2007a). Interestingly, a higher proportion of CD4+ T cells from SKG Ptpn22-/- mice 
produced IL-10 compared to SKG mice (Fig 5.12). Therefore, a generalized increase 
in the IL-10 production could possibly explain the less arthritis seen in                 
SKG Ptpn22-/- mice. 
5.2.7 Increased proportion of SKG Ptpn22-/- Tregs are more 
activated 
Tregs play a critical role in peripheral tolerance and exert their suppressive effects 
through various effector mechanisms such as consumption of IL-2, production of   
IL-10 and increasing the expression of immunosuppressive molecules, CTLA4 
(Shevach, 2009). Overall increased proportions of Tregs were recovered from LNs 
and spleen in mannan treated SKG and SKG Ptpn22-/- mice compared to untreated 
SKG or BALB/c control mice (Fig 5.13A and B). We noted a subtle, albeit not 
significant increase in the proportions of Tregs in the LN of SKG Ptpn22-/- mice (Fig 
5.13B left panel), however no differences were observed in the proportion of Tregs 
in the spleen between SKG and SKG Ptpn22-/- mice (Fig 5.13B right panel). 
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Furthermore, a significant increase (p=0.02) in the proportions of Tregs in the 
mesenteric lymph node, a key site of iTreg induction was seen in SKG Ptpn22-/- mice 
suggesting that Ptpn22 deficiency might enhance the propensity of naïve T cells to 
differentiate into this lineage (Fig 5.13B middle panel). Interestingly, comparison of 
Tregs/Th17 CD4 cells revealed significantly higher ratios in the SKG Ptpn22-/- mice 
compared to SKG mice following challenge with mannan (Fig 5.13B right panel). 
We found a slight increase in the amounts of surface expression of CTLA4 in SKG 
Ptpn22-/- Tregs recovered from lymph nodes and spleen compared to those of SKG 
Tregs raising the possibility that SKG Ptpn22-/- Tregs might have a greater 
suppressive capacity (Fig 5.13C). These results provide evidence that Tregs are more 
proportionally in SKG Ptpn22-/- mice consistent with the lower severity of arthritis 
observed in SKG Ptpn22-/- compared to SKG mice. However further studies to 
determine the suppressive function of SKG Ptpn22-/- Tregs and exact mechanism of 
action need to be undertaken.  
5.3 Discussion  
The aim of the work presented in this chapter was to determine the effect of Ptpn22 
deficiency on the development of arthritis in the SKG mouse model. Recent evidence 
from PTPN22R619W knock-in mouse models show a similar phenotype as that of 
PTPN22-deficient mice suggesting that the disease-associated variant acts as a loss-
of function allele, at least in mice (Dai et al., 2013; Zhang et al., 2011). Given the 
association of the variant allele with increased susceptibility to autoimmunity we 
sought to use the knockout mouse to gain an understanding of how loss of function 
alleles might contribute to the development of arthritis. To this end, we compared 
mannan-induced arthritis in SKG Ptpn22-/- and SKG mice to ask whether combined 
mutations in PTPN22 and ZAP-70 would be synergistic or antagonistic for the 
development of disease.  
Stimulation of naïve CD4+ T cells from SKG Ptpn22-/- mice with anti-CD3 mAb 
demonstrated a dose-dependent increase in proliferation relative to CD4+ T cells 
from SKG mice (Fig. 5.3C). Overall both SKG and SKG Ptpn22-/- CD4+ T cells were 
capable of proliferation, albeit to a much lesser extent than wild-type BALB/c CD4+ 
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T cells in response to stimulation via the TCR. Of note, the initial population of cells, 
which overcame the threshold of signalling and underwent division, was enhanced 
by loss of Ptpn22, as noted by the significant differences in division index between 
SKG and SKG Ptpn22-/-CD4+ T cells suggesting that the loss of Ptpn22 had a subtle 
effect in improving the proliferative capacity of CD4+ T cells on SKG background, 
which was more clear at low doses of anti-CD3 stimulation. Furthermore, IL-2 
production in response to TCR stimulation was increased in SKG Ptpn22-/- T cells 
relative to SKG cells (Fig 5.4). Taken together these results show that consistent with 
the increases in TCR signalling capacity observed in thymocytes, Ptpn22 deficiency 
also enhanced the responses to stimulation in the periphery and is capable therefore, 
of reversing the reduction of ZAP-70 activity which results from the SKG mutation.  
Of note, both effector and regulatory T cell numbers and function are elevated in 
Ptpn22-/- mice and, on the C57BL/6 background, the mice do not develop 
spontaneous autoimmunity (Brownlie et al., 2012; Maine et al., 2012). However, 
Ptpn22 deficiency cooperates with the mutant CD45 E613R protein, to break 
tolerance in double mutant mice (Zikherman et al., 2009) suggesting cumulative 
mutations might underlie the autoimmune phenotypes associated with variant allele. 
Our initial prediction was that the elevated TCR signalling capacity coupled with an 
increased propensity of T cells to develop an effector/memory phenotype in the 
absence of PTPN22 might exacerbate disease in SKG mice upon mannan challenge. 
Surprisingly, our data show the SKG Ptpn22-/- mice developed less severe arthritis 
when compared to SKG mice; furthermore the onset of arthritis was delayed by 
almost a week in SKG Ptpn22-/- mice (Fig 5.7). CD4+ T cells that secrete increased 
levels of IL-17 mediate arthritis in SKG mice (Hirota et al., 2007a). We examined   
IL-17 production from CD4+ T cells recovered from LNs of the mannan treated SKG 
and SKG Ptpn22-/- mice following stimulation with phorbol ester and ionomycin. 
The frequency of IL-17 production was significantly two-fold lower in CD4+ T cells 
from SKG Ptpn22-/- mice compared to SKG mice (Fig 5.11B). The lack of a direct 
correlation between the numbers of IL-17 producing T cells and the severity of 
arthritis (Fig 5.11C) could be a result of lack of Th17 cells in peripheral lymphoid 
organs as the Th17 cells are recruited into the synovial cavity (Hirota et al., 2007b) 
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or the kinetics of the disease progression dictated the presence of Th17. Therefore, 
future experiments to assess the IL-17 production from synoviocytes and mice taken 
at an earlier time point would be more informative and representative of Th17 
correlation with disease.  
The decrease in proportions of IL-17 producing cells could be explained by either 
that SKG Ptpn22-/- T cells were less able to differentiate into Th17 cells or that the 
development of Th17 was suppressed. Differentiation of naïve wild type C57BL/6 
and Ptpn22-/- CD4+ T cells was equivalent under optimal Th17 polarising conditions 
in vitro (R. Brownlie, personal communication), therefore it is unlikely that 
decreases in the ratio of Th17 producing cells observed in SKG Ptpn22-/- mice is due 
to an intrinsic defect in Th17 differentiation. Previously published literature shows 
that IFN-! suppresses the differentiation/ expansion of Th17 cells and IFN-! plays a 
critical role in the maintenance of immunological self-tolerance as lack of IFN-! 
worsened the arthritis by facilitating the differentiation/expansion of arthritogenic T 
cells which could break tolerance in SKG mice maintained even under SPF 
conditions (Hirota et al., 2007a). We found an increased tendency of CD4+ T cells 
from SKG Ptpn22-/- mice to secrete more IFN-! compared to SKG mice (Fig 5.11). 
Further, the proportion of IL-10, producing CD4+ T cells was also increased in SKG 
Ptpn22-/- mice (Fig 5.12). Therefore both increased IFN-! and IL-10 may have 
contributed to the increased resistance to arthritis induction on the Ptpn22-deficient 
background. 
The role of pro- or anti-inflammatory cytokines in facilitating or inhibiting the 
activation of various types of cells, such as macrophages, neutrophils, T cells which 
are involved in local inflammation is well documented in arthritis (Arend, 2001; 
Choy, 2012). It is likely that these cytokines alter the degree of T cell mediated 
control of autoimmune cells. For instance, among the many pleiotropic effects of   
IL-10, it plays an important role in augmenting Treg mediated immunoregulation, as 
seen in studies of autoimmune/inflammatory diseases (Fowler and Powrie, 1999; 
Goudy et al., 2003). 
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Phenotypic and functional characterization of Treg cells, which are essential for 
peripheral self-tolerance, indicated that increased percentages of peripheral Treg 
were found in SKG Ptpn22-/- mice (Fig 5.13B left and middle panel). Furthermore, 
the Treg/Th17 ratio was higher in the SKG Ptpn22-/- mice compared with that of 
SKG mice following mannan treatment (Fig 5.13B right panel). Both Th17 and 
Tregs are mutually antagonistic in their differentiation programs (Bettelli et al., 2006; 
Zhou et al., 2008), wherein Treg transcription factor, Foxp3 is able to suppress the 
function of ROR-!t, transcription factor required for Th17 differentiation and this 
could possibly explain the decreased frequency of IL-17 producing cells noted in 
SKG Ptpn22-/- mice compared to SKG mice. In support, SKG Ptpn22-/- T cells 
produced more IL-2, a major cytokine which is not only important for Treg 
development and maintenance but has also been reported to inhibit Th17 expansion, 
as blockage of IL-2 or deletion of STAT5 leads to enhanced production of Th17 cells 
(Laurence et al., 2007). Therefore, it is possible that enhanced IL-2 production in the 
absence of PTPN22 may favour the induction of inducible Treg and reduce Th17 
polarisation, providing an explanation for the altered frequencies of these populations 
in SKG Ptpn22-/- mice.  
A recent report from our group demonstrating that Ptpn22-/- Tregs are more effective 
potent suppressors of Ptpn22-/- effector T cells than wild-type Tregs is likely to be 
pertinent to the current study (Brownlie et al., 2012). SKG Ptpn22-/- mice have 
increases in the absolute numbers of peripheral Tregs that also present with a slightly 
more activated phenotype than the equivalent populations from SKG mice. Whether 
SKG Ptpn22-/- Tregs are more functional in their suppressive capacity than SKG 
Tregs remains to be determined. In support of an important role for Tregs in disease, 
a recent report demonstrated protection from arthritis in SLAP-deficient SKG mice 
due to an increase in steady-state numbers of Tregs, which further expanded 
following zymosan challenge without an accompanied increase in expansion of 
autoreactive Th17 cells leading to an increase in the ratio of Tregs to Th17 cells 
(Peterson et al., 2011).  
SKG mice develop high titers of autoantibodies (Sakaguchi et al., 2003). B cell 
maturation in germinal centres and autoantibody production are regulated by T cells 
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(Kobezda et al., 2014) and a recent report shows that Ptpn22-/- mice have increased T 
follicular helper (Tfh) cell activity and formation of germinal centres associated with 
elevated serum Ig titers (Maine et al., 2014), suggesting importance of PTPN22 in 
regulating B cells. Therefore it would be interesting to see if Ptpn22 deficiency 
affected germinal centres in SKG Ptpn22-/- mice. The increase noticed in the total 
cell numbers could be due to recruitment of neutrophils as the Th17 lineage is also 
largely responsible for the induction of granulopoiesis, or recruitment of neutrophils 
(Schwarzenberger et al., 1998). A recent report showed that neutrophils from 
individuals with the variant PTPN22 1858T allele release increased levels of reactive 
oxygen species when primed with TNF and increased Ca2+ after stimulation with a 
chemotactic bacterial peptide mimic (Bayley et al., 2014). Therefore it would be 
interesting to examine the neutrophils from SKG Ptpn22-/- mice. 
Collectively, this chapter highlighted that Ptpn22 deficiency on SKG background 
resulted in less severe mannan-induced arthritis in SKG Ptpn22-/- mice in comparison 
to SKG mice. In contrast to SKG mice, SKG Ptpn22-/- mice show decreased 
proportions of Th17 cells and higher numbers of regulatory T cells. Further 
functional studies to demonstrate that the balance between protection from and 
induction of autoimmune arthritis depends on the fine Treg/Th17 balance might 
provide an underlying mechanism of Ptpn22 action in development of arthritis in 
SKG mice. 
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5.4 Figures  
 
Figure 5.1 Immune phenotypes of SKG and PTPN22 KO mice. 
The figure describes the summary of T cell development, immune phenotype of effector and 
regulatory T cells and the susceptibility to autoimmune disease reported for SKG and PTPN22KO 
mice.  
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Figure 5.2 Gating strategy for sorting CD4+ naïve T cells from BALB/c, SKG and                     
SKG Ptpn22-/- mice 
Single cell suspension of lymphocytes from 6 week old BALB/c, SKG and SKG Ptpn22-/- mice was 
first pre-enriched for CD4+ using dynal negative selection, following which the cells were stained 
with Abs to CD4, CD8, CD25 and CD45RB. Cells were then sorted on the MoFlo on Aria by gating 
on cells falling within the intact gate as determined by cell size and granularity (FSC versus SSC). 
Single cells were further gated to on CD4+ population and the naïve cells falling in CD45RBhiCD25- 
gate were sorted. 
36.2 15.4 15.6 
Viable gate Singlet gate 
Cells gated for CD4+ 
CD4+ naive cell gate (CD25- CD45hi)   
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Figure 5.3 Increased proliferation of CD4+ T cells from SKG Ptpn22-/- mice compared to SKG 
mice 
Cell Tracer Violet labelled sorted naïve CD4+ T cells (CD45RBhiCD25-) from wild type BALB/c, 
SKG or SKG Ptpn22-/- (105cells/well) were stimulated in triplicate wells with irradiated splenocytes 
(2x105cells/well) from BALB/c RAG2-/- mice pulsed with mAbs against CD3! (0.04µg mL-1, 0.2µg 
mL-1 1µg mL-1). Proliferation of the CD4+ T cells was measured by dilution of Cell Trace on day 3 
(A) Representative histograms showing the overlay of Cell Tracer dilution in BALB/c (grey shaded), 
SKG (black overlay line) and SKG Ptpn22-/- (red overlay line) in response to stimulation with varying 
doses of anti-CD3 mAbs on day 3 (B) Gating strategy for calculating the proliferation index on 
FlowJo. First the live cells were gated based on SSC versus FSC followed by gating for FSC-H versus 
FSC-A (singlet) and finally CD4+ cells were gated for Cell Trace violet expression on histogram gate. 
(C) FlowJo was used to calculate the proliferation index and division index. Bar chart shows the 
average proliferation and division index at day 3 in BALB/c (black fill bar), SKG (clear bar) and SKG 
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Figure 5.4 CD4+ T cells from SKG Ptpn22-/- stimulated with anti-CD3! mAb produced more   
IL-2 than SKG CD4+ T cells 
Sorted Naïve CD4+ T cells from BALB/c, SKG and SKG Ptpn22-/- were stimulated in triplicate wells 
with irradiated splenocytes (105cells/well) were stimulated with irradiated splenocytes 
(2x105cells/well) from BALB/c RAG2-/- mice pulsed with mAbs against CD3! (0.04µg mL-1,          
1µg mL-1) for 72h. IL-2 production was assessed from harvested supernatant by ELISA and plotted as 
average pg mL-1. BALB/c is indicated in black filled bars, SKG in clear bar and SKG Ptpn22-/- in red 
fill bars. Data are representative of 3 independent experiments. Statistical significance was calculated 
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Figure 5.5 Optimisation of mannan induced arthritis in SKG mice 
SKG and SKG Ptpn22-/- maintained in SPF facility were given varying dose of mannan via a single 
intraperitoneal (i.p.) injection to induce arthritis. The animals were sacrificed after 4-6 weeks and the 
LNs and spleen were analysed. 
 
Figure 5.6 Arthritis is induced by 50mg mannan 
Representative wrist and ankle joint swelling in SKG mouse, which was administered 50mg of 
mannan via an i.p. injection compared to an untreated control at 4 weeks, showing an arthritis score of 
2 
Experiment Amount of mannan 
administered per mouse  
Incidence of disease 
1 2mg  0/7 
2 20mg + 2mg Zymosan boost 0/7 
3 40 mg  1/2 
 
4 50 mg  6/6  
SKG 
SKG Ptpn22-/-   D0  D2  D4  D6  D8  D10  D12  D14  D16  D18  D20  D22  D24!
50 mg Mannan  
IP  
Cull 
•  LN  
•  MLN 
•  Spleen  
Control Mannan treated 
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Figure 5.7 SKG Ptpn22-/- mice developed less mannan induced arthritis 
Incidence of arthritis and joint scores from 11-12 week-old SKG and SKG Ptpn22-/- mice that 
received a single i.p. injection of 50mg mannan over time is shown from two independent experiments 
(A) and (B). Joint swelling was monitored by inspection and scored as follows 0 = no swelling; 
1=mild swelling of wrist or ankle; 2=substantial swelling of wrist or ankle; 3=severe swelling of wrist 
or ankle. Error bars are mean ± SD of the arthritis scores. Statistical significance for the mean arthritis 
score was calculated in Prism using Two-way Anova, ns = non significant, ** P<0.01, *** P<0.001, 
****P<0.0001 and Mantel Cox Test was used to assess the significance of arthritis incidence with 
P=0.02 for (A) and ns for (B) 
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Figure 5.8 Histology of an ankle joint from mannan treated SKG and SKG Ptpn22-/- mice 
Representative histology of transverse sections of paw and ankle joints from SKG and SKG Ptpn22-/- 
4 weeks after treatment with 50mg mannan with hematoxylin and eosin staining are shown. H&E 
staining of ankle joint from untreated SKG mouse serves as control. Arrows highlight the area of 
infiltration, original magnification 12.5X. 
Control 
SKG SKG Ptpn22-/- 
825µM 825µM 
825µM 
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Figure 5.9 Increased numbers of total cells were recovered from SKG and SKG Ptpn22-/- mice 
after mannan treatment.  
Axial, Brachial, Inguinal, popliteal LNs and spleen were recovered from the SKG (blue filled circles) 
and SKG Ptpn22-/- mice (red filled circles) 4-week after treatment with mannan. LNs and spleen from 
untreated BALB/c (black solid squares) and SKG (hollow blue circles) were taken as controls.        
(A) Total cell numbers were counted using CASY counter. (B) Single cell suspension of lymphocytes 
was stained with CD4 and CD8 antibodies and the frequency of CD4 and CD8 in the control and 
mannan animals treated are shown in LN (left panel) and spleen (right panel). Dot plots shows group 
means indicated by the horizontal bars ± SD with each point representing individual mice. Statistical 
significance was calculated in Prism: One-Way ANOVA with post ANOVA Tukey’s test for multiple 
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Figure 5.10 Increased proportions of CD4+ effectors in SKG Ptpn22-/- mice compared to SKG 
mice 
CD4+ T lymphocytes from LNs were analysed for the frequencies of naïve and effector/memory cells 
from mannan treated SKG (blue filled circles), SKG Ptpn22-/- (red filled circles) control untreated 
BALB/c (black solid squares) and SKG (hollow blue circles) mice. Example dot plots with 
frequencies within the CD4 and CD8 gate are shown with mannan treated mice indicated in red 
square. Statistical significance was calculated in Prism: One-Way ANOVA with post ANOVA 
Tukey’s test for multiple comparisons ns - non significant, ****P<0.0001. 
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Figure 5.11 Ptpn22 deficient SKG mice produced less IL-17, TNF and more IFN!  than SKG 
mice 
Ex vivo LNs (axial, brachial, inguinal and popliteal) and mesenteric LNs from mannan treated SKG or 
SKG Ptpn22-/- mice were cultured for 4 h in the presence of PDBu/ ionomycin and BrefeldinA 
(stimulation). IL-17, IFN! and TNF production was assessed in CD4+ T cells with or without 
stimulus. (A) Representative dot plots of stimulated cells are shown with mannan treated samples 
shown in red square on the right (B) graph representing the frequencies of IL-17, TNF and IFN! 
producing CD4+ T cells from mannan treated SKG (solid blue circles) or SKG Ptpn22-/- mice (red 
filled circles) compared to untreated BALB/c (black solid squares) and SKG (hollow blue circles) is 
shown. (C) Correlation of IL-17 proportions with severity of arthritis indicated by joint scores for 
SKG (blue line) and SKG Ptpn22-/- (red line) from two independent arthritis experiments is shown. 
Statistical significance was calculated in Prism: One-Way ANOVA with post ANOVA Tukey’s test 
for multiple comparisons ns – non significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
0 102 103 104 105

















0 102 103 104 105

















0 102 103 104 105














































































































0 102 103 104 105

















          Chapter 5 
    163 
 
Figure 5.12 Ptpn22 deficient SKG mice produced more IL-10 than SKG mice 
Ex vivo mesenteric LNs from mannan treated SKG or SKG Ptpn22-/- mice were cultured for 4 h in the 
presence of PDBu/ ionomycin and Brefeldin A (stimulation). IL-10 production was assessed in CD4+ 
T cells with or without stimulus. Representative dot plots of stimulated cells are shown from the 
untreated control BALB/c, SKG and the mannan treated SKG and SKG Ptpn22-/- mice (indicated by 
red square). The graph representing the frequencies of IL-10 producing CD4+ T cells from mannan 
treated SKG (solid blue circles) or SKG Ptpn22-/- mice (red filled circles) compared to untreated 
BALB/c (black solid squares) and SKG (hollow blue circles) is shown. Statistical significance was 
calculated in Prism: One-Way ANOVA with post ANOVA Tukey’s test for multiple comparisons ns-
non significant, *P<0.05, **P<0.01, ***P<0.001. 
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Figure 5.13 Ptpn22 deficiency results in increased proportions of peripheral Tregs in SKG 
Ptpn22-/- mice after mannan treatment which alter the Treg/Th17 balance 
LNs and spleen from SKG and SKG Ptpn22-/- mice were analysed for percentages of Tregs 
(FoxP3+CD25+) within the CD4+ T cell population. (A) Representative dot plots showing the FoxP3 
versus CD25 expression gated on CD4+ T cells in control BALB/c, SKG mice or mannan treated SKG 
and SKG Ptpn22-/- mice (indicated in red square) is shown. (B) Bar chart shows frequencies of Tregs 
(CD4+ FoxP3+CD25+) in LNs and spleen and the Treg/Th17 CD4 ratio in the LN from control 
BALB/c, SKG or mannan treated SKG and SKG Ptpn22-/- mice. Th17 cells are defined as CD4+ IL-
17+ (C) Histogram shows the surface expression of CTLA4 in CD4+FoxP3+CD25+ Tregs from LNs of 
SKG (grey shaded) and SKG Ptpn22-/- (red overlay line) mice and the bar chart shows the MFI of 
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Chapter 6: Discussion & Future Directions  
Genetic alteration in PTPN22 gene has been linked to human autoimmunity. The 
overall objective of this thesis was to understand the functional effect of PTPN22 and 
its variant in T cell signalling and delineate the molecular mechanism of action in 
context of an autoimmune disease. Studies from overexpression of PTPN22 in Jurkat 
T cells or primary human T cells and genetic loss of Ptpn22 in mice provide strong 
evidence that PTPN22 negatively regulates TCR signalling (Brownlie et al., 2012; 
Gjorloff-Wingren et al., 1999; Hasegawa et al., 2004; Vang et al., 2005). A single 
nucleotide polymorphism of PTPN22 (C1858T) was found to be associated with 
numerous autoimmune diseases (Bottini and Peterson, 2014), however whether the 
disease associated variant is a loss-of or gain-of function allele remains controversial. 
To clarify the functional effects of PTPN22R619W on T cell signalling, we utilised the 
lentiviral transduction technology to express PTPN22WT and PTPN22R619W variant in 
primary T cells from Ptpn22-/- mice. Our data shows that lentiviral induced 
expression of either PTPN22WT or PTPN22R619W had no effect on cytokine 
production (Fig 3.5B), suggesting that the lentiviral induced expression might not be 
sufficient to dampen TCR induced cytokine production. We employed a different 
approach and used Amaxa nucleofection to express PTPN22 YFP fusion proteins in 
Ptpn22-/-. In this case both PTPN22WT and PTPN22R619W reduced the extent of ERK 
phosphorylation. Interestingly, at higher levels of PTPN22R619W YFP expression 
significant reduction in the levels of pERK were noted in comparison to the control 
Ptpn22-/- T cells (Fig 3.13). However, the results from ectopic expression of PTPN22 
needs to be carefully considered, as it is difficult to evaluate if increased levels of 
expression PTPN22 might alter the stoichiometric balance with Csk and lead to off-
target effects. Therefore studying the effect of the R619W variant in physiological 
setting would be a more relevant approach. Recent studies from two groups, which 
have independently generated the knock-in mouse model of human ortholog, 
PTPN22R619W demonstrate that variant phenotypically resembles the Ptpn22-/- mouse, 
suggesting that at least in mice, R619W variant is a loss-of function allele (Dai et al., 
2013; Zhang et al., 2011). 
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The R620W variation of PTPN22 is a prominent risk factor for RA, T1D and other 
autoimmune diseases (Bottini and Peterson, 2014). We used the SKG mouse model 
of arthritis to understand function of PTPN22 in context of an autoimmune disease. 
Taking advantage of PTPN22-deficient mouse as a model of the loss-of function risk 
allele, albeit a more extreme allele we generated double mutant SKG Ptpn22-/- mice 
by crossing the Ptpn22-/- mice with SKG mice.  
Our results show that loss of Ptpn22 resulted in partial rescue of positive selection in 
SKG Ptpn22-/- mice. Although we did not see significant increases in the CD4+ and 
CD8+ SP cells in SKG Ptpn22-/- mice, however the expression of CD5 was increased 
in preselecting DP thymocytes (Fig 4.4A), which correlated with enhanced T cell 
signalling in response to stimulation in SKG Ptpn22-/- thymocytes compared to SKG 
mice as shown by increase in Ca2+ flux (Fig 4.6) and moderate increase in pERK  
(Fig 4.7). In periphery, many T cell associated phenotypes in SKG Ptpn22-/- mice 
recapitulated those observed in Ptpn22-/- mice (Brownlie et al., 2012; Hasegawa et 
al., 2004). Memory/effector CD4+ T cells accumulated in aging SKG Ptpn22-/- mice 
(Fig 4.12). CD4+ T cells from SKG Ptpn22-/- mice proliferated more and produced 
greater amounts of IL-2 after stimulation in comparison to CD4+ T cells from SKG 
mice (Fig 5.3 and 5.4). Thus these results provided evidence that both PTPN22 and 
ZAP-70 function by affecting similar signalling pathways in vivo. Interestingly 
despite the tendency to develop effector/memory population, the SKG Ptpn22-/- mice 
developed less severe mannan-induced arthritis in comparison to SKG mice (Fig 
5.7). 
One of the proposed models as to how the R620W PTPN22 variant allele might 
promote autoimmunity in humans suggested that the mutation was a gain-of function 
allele, which suppressed T cell signalling more efficiently resulting in increasing the 
threshold required for effective TCR signalling in developing thymocytes and 
allowing the escape of higher number of autoreactive T cells exhibiting a higher 
functional avidity (Gregersen et al., 2006; Vang et al., 2005). This is exemplified in 
SKG mouse, where TCR hyporesponsiveness of thymocytes due to aberrant ZAP-70 
skews the selection repertoire in a manner that T cells with higher than normal 
avidity for self escape deletion by negative selection (Sakaguchi et al., 2003). These 
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negative selection escapees are perpetrators of an autoreactive phenotype in the 
periphery and cause arthritis in SKG mice (see Fig 6.1).  
We considered if loss of Ptpn22 might selectively impact the CD4+ T cell repertoire, 
however we did not observe any alterations in the selection of TCR V! repertoire 
either in thymus (Fig 4.8) or periphery (Fig 4.9) of SKG Ptpn22-/- mice suggesting 
that PTPN22 does not have an effect on negative selection in mice, which is in line 
with a previous published study from Ptpn22-/- mice (Hasegawa et al., 2004), Taken 
together these results suggest that deletion of Ptpn22 does not majorly impact thymic 
selection, albeit a subtle effect in augmenting positive selection is noted in SKG 
Ptpn22-/- mice.  
The repertoire of both SKG and SKG Ptpn22-/- mice contained self-reactive cells but 
it was perplexing that SKG Ptpn22-/- mice still developed less arthritis. Tregs are 
important in curbing the autoreactive T cells keeping them from causing 
autoimmunity in the periphery. The alteration of TCR signalling in thymus may alter 
the amount and repertoire of Treg (Tanaka et al., 2010). Despite the increased 
signalling observed in SKG Ptpn22-/- thymocytes, the numbers of thymic Tregs were 
not increased in SKG Ptpn22-/-, which is consistent with C57BL/6 Ptpn22-/- mice 
(Brownlie et al., 2012). However we noticed increased proportions of Tregs in the 
periphery of SKG Ptpn22-/- mice compared to SKG mice, which could provide an 
explanation for why SKG Ptpn22-/- were more resistance to arthritis. A recent study 
showed that PTPN22 is a direct target of Foxp3, transcription factor important for 
Treg function (Marson et al., 2007), suggesting that PTPN22 negatively regulates 
function of Treg cells. In line our previous study showed that Tregs from Ptpn22-/- 
mice are more numerous and suppressive than wild-type Tregs (Brownlie et al., 
2012). In support of our proposed mechanism to arthritis resistance in SKG Ptpn22-/- 
mice, Ptpn22 deficiency has also been shown to be protective in NOD and EAE mice 
model of disease due to increased Treg numbers (Maine et al., 2012; Zheng and 
Kissler, 2013).  
Tregs are indispensible in immune tolerance and depend on IL-2 for their 
development, homeostasis and function (Josefowicz and Rudensky, 2009; Malek and 
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Castro, 2010). The increase in Treg cells might be due to the enhanced 
responsiveness to IL-2. We found that IL-2 production by CD4+ T cells is increased, 
which could constitute a source of IL-2 for Treg cells in SKG Ptpn22-/- mice. In 
addition, a recently, published report from our lab showed that Ptpn22 limits naïve 
and effector T cell activation in response to very weak self affinity antigens 
(Salmond et al., 2014). Therefore, it is likely that Ptpn22 deficiency could enhance 
homeostatic TCR signalling, which slowly accelerates the turnover of Treg cells and 
accounts for the increase in Treg proportions seen in the SKG Ptpn22-/- mice 
(Josefowicz and Rudensky, 2009).  
SKG mutation impairs the in vivo and in vitro suppressive function of natural Foxp3+ 
Tregs as established from cotransfer experiments, wherein transfer of SKG CD25- 
CD4+ T cells together with CD25+CD4+ Treg cells from non-arthritic SKG or 
BALB/c mice to BALB/c nude mice showed that SKG Treg cells were much less 
effective in suppressing the development of arthritis (Tanaka et al., 2010). Whether 
the lack of arthritis in SKG Ptpn22-/- mice is exerted through the increased 
suppressive function of Tregs remains to be determined. It is interesting to note that 
studies from PTPN22R619W knock-in mice have not reported a diminished Treg 
function (Dai et al., 2013), thus posing a conflicting argument for our proposed 
model of protection from arthritis in SKG Ptpn22-/- mice.  
Another alternative explanation for the role of PTPN22R620W in the pathogenesis of 
autoimmune disease is that it alters the balance of effector and Treg. This is 
supported by a study conducted in NOD mouse model wherein, overexpression of T-
cell specific transgenic wild-type PTPN22 in NOD mice showed a marked decrease 
in TCR-mediated effector cell responses such as proliferation and Th1 differentiation 
but did not affect the differentiation of Tregs or their suppressive activity (Yeh et al., 
2013). Importantly the transgenic mice showed lower incidence of spontaneous 
autoimmune diabetes, which was marked by decreased IFN!- producing T cells and 
increased ratios of CD4+Foxp3+ Tregs to CD4+IFN!+ or CD8+IFN!+ effector T cells 
(Yeh et al., 2013). Our data shows that loss of Ptpn22 resulted in a significant two-
fold decrease in the proportion of CD4+ T cells secreting IL-17 and a concomitant 
increase in the proportion secreting IFN! compared to SKG mice (Fig 5.11) 
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suggesting that the balance between autoimmune-promoting effector T cell and 
autoimmune-protecting Treg cell compartments is finely regulated by PTPN22. In 
support of this mechanism of PTPN22 action a study showed that Foxp3 induction 
could restrain differentiation of inflammatory Th17 in response to TGF! in absence 
of other inflammatory cytokines by inhibiting ROR"T function (Zhou et al., 2008). 
Further support is provided from a recent study conducted in peripheral blood T cells 
from healthy PTPN22-C1858T carriers, which revealed that the cytokine production 
patterns in differentiated effector or memory T cells showed Th1 skewing with 
increased production of IFN", IL-2, TNF but reduced production of Th17 (Vang et 
al., 2013).  
In conclusion, we show that deficiency of Ptpn22 in SKG mice resulted in 
accumulation of Treg cells and reduction of autoreactive Th17 cells, which is capable 
of protecting SKG Ptpn22-/- mice from arthritis suggesting that alteration of 
Treg/Th17 balance could be one of the possible mechanisms of action of PTPN22. It 
remains to be determined but it is likely that the effects of PTPN22-deficiency on 
innate cells might have contributed in providing the necessary cytokine milieu for 
this skewed differentiation (Fig 6.1). Antigen specific Tregs are a potential route for 
reinstatement of immune tolerance, in light of our results, PTPN22 inhibition (by 
using a small molecule inhibitor) could be valuable approach to generate either ex 
vivo expanded Tregs or for testing the disease protective effect in vivo. Thus our 
results indicate that PTPN22 could be a valuable target for the treatment of 
autoimmune diseases.  
Future directions 
More work is required to understand the function of PTPN22 in immune-cell 
homeostasis and to clarify the exact molecular mechanism by which the R620W 
allele of PTPN22 enhances autoimmune disease. Reports have argued a gain-of 
function, as well as a loss-of function in lymphocytes (Bottini and Peterson, 2014). 
Recent data provides evidence that PTPN22 C1858T involves concerted aberration 
in other cells such as B cells and myeloid cells (Dai et al., 2013; Menard et al., 2011; 
Wang et al., 2013; Zhang et al., 2011). Selective deficiency of PTPN22 in T 
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lymphocyte subset and other subsets will help clarify the cellular mechanism of 
PTPN22 action. Expression of PTPN22R619W variant in autoimmune models will 
further help to explore immunological function of PTPN22 on disease pathogenesis 
and will ultimately aid in explaining how it confers risk of disease and reveal any 
potential as a therapeutic or prognostic target.  
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Figure 6.1 Model depicting how PTPN22 deficiency might affect development and effector 
function of T cells in SKG mice.  
In SKG mice TCR signal attenuation due to aberrant ZAP-70 leads to a thymic selection shift 
resulting in positive selection of highly self-reactive T cells and their escape from negative selection, 
shifting TCR repertoire of conventional T cells to be more self-reactive. In the periphery, these self 
reactive T cells recognize self pMHC on APCs with greater affinity. This results in the activation and 
stimulation of APCs to secrete proinflammatory cytokines such as IL-6, IL-1! which together with 
TGF! (derived from the tissues) drive the differentiation of self-reactive T cells into Th17 cells. These 
Th17 cells are then recruited to the inflammation site in the joint by synovial cells where it promotes 
secretion of inflammatory cytokines by the synovial fibroblasts and activation of other immune cells 
resulting in bone damage. In thymus, PTPN22 deficiency has minimal effect on selection, albeit 
shows a very subtle effect on positive selection therefore not majorly altering the thymic selection 
shift in SKG Ptpn22-/- mice. In the periphery, SKG Ptpn22-/- mice have a similar pool of autoreactive 
T cells as that of SKG mice but also have increased number of Tregs. These Tregs might be able to 
restrain the effector function mediated by Th17 cells by increased immunosuppression or by affecting 
differentiation of Th17 lineage thereby skewing the Treg:Th17 ratio resulting in the decreased 
incidence and less severe arthritis observed in these mice. 
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